var title_f37_53_38736="Ciclesonide: Patient drug information";
var content_f37_53_38736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciclesonide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/37/27221?source=see_link\">",
"       Ciclesonide (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/34/35365?source=see_link\">",
"       Ciclesonide (oral inhalation): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11608 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5CB361C86E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38736=[""].join("\n");
var outline_f37_53_38736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/37/27221?source=related_link\">",
"      Ciclesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/34/35365?source=related_link\">",
"      Ciclesonide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_53_38737="Lacunar cells and mummified Reed-Sternberg cell";
var content_f37_53_38737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lacunar cells and mummified Reed-Sternberg cell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 190px; height: 283px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEbAL4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwB02s6ZrOp6zLcZs5rKdklkuCwXlyBjnByc/wD6qzdOtrPUFabRtRK28UnllpI3CoxH54OOGx6VLBpWk+KjrOnWvnw3El6Z3lfqArMOCB79DW5ovhLSfD9tcCO5nE10m1tp4IzzgEHJ4/XjAqOdR06nptuOnQzdXvLuVPs9k/2qaYCAZcpuPXgkcEAH9adDqr2dvFBdyNGciOSGUMSwz8uDkjHHX/I0dU0/U9MvLK8sroz2kUpWRSihlUjBXB4yeOfyrmtZNkovr+7ilSGRkx5cm8lhxhegBPPA4GPenFqWnQpvXTYj1jTJta1K3uXvW+1wRgbULFAjcjPuAfy+laOi61ZR30ujTC7vTKwgknMgCqx6KMnOQcD6ioImka9ii0+3eWyZ1KyCIADPGSc/wnIx1HWnrYaJPrNzeWd3I8srlZmWPHlS4IV+mTzzx3FD8ypu6SiWHuv+EdGo3Yha5ubKFfKUOSHw2C5PfGf5/hQvvGOqa/olhcwyS2guBL5scSlgCpGMH3yTzxU+geEpNOtb+bUr6zmtrhSpWF22BSTuyx5yQR2FWtLTSNOsfMiaR4oyYoFMu6JSc5JI4wSfrzSTje61Is5PmMzwhNrUWpzpqhEGnujmBp5drNJtwNh64Pr0+lYmhafqllHcvqq3EMjTgZeQlmC5BI9s459q2/EEqa7qVo93aulhaoE8yCYbJHBztb0wT65FbepXdlq1nJfW00cFzBHm4LkgQRrxx79AMU23e/ccPdd5bGBY69o1vJPqlqZLzVrhDbvGjuI5JMcjBHRvX+VPN5qHifwWYzb3OkGO6CrCC22ZQOcbsHIJ9+R61Q8MeHNN1C0tlhaVoXnkme5cbcBeDkenQD3q9Y69ZXV7qNnb2jRQWdvNIt0zbpBtB+cfUjpnuKGl0I0Vm/uRe1Gyh0Hwm9ldzM8l4NwaOXng/Ng8jIAH5Guaj1Y+G9N0u38PNPO1xKLiWd8hsBjiIjnAyuT65FV9Jv49O8JKJ4mvGlu5MKzhEt+EyAR1J68cCtXUtIk1nXpLzRhFF9jsVJgnHysSp+4OFIORnP8AXFO1tWPn5o+ZvaBFoR1SO/tryS2muy5FrNJ912XnYO4OWGT9BWVqUMv9tRw/aZvlYojrIduFOAAAe45zVa1hhPheL+32udPu5yYzsA3TRKeNw7YJI7Vt3d/b2mgS3ult5tzaWrKPNAclscZHtyfyp3tqgirK7OPuNf1S71DZYQSi0glLvCM/NjgFm6np1PFdQk7+J/Dj2+o6iLRIJNwuDJ8rd8e5B7Vz9rqV5rvh57ab/R9UugC06x4VlGTyAOrZwT7VAqSad4GmF+skryXaogUbSAUbLHOcDtnFN32BJOPN0Nn7PZ6qNNtdP1GVksnZpWZGBnYhfujOQMDPNXdNvZINSSL95IjqzRyrKewGMjtkD15xWT4KsbGJjNaNLKICrCOUgbgeC3HtkfpXRadpljDeJLbTNcN55SVHYExDrjjnsBSbte5orKKS2IdQtr+HRYm0OSa3u5JmlECSlCyng7CT/eweucCs7U9fnGq6dbyXXn6jbpHHPOJeVk74xwcevfGa7MPBqUd/9qkQvHkh+nkqp/TGK4t/COj32qC8aRkdv30pRywb3/PnFTGb2YuVXuaNvqFudXls3Sa7uiWYK4IQMvPP1xx+FWvAvjO88SeKr2K/RoLSCBvK8gnrvXOcnk/yq2lnFABPsLyIvlmYYGVBGT69q57wPNqUXjTUxYxx2ltHC8YRoVw3zrg5x7fkaakmwqLTQ2/CCNpfjDxDpq3BktJnkmglYAHfkn5fzJxWN4y1K6tbyAsXZ5pkhWUE/ulb0U9TgD861Rr1toKalY2dsb5TJNdtdMDGqSbzkjhuBgfiD64qew1K38TaYJpcLcgldiocvxjcnH8s1OqlzWMbNklkGu9D1aBZnZgrxIxUrkjhSO/UZ9sVx7a3ZX15eaIdNW58sOzzebgb1wOSO2QfzHvXR3GqW1hpk0Sb4WY/IRh1XHrwAOuep6Vi+HrCxgu72/RRFiaOWSORgTIjEk5A46lePeja7NoxaWp0+i6Ysb6dYHbBI1uwBQ9Ny/MVPfAPesTWNNfwdpf2Lw5Mk01xKSLiVxleBnJ6cZ7VR1DWbq58TrBYWiRWM6tE4YjKK+AzA54JwDx0wKXwdJYSeFZNK1Bw76b5rb3BBC78hxj/AHumP0oSad2RK99UaWh3k1/b3Vrdzx3M7xkrMrgiVcfMDt4xnufwxWRo89nqvhe707SLiKyazuRLLLcEKrbsrjJ7fzwK0NNs7LSdLF/azxvZ8BYomJLnurDAxjngiszWvCslzo9hb2EMVla3Urz3gY8xsPu98kAE4AHUn1p3SYO9tCxomjyG0vdFj1G0F5OAYi0uS2zPIzyc56j0rFl1c6bLHo09qZ4ZgIZSjFSzAgg57cgflW34v0+y03UbTWkluormFY40QAeWnlrjcDnJ4z8vGT+tG4urOFF/tY+awIdZIoMSA8F15OAPm5IPenG8tSlKyaloWbzWr7QH0qHTrFG0y6yHijBbzkzgrnqXyxJPqa1dE0NNOnZZ7h/InjkXa0e0Krj5s5J5HXnABrK1mPVbC0tLjw/qG2wulE2FYIecAfJnsOOKjkt7+58N3kslz9q1KWPdvDDg5yR6D5emPWl6CjFNt20I9K8MPFa3NtcXKPbiVmhjAypc8b/cYrrvO+3xrpwkaG4hiwsoiyCo+6M9z1HbtXH+DtHuRp95NLeRzzHyysTSZZVHLfKOfw9q6G0hUQ3V5bXLQQyOqhJOA5xluOo64H0obuVGK0SK/jOzbUtTWW2c3aW0AieCN9zRsuecDrnrkdwazrazV2ljn8yITRNJHH5f3gDg47DqfzrQ02yt9O199alnuUnMbRiNW+QHHXP0z1rE1y31GfWkm+0RjSpWVxPs3K6ZztGeM57DuKpOy5RpNaNGvbpEus2048yJSixoFJCogXaDkfTHPfmk8QTTWOiStYyKBMuxiyBg2Tnpgg8d6xbnUbt7y4EESNZRlpQFU7mQNyfXHTP4Vo6Vd3+t6bC2oWgiVHCoixhfNTntnGOeDx+maJLqEGm+WxL4EabU9Fiup0EckTtFvRQm7gfeI649/WnQGa28RXt0i7YAhZwMLu4xnA75yc+/uK1LfTru2Q/ZIVjAIG0yZj6dj0yc84qWPTr7VNOu9JuIgrXSMEnC/cAwcnjpnH1qebqxyXKrC6lDNJpDxWC/MSGlaMnLADP4cfWuc0OKe/1Sd4o2tolm2Rjuyjht3r0/QVu+FdF1zQIJLfU5FnWP5E+bcpXB2n14I79jjtVKy8eJNrFxp89gYLldwDFf4gMnOO3/ANanGT2jqQ3ezfUp65fz+Eme+EovJ7ghUjlJCJzncf6Y/wAK9F+HtxY+JLVNQubdluyrjbErABSw/wAB19DXnU97NqfjIWVxZRPY2gZpA5AywXqSf4ScYHtXs3gyJbK3T5UjSSIMFHGOnHpwKmb2vuRN6OxwYLX11Lb22m26vI0ixM7H5TuYndjqTjPvXL+H7u40/wATx6behvKV3t2gRs4zGcsrDjdnB+h6V0F59ol1PULzRZWYvO4kjQAHO4ggr2IIPIrnL6ae81Vri7hhV1YGFYYdsgZTwSRzntn8+1NdUzf2Tlbl2M7wxpsVlp+rXct24sY8iRriMjyxu+UYH3nPTA6c+1bdvbWsOiSXlozN5rlVOOCCRg+vv/8Aqq7rk2mwaba6XrUDXM12yTOkRx5Z+6uT0PU5HvV2H7LFY3VpaRD7PdSKLWM5YqNozn8vzpOT3JjdPljsc74atn3tJL9oSGECWOS7TA28cqD0GQO/eom1TR9Ae6awtSVmIWbziTuByCEHYZwcf4Vp3vinULzdA8Ns1sMo4ZTzzkDP+FFjBYahNLDLbLHfMC0JJLx7sZ5/w5ov1ki3Sly3kaw0u2k0DTbi0s2WB3LSKrEcHJBJJzycc+/SuOdLnUdeUIxjshOIVffl++cqDxxyc+9bPhe51ga7cx6x9qWKL5XZ+EcZwOPbOQRjtVOG3iivbq50+0ia7AKs7HuOGJ7dz6dTRG6urkJSkja8TeIYbRZNNubaG8lgXdO8sYCsn94Dqe3ORyOKzdMu9F8RaKJbrSYrRLWQ7GyUjkJ4J3Ag4OADnPNSadD51ubrUjZtDAigzACXBx8qgdz7VQutTmupUt9MSGyiQPMCEBY4BzgYOWP0460lFbIXs7at6Fm8t7q6uorp7Mm32qsYRNqxIBtAGfu44qtZ63caHpeqPb24urqOdIwzpxubcWJX6jA+oqKTUrmw12Kz0vUb5r423nocLIkwxuAVgB/Du5IIyK7rRJNP8Xab5lwSNRhA84btx55DAHjaeaJSstVoJyTTPPtK1az0PSLLX2DPezmVI7YMAsOfvZJ7kdB3z+NbGuXkEWm6ddW7XEUd4gkJCBnRWPTaffn6Vt3USRHUoRaWeoW8TB0b5XJ4PG0Z6dM4Fc5NqC332Vb63KJMSyLG2CnGOnUdO4qk7u4QT7kOoWOqX8SPG4EVzCqDY4Co+MPlD19M9OtdX4e0a6h0OHTtSvYZwWElvCuHUgctg9uvTtXO+LotXnspH0qSWWWDDsqxhC0eOgHtT/Cl7HeaVPZSB4r5CpkD5HkuxwHDfXg9KmTbja5bir+ZkX+ozw6hpthpdxawtPj7S5UBs7/ugnoMbTx1Jr0LS9IkcFXnecSHKsWBIHfBHr/9evNF8LXY1X7VNH5F2siKgmXiU9OPfp/jXsukSQXGlW7WVwFjiHzP0wf59vyqaktLomTcG15lTVLnU9MkSHS9OW4hXIzjGPrzwOnJpv2m5kkilhEUJMfmMxONvH3QMc/jirKQyNI00EnmA8M6fLkn/I71w/iW7uLe6u2eYRiHEccRfYQWIAcj+IEk9+MGpglJ2M7LqdrDdfaFle8MqGMYJj42t15Azz06ZrP8R6bptpG+sqq2saxrvkCZLL0Ax+I7+npXnut+J9Y0t4oJriSRZHZIriLbtYLgEDjPX1rsNBC6/aahZajP59nGqiNj3yAGB7Hvx71Tp8vvXGm9bGbrU+m6n4Oi1C0ZkRWYZl4beOuQM5J3Dj2r0/wNdPf6XY3MEyZkt8uMDG4EA/kQRXATrpOm2sOi20sdvdo5mthHnnjvnOc4I57dK3vhZe3j6xqscieecGWRsBArswyFHpgDPvk02romabjqYlpcJZ65rEt1dQLHBcYgmto8iYSlsBx2KkYP+cp4jurW7gMFjqEUtyJBumRgXGM8YBB4zn61T1BF/tTWNQ0aePULd52WWONipikViQGXr17/AJVl6PdRiDz73QILcRuohdXYPIORyc84znOKq2tzZLZ7o07rSbTV7pIyl097b/KJQBtkVTySMegqfUru30eAWFutxcNbkmWXOEVsEgZPXrk1labrPiC8vVLD7JpMBw7NGGMgK5xuzlieMY4/lVvVwL7Q5RcDZiVMtGAwkckBTg4PIwMdBjNKzvZ7AnfWx5bdatcW2omRpCrbyChzjA47/nXd+GCdZZ/Ml+xpZxPcSyH+AqO3qOc/ga2JNI0W/YxahppU2jcXIDRyNlc5J7gkHjt+NXtI0zR4EeaIyxiNSGjLA7Fbr5mc5z3zRKemw4ylG+u5FoviO61zwXc3EiBZ7e4WEzO5BI4IbjBzz2rkUsBqUEFjpiRXeo3bOZnDlJIAuclmzjGT36gDvW9qk6HT/sWg2zQ6LZTYZ1UgyOckknP6+9ZeiRmzn1NLZHluLllt4hGnzMmMtkD6jt2oirJtaExi7JMg8uCx0+HStPYS28EhdnB4ZzwZD0OPQeg963tI8NpqJ2XsyrDAglYLJiQZGQyn8aq2umwwB7i6trgknaygYKtjg4PoSK3by3MbJZ6XM7y3aAsUwflHBy3XGOB0olKysjZqy5UcxHLdTgJJdho44hGJYYQkpjHRd69B19Kl025smS505gkSyxsJZ2O3gA/uwfz/ABNdRpekwTRxS3gX7ICVSFOBuU45A69/yrela1Cc2VvHC3PK5z0HQc56/lUSqJaJGblGOiR5v4en0Xwjqdu1tdXMtxejy5x5ahIxu+XOOW6Zz6HPeujtdMmk8SalNewxQzXARFkVegHXA9TgEn2ql4k8HW0lz/aOnW/ngYY2752sv+z3HbuK33vHvre8w7jzUChy4Lx4Gf6kY9qHJPWJEI21Od1nWEtbi4tdJkS4kBwfnJAODuA+uR7ZFcZotzDaaXKqySrqd1O0Ss/zDYvXGR1yRz3re0jwq+h3909zObtXtzIbQjDyEsMlW9OmSOetZuu+HApudV0uWZ1b/U5+9CePlOMc+h6H61pFq1jRJ7panYvLf2NgFlnb+0DAHSaU7gfl449xwfpWV4Yuby0sJm5SZ5F2FSCJjnJ4BwAOPzNGlMt94Z0/TdTu5VvEcr867gW6gMfbtViA22mlbH7WrXxG54mwuSDwB253Hn6ULsDWzehQGuaml3PLBcsrxHf5fl7U553M2cBRzk8fSusEFr4u0+A3IFtqUO2aKUD7uQCCM9RnHHSsbVdJW6sYxG4E8/BjEuRgnkEjpkdgKPDUVzpaXkkdxFKUckJHJ5hQjkKT/CO2P5USs1daNEON3oPg8JX0Ez+dNYynzNxuSxd48DBCoc4YnvnvXXz2cek+HH+zwKgt1OCnykZPJPqecmq3h3WReWkd1qMEdveuSu0cl+euO3PpmsfXfEMMLPFJGUZAB5hO7cueeAOe/FYvnnKzJSd9TmJrODXtTsri+vktL9GVLcMcCZQT+I56GvRPAFq2l6xezRS+YLiPLh2JIcEZPbP1rzzULC007xTBrWozGeR3M1pZhfmwowGY9gvYY9a9P8GXbSThlRWjkg81RIBwCRitntpsE3fm0OI8R6BfeDb7W7rRXM/9oXHmxs0e5k+ZiycdxnIyOgPcc5c91f6lbRfb4xb2U5RmMa7RlT1JPOQ3OOBj1r1zXDv+3tCgE6Hepb++pJUcdjj9cd68pTWIPENrJeG1i0u7gdA0kT/Jl8kAIeCw5BHrU0pN7omElomVPCV5qL2Vzpt/ZQCxaIyW9yqHCkHBBPUkjJrTEM2n6Xey3E0ZiyTsXOIwew29h6f1qtb3MdrbTG3M5eOYjMsP3N3OAevTnv8AhVqyv7iXVLt7mKAWcaqVXafnP94+2Oappm8Y6aEmp6nfT6cGSJAThfPjiI+TGSSCSRzxn3rmNC1G3WPUGuBI88lwGJAJXb/L7xrS8Ua5rl1BBceakVq7tHCeF34GSV74A6k8fXitDwt4TkvorS5mkS2SQLN5awbXJwOSTnOMDjp3xRdRj7xmpW07ELah5MRhCFFCtvgA3Fn5OcD371m6Cbux1GK5t2eL5HCRHkIdpAOMDkkj1616zp2jRaQTLZQLOz4VyyjzcDphvQelZ/iqzs7CwvNVggh+0RoAQRgbshVJ/E9qzVdP3Utw54ydjz8y6vFtlvJnMpXEMDITJK3PQdfX2rT8Ga5qGmSOmoWkUVu7KIpX+WVgefu+nI/OqGgXV3Nv1HxXcEPbuVtXVS7SDq6hAOVAwdw75Gak1C5t76OG8aNpI4ioWKFfKLSFtsQYDkcnqT+tW1zaMvn5o7WOxtFM1iqJIkSyYuDMgP8AFkkkemc49yKnTyo7svcyDdsJ8osSwTrxn1FZOga4zSXttqMBtodzIyNyIWwCyn0GSME9O+DUusabJLrlnqFqyKkMTFltxl5cj7obpnJzgVg1Z2Zm9zXt2hd4YlnaLKbthBJBJ4GPp61maTawQX99LFGksv2kqzE8lSowceo/xq3pqzNZzzag8rtIxZZJAIyF6quB6ZPpWT4cvLMf2neSXYjjef8A1jMFC4HOCeAOM0JaMWqTJfGl1FY2enPBBDPbCTy1y2CnBywOOmOPxFUfDTadejUHim2aW6lWjuF2lGz8uDnoMn35qxe6zo+pRWNrpSwX8ME4DZzmMk8MenU/hUWq3As7KbyZEFykqoqtggsxC5x6ZJx6dauK93l6lxk+Xc89ltRBGbTV5buxkSUvHOIy8Vxk8bXHQ4PT8yMVreLLjTla31VI2ubmCNQGL4VynCvIoAJOMcdP66d7rFzLetaz2tzcwIr+YZQnkuijJAAHthe+QeuKp6pHYpq66dOrRwSRh45VTcz5GUX/AGfetkm9wTUl7xa8HXV/qdxJLqYj+yXaPbrcQosZjLAcggdeg74zVfSvD2pWOuLDaywXMcTuz3CkDAbHy7fUBenvmtS91qztE0fQkilR2KlnjXje5B2D6Z5PtV/Vlg06BNLtd0QLMN4Gd2Vy3fr2/E1KbT9QdvmTLbedbyi3LhN5WMI+XAH8iTXEeLLe40mKzn8p7iZJWaSYw+Z8/VFYZwM56n1rf/tF7LUVijtGhLN58RHzLsbAA4OOcH8fwrcutywyvAkgKNuVjyGUDv6c/wAqE3Fju5Kxm6g+m3TXFzrIhC2QDNn+FiudrMPcgY56Vq+CtSg1LVGywni+zkxtGp2oAUBXHY8iuMl063g0XUY9caZYZmUgx8tkHcGBPXJJH411HwrSztrv+zreG8ig+zNP5jlVeU7kGeOgxjirSViZXV0zs7+SKa8lkA85I5Hd8EFSASfyH0rgvE2lTQMLy0xFJcw+ZGy7VKONpOPUkdzk12N2ItLN7ZM7kl2bgcEPISe/AGT+FUPEJe506wBjdIUulhlCttbGMFh7d+2a5oPlkRDsc3Z2O2BDLtJj3eWzcpF6D1Yj1OBVFobm30a8Mu+QDJVR1boA+T14yf5VqeLNVsdMuoYBJG1mdq5STaEPOR7npmtfwzHb6swllhBjtnGwY4YnBzz2xjrWrm0uZm17RuQeFfDs95BDP4mhE7Qtut0lGdinH3hnB5VTjtXW3U4t5UIjL5IjAU4689/p+tJJdSm4CQW7MqsQ7McfkOp+tVXWAXjB0fzpyY1ZSeGxzk5wOAOf/r1yylzO7Oe93cgXxfpQ1BbF5mS5YlRlcruHbI46/wAjTvE9ouq+GrtY1T7SF3pkdJEOfTPUVm2fh6EaysmpyhIjIJoIN2FLjn17Z/TNdDfPDb2FzFBguImO3Pcgjr9ab5YtcgWSa5TzDWtI02GK0tbvViqKgG4Sf6s4yQcHO05/HNZWkapplqLqPzg0MxGIZsEyL0PXpyCwyeOueKl8V6I+oWkNskssdxbKJU2RlmbdHnaQPcEZyf0qbw94bsvEd/F9mab+zhBE0xlC5WUDlQVHp2PSuu6SvJm8pNaDPFltHFfQLBZwQNcNFNEIJPMYptKkEDggnJOeST3xxqwx32jIkVv9uMJ+chYC8an0xzgZ64rt7bTbPR7Ro9PhWAKyq7hSGJ4G4sev/wBesmz15l1F7BIZbpiDlI2yyckbTkdepxWXtHJWS2IhKytYwdWnvNatJpZbuVNPjUiS3hQIVc4wx7svXjqcVRsreK50byvJKLKfLeN4yj4GQCV6rxg4/wD116RquhWWoWY8+B4iY8Fo+JVXqBkcnBArio9ENzcT3FtfT3M0IVZ45W2bMHqzdxyTxzThUTXYum03psVNA0WDRdIkewQlrhvm3E73wRg8+hBwPet3xEglwJ4wbWeJQhxhlbrxnuOv4VztlcWL6/HZpILqQcFlXdGh4zkk4zjpjNTTeINRXVp7O3khuAs4jkjZCSnQnHc4z2qnF3KdtolaLS9Rlnsbe0nMcMLMXZJt6OCfvlG6Nk5HYVHrukveeL7WWORksYII4gynAYKDkAYznOOfap9cudYIigVZBHkmW3sl2SsRgBCQDjPXJOOvoK1IZbiG1sbq/s7iW8hIMkmVCowB+VsHrj27Gnd73IjGzs0Yk9xNHq1v5ax3AtwTDIUA2r0IJznjgZrt0tbXWrXzUnCNLgtE6H5Tjpnr7j61x8+oX9/etHp0JyAzmC3iRz35CkZ9PUe46UalbX1zbW0ZnOn3LuAJpQ0aSpjADYzhsY7flTkr2voVPXbdGzDoHk3cUaTtIowqln5XH90AfrVxXdPEcdhbuTYx7UnQjnPXn1HQ1zmta5qM8R0zTNRgEr7EeeFCZSchSS3Yd/xxUmn3VxPrtxo62UyXFqoZbtAcsfVuxz271Di7XkxLzND4gNIZ1ubKyW+8hvLMRG4bhx932OKr/Duwurm+uLrVopopihSNIxsYJ8nX2z0+la09xLqdmk1n5LXoV8gxkE856djn9a1fBmReBp8w3sluXlTp/EMHHanCVlyilFqN+xPr+FuZku9zb2c/MwwMk8fzGOlc7qsu7S2a1jEdy0bo7YIIwvP8sg+1bviiVIr5X8mcyTSuj7QDtGSRn/Csa6kC2lxI7NG/lNEkK4OSQQPwFZx7kQR5b4n057m0t5pmltrRA2UlbzGkZQu50OBwc9PXNex/Dtol8PwQosiOEWQLKoVyjAYOPTOR+FchpljavCp1K0kJTAUuHdWPseQB1yBgV6W4jurPKXCq6rgSxMPkP8vwNFd3Vh1Vy6MlvryKyWN58hXYKCBkAnoDWY6r9tga5BPnkFSDn96B1Hpx+eKtfalwUvUUoh2tKOUyBkk/3agt/LVk+ywq1tFIXz1+9/ECfx+lYJWM1oWmskuIUF6ofa4lIPTcO/0rF8V3y7xFFNFEigb5ZJAqjPYev4Vo6trEcH7m1uIBOBliSDsXoSef0/SuSk0i+mex1SxkhltZIPKubeQgnvu2nBIOeP8AgNXTj1kON9yHxPpEN81hJBOsIlUx74dzgHaWAwTz3+ua3/CKix8PpcMrzKbiQs/lne53lQ2B7Yz6VRs7QHRlsorpTd2rNcRBVJ2nJKgD028Vu+G7yO5t7uKIom2dsgZwN4DfzJ61U5PlsXL4R/iK4lXTXjSMmSRgiv8AdCt1BNc1ommR2uqX8ctwkVzAguEVUw+wAAYPflSCPQ89q7AQyxwyOsgdcFgFPzK3oO2MZ4rClsEug7zSJDflSo24O4n0yOOMcVMJWVhQeljprfUrO7iaW2njZVO1geCGwDgj15HFcrrUq2i3XHkzakvlxyKnICk5zj2cD8K1dHh2oYJY5BdEBjkDaQDjcD+GT9a5uZZdf8Rz2+mXMggtGZXkYDbg9cE9ckYAx2zRCKTfYcEk/IyvD+m31obq33ie4kA3CMZ7n5m7Drx3qOTwnrp2zWsbb2LY8yXYRz1wMk/jXqmkWFvp1jHb2yCEAZZQcksTyxPc5zzSvcxs4dZUGxijHqT14H+e1U8RK+gOr0SPO0i1HTdMnhurGZL5lwZ0JIZcYB3LyCT1781l+FryS207UrzxDJNbaasIiWWcgu7eqkDnkkDqa9dUJKj/ACvjO05H+c9a5DxpoNrdW0KXuni8tp5wHt4XKFX5Kup4xx97PH5UQrc2jW4ubn9TgLDVNK8J6yqSai17Iib4ktoyQ3mKCGLMcAAHoO5rqfElj/a9skcd4gVx5cUKNkkEAlsdsYP/ANalX4eabqN0b83SO5KpHFEfkjVQNq56kYA9K3rrwysaNLBdpAGRVfzV3Lx3znI9PSqdVOV+pScVuzktK8IWGlXFqGvMyFw0ZIBwcDJLADnp06V1MF1PFDc2k0kVtJCw+ZV5eMn7wJ4Pvwaz9auzoUFsb22jlKzlAsZxGwK5JZjnB7Adc4rKsBqeu6tZT25kSxdXaJJAAY0wOD2IJz1p6zV5PQd09DXVkh1d4rVCWCiSVhzjkg49SRg/jWP8N7rXV8TXy6vci8h+zny2yMfeXGMDjjtUup2n2S2vbNGaCC5jaFbonHlHPYDnGQR/Kp/hBoaaBf3cgna5eaH5g8W1M7hyB6/XFXDRXHUjfW2hHH4l0y98Rahp8bXcA+0ysHDEqSJfm2jBxz2A6c10KaZZS6HcNYSRSTuhzdb95LZzkn0yOlYviTQbTU7jV7nQUhsp7kOJ7hgVZW34YYH94AjIrBFjb+G7WxsJdQnmvHj3usMmzbz1C5ztySKlpS+F6mcU27XOl1nRb5xDY6feiO3GPMkJKuhIx06HjnBx2pv/AAhenXLJDPPeN5aAPicLv9WOBW1oxjeJpFkJkJHmIz5Cke3vV27lhVch1hKn+LjHXnH1rB1JLRMlt7FP+wLPyhHbyTshOWBupCD29f8AOK5xvCem6bqymS5vI7aYGNgZ2ZEJGF69M5xn1rO1bWrqG7muLfUfsSQzxwFC6jzXOCWIbPy4PAGM810nhrVX1HS79dYWIS2svlSER4RwcEEDnse3pWjU4K9w1Rmax4TaB4Ra30xtwQDG6gheT8x9uvasXxFfXBs7uTR0eZoNr3CIdjzBiQfmHIA25wPUDsa663gEwkha4lDRqQ6ykHMW4FSepyBxnPX8K5OayvotVuPsCRsShRo50+WWNixAYdgOveqpyvuaXlNWZB4Wvryx1rTbZ/OSG/jBe1mcloSQxBUjPGMEEnmultpP7AuVwjtI2fNDNuEy9AfQEdvXOKytFsZYNU/tG8EQu3G2C0gwUHy7S3HQYAGK3DNC7ySTSl4wAWKkkeWO2Og6mnN3Y1dKzNfTbrTp4kOleXcYZVlXed6DOckNzxz19OK1jLG/mmUAPGjAsxwoU+59sc/WuMee0vmXz4Y/L81SjgYaPnHUd/05+tZXi6zuLDdqDXlzeWKMGkiZ+Rk9No9yPTqKy9nd6smNNN2uTeL/ABd+9TSvDllPeSXCFDc2/wB0OflCKfXoCeOPzrtfDFhJpujwxXEkMt2EBldEwN2MYA9AOB7CuB+E1kq6xqU8MZ8q3iUx5zku+Scn6L/49XfO9xZyecFaQSycxoOF/Ht05OKKiS9xEyVnypmd4g1m6gk2x2wlm85YoArFQ7EEdcgkDOSPQfSsbQp7p9TFgwkSeeI3ELsipuZXBZSQMc9cdcVn+OtOlvI7dIJ5ILqeWRvvbtspUEd+D8pAxVf4c6dqEl0l5PKbkQs8aTSE5lbAyq564289OlaKMVC5VrI9Q0e7uriwhOpQxw3/ACXjiJZRg9j7jBrMv5pb2+uBb42wRNEit/HIcbj+WB+JqzYm5sNOvLrVJgSpeUbMfKgHGePvcfrioLGI2unxpPiW6mi3SgtgszMWJz9TXNs7kJJbF3S9NgsbRAhV3JLtKR8xbOcD0HYewpmtWdtqFp/ppR7WMbtpbb8w5BJBx270XFxOo/clIkjAL+cCSAemMH2PpVa8tzcwuFmkkDsRgqPlYnqo9hkUK973JW9yWytLOfTZLVoke3Jw46qScZAP6/WuL8dtrOjWFonh6ANaBsqy4Vo/lwFOeNv+fr3VhbQ2085R8PM27HYEDv74IPqao+MtKTWdBurJ3ZI2G4spwRjmqjK0vIqMtbHkfg2bUX1If2vOZlhkLNKJcqQ4A2579O1el6dO0GqxLHGBE1szbXHAO5f1rh/EXha1i0mKzs714LSzUMV5aVz137R1B9egrqvAHirQ7yVLe4vS9zbwNGZHi+8FZRnPqeK61q+ZI0qyUYpHR6hpFvb3kxW8vYpZpWAMcgUklifSuW1fw6zSs0NwJ5kQqDLEqsVznb5gHTPODx9K6m7vF/tC6kmhuHYSN+7IGI+cZyemcVz15e3hlurqCVPL24UbjgHjHUdOAfx71zx5rkwcrlHw1JNdR3No0bW9whTKuM7lyQc59h1966Tyng2LJOFSQquxVHAPGOeSOef/AK9Y+uaZLe2MWp2k4hvof3iyR5Kcj5lz1x/Kq+ieKbW4P2fVCLKVFMZaTHXv8x6HPrQ05axKlr7yKfifwlYa/cMrTywjzw7bEyjuQA2CcEHCjgHHtXQaPo0NlFLbveS3Ez7XkVmAJAAA49OB+H41OkJntZAbuKYIBtfcpDd+SPp+NRXWraZpmGmmjabbtAX5nf2AA56VPNKS5UR6FHVIbjyIbkKIJo0kXG4sT6cgDOcVyNzrN5rF8sENsgumaMszoGJyeRhj90AHseSa0Dqo8V3U0nlyR28IMaICRn1yQeM471jW8D2Wpg27Na7sRqVULnHLZPOAOx710042VnuaqN1udLDGtrcz3hji+WYwyJGwA2/LuP8AOr88MUsO9CwjYlN7AfIOoB45Poax9FtGYWl3OHmRjukQsclv19TWnJ5Qie8DgqrEMhPzDtnHHT8aiW45bjdEsp0lmVkV1gTYokyOSc88YGDnA+lbN1ZDUbOaFsMz22NwIVnYg8EdcDge2apaXeiaZleWSJ8N8q8j6nqM8/pitjT0srBn1FZf3bjAc42oDg4B7e9RJu5k207nK6H4w03R9VstJvcwNMNscgPyYPCk+nIrt7kTPFJLF5gaZCSQudqgDrzwcf415lrlje3emiXSfscN1cSMRczJl4owzHbvwdnfr9Kh8M/E2W0ZdP1G3fUrSGJkmukONzDOSAeo7djVzp82sRVE+dnbz6ZYTRyT3UkZtkTJtCVO5cZHQeuMYrd0K0tE0+1mgjkiKx7QgbOATnGBxxXF2PxC8PTtC9hYSs8pVShjXcADxznH/wCqrmratLqry22iXkUT+awnihkAkfjBAYkAH6enWs3GUvdKalJX6G5qN3HqerQaXbsJoUbzLplIIwnzbPqTjPsa0Hm02Z5UUxSzKmDAmC4xz06jk+lecfCLdLfajLNHJD5MeDvOOSx3Z49utd1aaGtt4nXVvLiknlgaN59x3dRxjoRgDnrSqQUHy3IemiMXXfE3yyWSFEzIIBNcHaqy9QCCO35dK1PC01xqdjDczXxMlvM8E0cYAVmUnvgHHQ46Zrl/iHo73vii2aO2Mu+EElHx8y5yW7ZwwOPatLwnqtxp2py6bqiPtu7gvHc9fMcqMggdBno3TtVuCcLx3HKPu3R0WsW08Usd7ZsCYRmS3YErMAc5A7OOxqhrmsfY/Dsl1cxeWzRHcNwOGx90Y6/Uemau6vfHT72OSeUx2qL8+ce/OO/auM1oXvieOKSOJhp27yoyx2sMnBkPt1/Cs4Qva+xVOPNa+xQWeXVriaXUrVftr20MVjHBIOFYDlG5w4IJPoOvGaveDWsdN1mWONbW8vHgYzSIFXJBQHGR0zVqLSdN8Oo9s3lzziLZ9rI/eEHAx7ADPT1qLwr4YsLrU98qPFfpA4IhlUL5bMpGQ3fI/WulST22LtywbOi1LUGm8U3MMdxCoRmAiZs/NnoVHXp696wb7UrGK+WISyefM2ZSBwGPoOcVv3+kz2/iqeSwgt/s8gkklkZz5m8t0HHTHvnmuf8A+EZMdyXvfIaaaXcluCS5Uejd+gznisk4XIg4nQ2FomnL5Et40hYs4CpnqSTkc8ZrhPHekWlz5WriNEcSqioVyHUYyCPqDn6fjXeXUiQWKq1w8JdwAUBBBxwq9evIx2qtrGlDULqO3mhmjt0hYK+QUXkcfWs4StLmYQa5ve2POJc2Njts9US5nWYFIhE6qRyWBJ4xnGOTWrHplrEba61fy7C4YBpGEpPzDkfM33T6gdeazYNNv01WGI2pxG+2RwAVIVuW9uAa6XxIbxblSpjtotnlfapV3InzhypHYsAoBPHFdDlrY1rJRSUdRunaettEsEMiXsDOZUkZQfmGOCe4yM/5xWbcquo3ctiyAFIV8syAB1bqd2PritXw/Kl9JeJKwEM0omjeMgCMsM4H1bk/UetYceo2o8WXdsIkednaPYcDew6kc9fbvUq9yqbvfmLmhyTW0bRmeZCshDR78fL1BP4Z/Ote8t1hjvE8uSVGGVdSOwyuCf4TkZxXDW3iM3XiNtNhskX94wScNksy/MCfbjHpzWunii/GsvFJb2sayKNpb5VjfHHXgDPY1Uotu5PLzXcTptFtksXlubmTywysPNP+rVeuOT3J/MVzd54jTWL1bCzhkbTUYy71Y5lIOBx6Z6Crl9Z6zrj7b66AVHJaAIUAAwNyqOpwTz0qXwhDp16uNOWJvnOWcb2wpxkt/ePGOe3FCsrylqyErPmZzNrexm3a5u9Yk08sCEgSEMNx+7uxnI45Pvirt1ot1f6LbF7YLNclfMCRgSsM9T/9fn1rqtX0vRoL1Z30+2W6Q4fapLKeCWAH061Ss1Et2ke5Su4/PIpxG24HZn6Y9PSq5+ZXRUZNasyIvA8WkWQutPe4hvVYN+9j6kdMEcDr+vWsePwrNZeIPtdujrEZd4keTaqN1IP4nj8K7W3M8sGLhfNd0EpRGKhJFwBtB7GtMxwppksxKhpGUzyzKcEA9D78frUczQKaSSaKVvBaafeTajqEt3BLKu3b1jY4AYf7SkYrWg8X2cTvDPBcKkYMYwAU4OMDnnp19K5OW/tr7XpbK43R2oRSkok+SUtydo/h/X+lY9zqNgkV5ELo3UA3xpvkI2t6heMnoM4/Cn7NS3K5FPWR2svjLTVSW7W1lmhU4dmK7c57cnnjpVS88Q32t6cz6XoE0U+cW85iLFGxgMCRgYz1rc8BeEbLQtLjkeJZr2ceYzuMhc9APTiuqJk89QijysYzu6H6elYucIv3UYOUU9jyGHRr/R7F7rxQz3VtI5LQyzsz54Awew/HFb+teIIf7L+z6dE0KGMOVDZxxnaMcD3rX+INvZHSklvZkjdW2xeY2FJ9/b1rz6Sz16fMmo2H2S3MpAlkkVonBxtII6L2Ge9axfOuaRvS5JKNyGXXo4IUmaLypGwdu4ksT0Hv09a1fhvdLea3d30tw8sk8TAxhVKptKLwD6gDn/69Z1jBfafplyPE8VjdWzTmOyRwGCbiNxGP4Rxx6+lWvhyduv33kFEjijaJkiTCBty9Cc57961Wq0FKalvserW9zPdXl3L8rWZYrH8vzkgkE/SpEeGeRjG8bunynBBZSe3qOxrHudLv7N7o6befu90hMUwCryxOVI6H3rJ/4Sf+znjtrrTpIZF+TcTkMcDo3cniuJw5m+UwVPm+E25rIeTLa/aVYlg0cbKo2Y9u5zz+X1pl3cizS4nK71SPJf7pYgck+nQcisNvGNvJdJGulzvc78ISQo5OBz6HNcXd+Mb7VNTlgkWSMBmhjSFhlX6gOvXHX8RzVRpSe5aptNKWlx+jeIJ7q01C6CSPO0uQqgbQByevbnt6c1u2erQXEci3SSQyyDdukYordAOOmP0rAvLS2gjt4LC4Zw6lpQyGOOJxnJyB357d+azoES+mcXsrxS+UoAwAGXjDbujD3z/Kt3G+qOlQi1ZvU7u3v9PsXFzPcQvcwqdiDG5hxhc9uQOcjp3rgBpFla6/Jqgeee4mdpkWbCiNm5yOuSCeM+man0+XT7e/eGeV5Uk+WORkBCNnrg9uf/rVd8Q2N1p88sEYWSZWHkgw7Qy5wTkd/wBKIpIapQUtdQh1U2zut3NGZdvliRYx5n/AjjPvV2HDMJXjSQySCESuvVm6BQevfiuXsJb+71C4ZdLVbG1QO0ijdl+wJ9z2wOOnetW9ubmy0y41Nji3lKuY4lDiMg8cduuc5yMVVlfQOdWbWhHHa30M99ceJNTRL63m8iGGG4UndnrgE7FA6ZwTnFP07xDF4d0+/MX2aMAyBBECHZwcKSMnHc56YFZ1xeyrp8/iOC2llury5WCW2dMJPxkkgdjt5BxzWo2h6ffRGNVaO1ljRplTDm3y2SNwHbGAaenU5leUbX2N/RJv7W05NYkhN5OY9kUCOvBI5BPYZ/lV2bRNqNefZJIJFyHhaX+InO4MD9a4eC+htPE91ZW9yLS0tYNun3MUhKvjGA/qTk+mDWzpPiTU5o54k1MvJbI8jq6AsVAycAru4PB9KlqV7xBe8r3Os0i3EMbSPLOJpS0aMy4O3n5uegHb6e9YviXWre/tBpWjXLyCJQjzMvyswGOv4cmsDw/rWu63Et1q4u0s3cIrxfIrevHp159qzrCz8Rahrlxa3NtMIbcM7MoChcZxjnBz69aFCzu2OHK2nLqPUanY6HfHVCtxHFMnkx7wxiODlif7pz06VyPhmybWPEgtWfa1xv8AJYAhRIQSv6967eW4mg1mS2LWk+nXcKqfPIYhtuM5znO4fTFXrW9fT4Yl0OKxtrhmCTXNwnzBmBwAegGR9ea016ClBtadDa8KeO30DydA8YRtDcw4iiuI8sHHRd3fOB17+1dne+MdEtYXZbtZ5E5MMX3+Dg5B6Y968ktv7UudegvNU077RPGgxIwzuwcKDz8xB5+b+XFWdG0e7F3dXFyst5sdria4aZeEHGOP5e/tWU6MG7smnRvvsaV3v+IEl5Heh7a2tvLCyJzsO7d07/KRnp7EVgO+v6X4c1XRblGbQ4nHkTlfMYnfxyO3c8cdK6HR7S2uZJzbaveMWQgrtKHP1/iwP/1VnTWVxZfLbXFxKWV3JBwXwudvPfg59sVUbXt0NpUYt3vsaMVlLqWlxacwhvLuzhAaOLgITggjPB6DP0q14F0S8l1y6juFESxxMSDJs+Ysp5GcHjvjpXG3OuNHbF9Pnd7+6Ty5ZgpVdnRgAQck8fka7T4bwalaalcx399atapCEgbeNzY2556kDIHtVq6IqJWsjrU1KwfxVcWV1Ir6hknYxXK5Pp1HABq5r2nwalo9xbtkK0ZKMvBVscEY71hvo0LeNLvVjavBdNNslkRTibaccAn2HYdK2da1eO0s0kgHmSu+2OMqQWbB9enbn/8AVXHNe8uUw1urHlWoWbadfnUJ7pxfrbLYw25IEaEYDSepUHnocHB7VIdf+x6jBaXtjvu7pWma6jhVWCAkbncAZPHoOxro9S0a0vr0apdxY1CMYaTOQpA/hQZHr1qhqC6CmrWthq13MZblG+zqisiZPQccDntW6knubXS1ObuPs91pDz3Oqpa28m+KOKKISsrDvxzjHX6+9RolvDoyBb261F4SALhlwoL9E25yMA5wc+lUrDQInvtSiId9Ih3LbRZ2yyPxjIIzgY5zgdOla/huw0jVZotMjvLhNQhY/aLSSMKiKD8ygjqQT696ttIFJ83NJ2K/hzSjqUn2iJZpLYLxNLHsy2egGckdOfUVt+GdP0/xdqF7aawdSabS5cLvm2LKrE4Jxz1GcZ7iu/s7GC3UpnMSgq0bZwPTHp3qC6+ypJFa22yGVxujcJwfQZ9TzgZ/lXO617pClUcly3OT8Z2cWixiKyaMfbhmdZMM7bcBWLdSBnHNVbbwrdtoAuLCYxXDL5xRuGcDPAGPrVs3FnceIZLjX71HisyA8si7I1IPCfTLZrrP7T0fWhc6fb6hDKzRFX8l8lQy9VPTIH1olKUUkaOr7NKK3PJI9OvtHuI78TM0F0SQ4+eNzgcZzjPsan8RazM3hR/7PsFWG8nWIhV2OgTHZT8xOAc5wM1PrCReG/D9poOh6ik9ws73TTXIz0IGAACo6Z57g461mtqEGp6kqy7Y9sZKv5O3zXxzjPTJGPxrpj72rIbUo2ehq6Rpl5pOp6S6wWpsjHH9qaQgmJjy6kEn5sbeB19B3sWOlDR/GH9oh7mNb6R1tmuBtPzrgttzlhz3wOlVNDlkm02DUbix8q6junijkLn5iB1APUc4rb8Sa02qW9kLvT4mv4GZUzJhFcgfMTwABwcZ9KUuZvQIwjZPdGJ5lp4qsNT0vUor6yS1m3/a0AZmccHKkYAwDx0FWr2Tz9AGnWd/cQGOEQpK33ivTBx14wB061S0Wae4E81xvSTGxklbf5jZHX34ycdiBV55C0oADStgj92o+X3I9PeqasbU6Sa5mO0fw5Da2FtLeuzQ2ylC7SAtJlslSvv25PFJrnh7TbyB762vfOsPtEUk9vEcMOSM+3X8qTxLHqt5EbeyRJY0wqqrbsn+I9u+aTw5ZS2TTRaltt/NjKMN/c9D6DkUdOa5Fr6dDpPiMt6fC1tbafFHA9zdKm5fugkEjAHfIrHj0qS18U2Vn9peOK9thE/mrwGwRycDqQDg4IzXX3+o6Hrmlww3Vw8BLqxRG2MknY59ieCKp694Pbet/Nqt5cRW6FnFzJk4CnG0gAdT6VlCXLo9NzKN07PQ0vCelaVcaPE0dpEzozRlj8zKQTnBrLvtJurLWYtQ+z28+nWok/fySfvIgFzkDHOcBePxrB0R7m00/VLmK6kt7e2TzJZOSMAE4wO/TtWVpN4jJNr81+Vs53KuDuTZ2+6M8cfQ0cru2mayg1NpyM/SfI1CdpEhjELS7iFPlkc9R6DJyR7133h6xgurlAqystvHJGJIm8zadyZXB4wSM5+tcnrSWtkun3WkTy3s9+WKOY1WMDoeCOvOMY+tdN4d1l/+Eja3tdKmuGFkJGeEGIFiV3cBeuc59611fQdacHHe5uv4y0+XVrmOzs7iWYsxeUAbVxkYyD/sn3OPTmsrWLyaWGS9IxK6nytw27B2X+pFZ58QxXHi3VNJ05XSe2V5GI3KpTJJABz2PXjNalpbx/Zo3gvBOsmGSJ/nKvjHXJ4PNYuKi72MoJLY43VpdXsr6yGlLMqC0kuZ7sOTHc4GcHPAIxjAycnrW1qeq2th4e/tCVDNG/zqpXDjgZKn19+OQKXVlGkRxafdJqEFrMQi2ysu0jOR+8ySq5LZH1rj9Uu7m6vxdXbKNKMZxFEVIWDcFK7T1JJzzz9MVaXOKzjr3HaJ4bsru4t/Ea6y5t7dhNsmiPmPsOdrNn0GCea3PDd7otn4tSC3aP7deIJTKBkOGGdobt69BV4adbnwlDpNsszadNE8okY7WduCq+y456VzNlDa+G/D8t/eabBc6lbNstZHYl0BUg85x8oOQf8AGl8Sdw5XGN0j1W3Saynu57i5maIjIjYFguMkndknGP0rl9L8SzXV4IJYESOQeVH+86PuOB+ZH0/loeB9Xi1Dw1YzXJdt8TRoZiMkKcHIxz+vH1rPudCj07UQUvYTpMRN0I3OWQghiO5wNvXPfH1xjFJtSFHUwfHl7bX2qSaKsMsktwoYODgqxG4KB36DvnOO1Zukwx6dYS22wWMgxGbmXBkCtwRnjHXPHYVNdeJbTULprqSMefG6hJIo/wB4V5+Uk/gPpxVGC6nu7220r7Db3K3DLuMilnUOeeQeOOfwz3rpUbKxonGMeaWpt+EfBepXH2nNxA1lKylblGLdOQ0fQ84HJ/Wush+HemKvmXFxd3Eq/NmSUoFPUkAcZP8A9euvt/KtkS3tYBHEm2OMABRt/wAAKg1kQzW4jll2HcGC78FsDofY9K5HWnJ7mPO9Ecnf+A4mCPpl48Y2keXcgMrfj1H5GuY1C2ktiNNvrApczS7UbcWUcHG3soPTPfGDXrtk0MlpEbdkMOwKuw/Lj2xWB4iW7e+eX7KhhtY98UvBycHcp7+2Onf6XTqu9maQqybtI4n7GiYEySW6y8BHjxtB7+pXAOTV3w54Ti0ppr+/vnvtRuA0TAfIkY6kAH2x+A4qSW4abVLY20nn2cqgxFn38Z6c+nPHI7Vt66XhM62ojwhE24cO3y9Pb6VrKT2NKjcrGXHayW8wWC22XCcpO5Dgcg8nqOh4rSKtrtjqlldrGsjxnAjAyrD9ef5VnRXixPdSarcCO3RQ7uOuTjoO+cYH0rd8M6tp2pRTTaaS9xgiQyjBCc4B/KlO9r2MXK2pxkmgahYHzYfstxuiYRRStt8x9pxjP0pttda4NNNpr1wbd5SNtv5uQFyDyBk9B3puvTm51PybmdpbW1ciEIm3yz9e5Gay75dRUJLp1t9ojDCLzXYYRR6nuelaxTtqdmsmqkjpY722s/DN3FeIzRyyEsofaXBGNvuPWsyHw/f+IbGGd7XydMjQZBOzKL/dUfT6VDFZXI0ZZpQklwMERqCQB3Kg9MCum0rxp5WkpFqCkOse2GTBImwOVPo2MVErr4RSuk5QV7mFYS2viW2VbWGOKPTkLJEGw+CSc7uo5wT9BXUeD9Ua3vDa3EMVsLWEwIifMCAVOeTgnJ6+9cm93bW2lT3HhJGS7ndjKtwgVgB1VeecEgnPB4qXwlqkFjrRgubeV5ZIJJGGcbW3oG6+9Xq3oYJR5G5I7fU7WcaleNZtGyTSlHkcjO3J4yMHA5GD0rnrHTLiZZY7ucxvHMWRohtDdRhfTA9qiMWpWetag10wjjEzsiF9pJ3nqO3HIJ9ax7zV9TbW3treZIWmk3LbckSDOCM44JPOc98cYrPleyY02ldHR6fZlk+0S+ZIxcZNxmRih759en8qx7yZ5tX1K3j0h2+zxHyZZYCI5mGCQv8Ae7nn0rotXmWz+yWlvZLf6g21R5pKovTqBx1P15rO1yym1qwj026eXRr+NhcK1q3yuoIDbenTPI+h9KhPqxOo73Rz/ge8/tWW5udRdort/vBxtVh2b0HYYHStLQb3w74lnvoJmmvIrNdyxSlk81ueVBIJxt74/KsjTLfVP7evYnO14/uSugDD3IH3g3AqtPpYudZnk17TbfQ7iFz5UqfuFuGyf4f4vXKnHIzVuKfUdRvRXOm8S6Ho954q0m/h1uGFkVI47JTwUA+uV/rVCWW182dreF57YboZsy5wGyvbsR3rj7bT72z8SalLPbB7kwF4ZmfhXbABXseCce1bXgqRLHSdXt7q4P22aRMb+BncQRuPoBnOTT5bLe5NJuLs1uPOiadZwyW9j55QkTSvI6k56DJAA2jOfXmr3w0SG98Qws0FsJLC2lBkjycsz4DEnv16dqXXfFYstM/s+ytoZ7nUJ1tyGACqoAGRjqST1ro/D7Wmla7GILVLa2mBikkBypc9Ap9M1Mm+Vjla3Ilax1akm4juFdrmJztC/wDPPcTyPbt7Cua8QadYyXuv3Utqs1xDZqwLocZO79cAAV0+t3ltpumT3U8MskIwGESbm5IHtx+NchfW73sN5dWl1PAbwoCXOQygcceuMjPauel3MY66nVaVp8trbwCOcBfKQMuCfmA6jngHuMVLNcsLa5e5G1EJHykMGHY+30qgJrmCyEWmfvZGkKHe4IhPcc9celcR461I6ZocumNOWu7v940iyEFV9SD646D9KcYOcgt1MaG9uZ9QOl6o/k6xAzgW4TaPLGGTaR1IHOPQfWvQrC9j1GzdwEkmBKuOm7jnIJzx6D2rzfw+1zps1ousmJ79lIjuJ1y8URGMFz0GAT7dK1ojA4N5YzszZYo0bgo4z0Hr/MeldUo3N4rnjaT1OtvNHEumyQRWyOSFaPzMkOfQ+3XjtxVCG3n0C0up5FjTUDG7KkR+6W4G4A9vlAHTr7msuK88QMhF0s1qjpkM+cOeuM49PpUIkmnbaYnlQEO4HQkdgev8+lJRezY40299jMhuJksLO11e3e5keRgGgUBUHYscc55ziukt1LyFkwI4l+7gfeI46e3fviuS1uxbWbXyLS4eGaRwOSSmzJJGB3ziu2sbR9It4o5knaN4o42cxsNjbQM5xgc46elXJoJc0fd6GP4h8y5tTFGYoo0ypeJSQoPK+nfrVG2kuLy1OlCRGUyFmOBiPA/hYeoFdDLayb2jC7kYFW456evQ9uRVOWaDToCzgQxxKGcnAGAeh+n501LSwk7O6OU1q3u7HxCLePY9sqgSEjjIGSTXpHwgSzXSJDqsSSyLJIqMybm6qWPrgkqfSuejOk3N9aSS+ZNLNCJ5JZH+QDPAA7gAGul8O69a22peUgjdpo5JwYwFXGYweDyOw/Co30HXd4XMTxLaa7P4yna1j32bSZjuCxaJEyC7Oeh/iBU9vXisbRZjeeKL68igmNtbzfuA3QqGOOvtWrDfKuuX1vBcK1uZmEjLJvQK7MNxH1HI9qu3eian/YTTaTfqsaE5hCKPNGcfexwT1/KlKXLoyYpLruVfFNraX1zcS3jT/YbhSDNbEjYMgqSB24IPofSpfDsF1NrC/ZmhGkWDMizfNmRGA4Ysck56k8fKPeorTTJYbK3b+12tbiZSz5YMfXnnn0zTNdg1eCwS3F9Le2shC/JlSPqv5Vm725R+zi5WTL3ibUZIdZs9trm18rmVW3EnpgY+uf8A9VcJdaKb3xamkXNlezNGpJvriQgqPvbunIGcAdTmuiubi+i8QQaZJpQfSpbUN9pKliXZcZVs8YIxjPfNdB4TsTYnUDapuvZIwiea2eByAT2ySfwFO/JG6JlZr0NPTLa2tXSx0pJZrjZmaeRd2B0+Zzxu9FzVy7tLOa9gthAsucrKAgIIKnq2OvSuRXVYr+8ktdduLpEeQ20YiZlhQYGXLJgMxIYc8DFb/hK2054L+205f9HjlZI23MflyejE5685+lZSi1qyG3uzmfEfhrULC/v9RtoYhEifufK4YEqV5HQEHB4/nXF2eja/fTRSX17PbQxuoCGcP8pPXGegHrXt2jiZFWK4hdbdVOySWTe0rZOSe/PUV5t4ivksNdmgitvPhM7xyfeDgDkAH27YzmtaU2/dKup/H0NLw/q9xoNq+m3muJqN8zlh9oGEWLbnk9egJ44qr/wncUTQww6dDNZ7TIWjk+SNeSTgjoPfHUYrmdR/sK9uL+eKQtPbobdJlZkbcwA5Q8MOqg/zpV8Lac9hpKTG6sp1bZcFoiFmVjwQzDAI/EH61fJHdoTi/sHQp4u1HVbATwBLCCRjGskKFzgHBPByTj6VzM+lWh8XWcl5fzQi9USw/aYSWPzHCu27HOOvPGKnmnh0XWdJ0s2s0+mRsbia4d2DOrHl2xx8oA45qt4j1L7Rd2qx2keo6Iz+ZG8e7IcffG7OVGcEqfYiqSS+Eltctrao7yTUNP1HTgz3GmvZtuSV7g8njaUDZ4PfH+TgJaaD4UtVmlEyx3kgAMTtIu5eVwp7fMRn0zVJND029WGyvbeaO3GJIo4ZMYPdixPfABzWzqBa3EKzrHAsQRYFkkVi6r0wTnPA6ila2iN/Zu+tiOSF7PWdYv59QnuPtY/49HB2xc5BB6YGcAjBAx3pmrrqs+hfbNDU3twG2zwRyMT5fHzBc5b8OmOBSG8S4ilu9yqhJjYlhyTzgZ78/rVTVLK+sb9df8JrN57EJJayucwjGMhcfMp9jgU7WJqRVONoE9n4ikfxDBpWladNbTzWymQ7uY8jcVXsMYIz1FPt9Zvlju47q5t9kx2PbXm5Szh24d8gDAA4A5BHFaGv3sGn2cWqyusWsWdmPOSPGZ3fG5APYnNc1qmmNrlrDqkaLZ3OYvtSXKlm3sSAEAHptODjginGz3Ri236mvY+KY3itbexX/TZpHMaxKzIg544PIPbpXXW/hZ9Rjtk1u9VmIy0KABnXqQx7847dqytG0V7a8VLqPyZFcrazLHsj24yFyvH3mOQetcLrt5MLi3n1IXjXUs8jLJEwCccYIHcE4PHSptzP3WXKbSPYNY8K2D2kcum28cUlupwiHAdO6+1YvgK1tZdW3QrE0ptnJdm+YLvT5cjPQg/jVr4X+dNpEt/fMWO4xo5Y8oOvt1JGfasj4NmCG41b7NcLcxNNIy7RtKqWGBlsZ9aULxbjfYXtJWcGZt1pVvoXiS4ZLeZUeZxNwcuWZuOf4Twc+1a2m30dxagFhGoYFjk4cjHGOnQCuh1eJdYluYpD5kMkkmJ16RsGPBIPTiuQhjiuNSbSIYjZqcrLMMFdxXrzxg/1ocr7m8EnHToUdQtfPXUReTIjrMiQSIVkI3HduC5ywwQTzj8q6nw55slhBE/zqkuWZjtymBhjgegrD1C507wrrEWnXtvczNdooR44N+cMcYPUnOP0q7e3d7qAm0rR7O4gMpUXE0pBCDP3RjjpUz95abGSV3oUddS91PTLk6fI0ybneBVGWeMHnaB/wHGO1S+H9T1DTdHivddWWOFZRbqZ1KSsh7c9cHv9fSsXxK194d0rU7d3lxMDBDPG+xoW4LOpx/FwMZA4Nc9HDnR7KCS/mljcGRpJ32Rg7sbFJJHbj69KtRurdBu7lbyPV7S10G6jjL3K3EUwBYK3yMASQv8AP07561buNU022IXS7cPcEH/VHYgHIyzdNoz/AIV5foF09zqeoWSWzvZ2iN84yScHaPbJOe1beh2qak7RjEGG3O7ZAVR97j8DWcqfdlxhGS5my/4x169bQIxFcW1sykbUtmJLEcAFxwvbjqcda4fw14ojtJXvbqB5ZPkR7dOAz5J8wnnDDkCu7g8QWU+kXp0ZbW90+LIlDRbT0JGQ3XOOpxnFcZouqayYNJNrFprC7umI+SJZTHuChMHBxndggZ96uCsrWMZtJprYs6vp+m6rY38mg+QDK6S3DB8sjk8DH1J6eprTGsaouif2Loeo2+uXFjEWvEuICWUA8BCeGCkgc/yq1Fptj4enuf7NtGhaWRN/mv5hkPOVweFUe3p61ma9Nd6feWt5Fp2nizu1MczW2Y2f5+d5H3s7e+epyKN7FSg+VO2vkPsmklhtb64AW/aLyTaclSPUL3GMcfWrNjd6Da6Surx284tftJgjjhQZWT727b0IwvP1qtqs2qaZ4itG0jTSIrlAnnRx5RGb5chugKj8PanWmni38P3lh4hulmtILsTpLHLsfdsI27jjBYE+vFNu45Sa0j0Jb3zNaig1CO4jljuXdVcIImUKeUYeucYzWHFo91q+ox/27AjWFrEfJEcmHf8AiVSRkgY6k46VqaNfXl7byQWuk29hb2qmS3uZmdsyEkkhm4ZjkkH+lT6C+ppCZ2v1upolkl8ozKyM5XhWPYAnP0zT2TBz54qMuhj3WnyHTA+n2dolzbFpfLLFzKAOFC5zkDjFbQlfWtPhuLEm0kli5jfAMLZwRg8jpxWnpET6voMt9q8i6Yw3NE8MQQsoHJHQ8+gNWbnQNZim0lIIrO50xkEl/cT8yvg7gOeRx0x36mpdSzsxuUV7y69DjtaTTrSXS21KSdi0m3fAuScdce30qG2uNS065j1LXJpodBEyobdMHzSudqqv8OFAyTg8dc11ut/2KbnT7GWKMauR9pURrtSMnnGRxux/KqF1p97CXRlDSlhKyschScYOeVPFaKV1qJx53dMr6HbeIrvVJTcO1tpk7LJCgZQphzn5l/h4xz1yan8Xafp+nXsUEE8MH2rH7rqC2cZGTwTnt35qpJos51prn+0r2GMklUibIY9cHngH3BrE1u2hiuY77W0uY0hIMYXB3jI2qRnpxnrSW4KEops6KTxaNEhsND0qzuJLR3aGZpjnOTg4C/XNdp4B8Prpl2UsQ0ds0LMGyxDHcPQg8YriPBgvY7ue8uJY5/OTMTqwyfov8PTB6V02iakb/wAQSRQxytDDAwUqcKcsh6Z+tCi07IiSWrj1L1tp66hpV2+kTXMEUs06MHxknewJGDzzXnCveWtnfjUbn7VDDIUtyh+diOoPfAGOv4V3/jbxBJpOjXUFvattMzw74fkEabjnt+HFcR4bWSR0RfM+w3SeeHlUfd5BUHt6VML6tmlNu+pFZapq18qxJNcybCpRVB+QnPy+vpz2rsdK8L6tBK7SXZsllAzhuSSOeB6cd61fD9laaNd3VzOqoOIkKqP3YxnGR/npUosZ5dSWeS6mjglG6OIMCWPQHPUcE8VnOfRFOo17qKOp+HpZmhtRdm5YuPlZs7RjJ3A9RxXEeNdJu7Z7hjFGkKKS4+8gC8gAY4P0r125Men2sn9nwxGeOPc0fRtp7nv1Fc7rv2W/0W3W4QRi7lLS7V49iRzx0z+NKFR38iYVHL3WeeaBeG5uHlspM2LShTK4CGR8Zw47n06+1dNNrVrZadcPbTRyzW4Cz+XksNzDPHXaMYOO5xms6ew0xxHp80E8cejBrnyLZBGl0zjP3u5yB7/hXNaLqlpDHqur3lrKGZhGkFu5WMK/LEhh22jrwTWlkxyquyjI6LTdS0qHw/f7bS1s40dMQqCTK5HDHPsRxzjms9vDFlrrNdi++wX3/LVXfbHGACARxznjjPHPWotS1OyW5sDptpIgdlP2jAUR88fL06jPOOR7VPp5a3vbhSq3ceS3P3ck44HuarlaWg4wjP3WWNLtLXQdOa0F+l0DceZJPtIjjyOiA5Y9OTTdBU31zeC+1aK+Es6DZFu2R8tnBIGOfT05rUGjreLKt+77t4LooAVBzkH/AAqrF4Vm0eY3+lXoltHxFMJAyvCD0IAzkds/n60r92OcYx5Yw6HU6vezaDYQw28QuEU42sobzCcfKP8APauM8aaZPrfiK0s7IyTacjqZreFTujyeW6cnH4jOMV3WmSPrk7R2aECMDzLhsBkGMYXtuP6Cuh0e3+xS3tsti0ccQDLNlSLhmGSR3z2Oax5+TpqYzSStI8wn0yfUtOisptOuLCztQ6WspBYquPuMCOT1wexNZ3w40vVIzq1pKo0y1Qb2nk/1isBwo9uucevWvR9W8R6RoU9yl/ILeWRUYlFLmMkZ2Njj3+lQizj8SaPHJLPYuHU4mtydzH/aBHp2P6VSm7arQHySlfY4O+ubPxHolm93PPAdIuDBHNHID9oz3x2Py9e1aGueIb/Uo7HQ7O/ls9SuwssUik7HTLYDHtnHUD+dULrSYNK017W2W3aFZRKZELMWboMjOVIrU0ld8NrCJjPJChWBEtw0kStnPJ7dRx7itLLoU6Vo3ZVtdRtLvxPDaXMUUl04jjgntxkTSDh3O3pkn2xVjxp4n1DTZo7TTobYw+e1qEWISMWU4wR2yeg7j61o6NoelwQQtoY8toGbzEmYFlfkbvXqCPTpWktjPJdPPFNKgYjO2JXDsq7d2WBw+FHPtSbV9SJJtbmZ/pAeQalFGktoR5nkn5BlQRnPIPPT/GsjWIZrm3gjkgtp7cKisSQSerfNjpxn9ea0dZnjkmbTLBQsKyeZJK0m5pX4yWY9QPwHHtWG1jZ2l3c3iq0skwwLaN/3cu7g5IycYPFUlc6Ipxjtcitrm/tr+a60+W2bSY4zEsdu6squcADHXOfXsTXSeAL+WTxBcQvaeWiWxYblG0HevTPryaq6Bp1tDpN8bGxS0kkOyX/SC4dgdyrlunOOeMVv/DC21FPEN8+qeUyGAiOJQr+WMpjnHf19qtPcwl7sdShF4sTU9evNMFt5RWSZN8g3oNjEsX4GAcYz9KzYLpdTkmkhlj+zq5TcuVTacfkP/rVe1q6mstKsLi2ZY7i5mKzS7AXkHmsMMxGSMdq4Txsi6f8AEO3tbIeRboISqJwASASfzqEl0CnVcEn3PVdAeNytjIWZpUEh+bIyOhz2rVt4S0qq6SGSJjiY42nP4546157psjvNIWZiyZKnPIO2uktdQurK3t/s0uzNvG5+UHkscnmsZwfQ3rUrO50rwG1a6up8LcFAk0nqn8PPoMn868/sNb0rVppmso5RLaOsaSbj88ecl/xzit7w9q17qGrIL2YSrKCjqUUBhnuAMVHfaVYW2q3VtbWkMEMturOsS7OQeMY6dO1OMeVtMyjFxkiT+x5Zbhi2EjJJUFs8+3HTj86wl8P3NvozNdt9rS5mHlsfvom7ke+cd+BXV667WAgFoxjzGgPfg49fpXJ2V7dL45aITyeVHZoFTd8oyyk8dO5/Oqi5NXLTaSZUsLTR3nlt7qzleDd8zGTEgwcZz+nHrVRbKODVNOhiR4ra3ZwGYnEhBJzjPfIzn0ro/EkaReIbry1Vd6o7ADgsc5P6CjxKAuowSAAP5wXIHbKj+gq0/wATf2cW0zO1rWtROora6ZAkuJArrtxvY/ewe5wa6aKya30K/DJJFHj5jgMFwwODyearafEg1fT1CjEpAf8A2vm7/lXS+KAP7AkkAAdgyEgYyOazm7Wijnk0pJEWi2DW3h43MCSb2lNx5MJyZcHG0/Wthri4lt4Wt4yZ5AGaIjIjyCfmPGD7UmgE/wBm2wycFnTj0BNaO0G0UHuBn36VyyeuphOV5Ns8jvbKBrPVLLV4ZrjUkkabaLdnXzMkAqyjkYwDk/4V2nhfw9Hpcal4SZrz95LhcImFAAx27DArpLGGNYVdUUMc5IHvUelyPL5pkdmIcqMntxVzquSsglK555qvhnWB4og/0yA6ZLM0joYgCowNuT+Hb+tWPsU2japcTxW0NxdxxgJI+35gP7pONp46c10fjZQ1qobkeZGMfUsDWb4Lnk1A3EV45lSPYFDdgd2R+grWM243Zpb3OZlfw9pjiaXUJldZLjLGN+AuTlhnHI4OK5W4sbmPUb1bfUMLIHeOEzfNKgJLHGcdjgj09q9ZvreKK3jijQKnzDA/3T3rxXXrWC78Z2oniQhIXhUKNoCBSAOMeprSi3UdyVU5ehjWWmXWpvqd1YNJqFvsNpOquUWNW5zu6YGO3tnrVy+0BTYabYxSpa7CA++XdyexwM4+bOcYr1LwtpdlaabYafb26JZyGUyRdQ/X73c/jWvpWl2VnPFJbW0ccmXG4Dkjg05VrFJpXclueWeIfBmsXE1s9zeRpptuoBWCRnVNuM4AHLHrk9a1fCup3t/4yvJrm3i2m0wkKEgRgMuM4x83rnv7V6PrDmPw3eSR4V/IZsgDriuB+BQ/te5vDqOZzGjBSTgjJTuOv40UqvNFyfQybVrn/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several&nbsp;\"lacunar cells\" are present. They are characterized by&nbsp;multilobated nuclei, small nucleoli, and abundant, pale cytoplasm that often \"retracts\" during tissue fixation and sectioning, leaving the nucleus in what appears to be an empty space (lacune). \"Mummified cells\" are neoplastic cells that contain condensed cytoplasm and pyknotic reddish nuclei&nbsp;. A \"mummified\" Reed-Sternberg cell is in the upper left corner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al, Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al, (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38737=[""].join("\n");
var outline_f37_53_38737=null;
var title_f37_53_38738="Patient information: Colic (The Basics)";
var content_f37_53_38738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15897\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/7/8309\">",
"         How to swaddle a baby",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/33/6675\">",
"          Measuring rectal temperature",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/0/2059\">",
"           Symptoms of increased muscle tone in babies with colic",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/63/29691\">",
"            Tips for reducing colic",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/2/24610\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/27/35250\">",
"         Patient information: Food allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/49/26386\">",
"         Patient information: Poor weight gain in babies and children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/16/16643\">",
"         Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/7/1140\">",
"         Patient information: Colic (excessive crying) in infants (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/23/37235\">",
"         Patient information: Fever in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Colic (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/colic-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H32077971\">",
"      <span class=\"h1\">",
"       What is colic?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Colic is the term doctors use when babies cry much more than usual for no obvious reason during their first 3 months.",
"     </p>",
"     <p>",
"      It is normal for babies to cry up to 2 hours a day. Babies with colic usually cry more than 3 hours a day, on more than 3 days a week. Bouts of colic usually start suddenly and happen in the evening.",
"     </p>",
"     <p>",
"      Colic usually goes away on its own when a baby is 3 or 4 months old. But sometimes it lasts a few months longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32077978\">",
"      <span class=\"h1\">",
"       What else besides colic can make a baby cry more than usual?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Babies can cry more than usual when they are hurt, sick, hungry, too hot or cold, or too tired. Babies can also cry more than usual if they are allergic to their formula or to foods in their mother&rsquo;s breast milk. (The food that a woman eats is passed to her baby through her breast milk.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32077985\">",
"      <span class=\"h1\">",
"       How is colic different from normal crying?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Colic is different because:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The crying in colic is louder and more high-pitched &ndash; Babies often sound as if they are screaming or in pain.",
"       </li>",
"       <li>",
"        Parents are often not able to comfort or soothe their baby during a bout of colic.",
"       </li>",
"       <li>",
"        A baby can have a hard belly, stiff arms, or arched back during a bout of colic (",
"        <a class=\"graphic graphic_table graphicRef76502 \" href=\"mobipreview.htm?2/0/2059\">",
"         table 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32077992\">",
"      <span class=\"h1\">",
"       Is there a test for colic?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if your baby has it by talking with you and doing an exam on your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32077999\">",
"      <span class=\"h1\">",
"       What can I do to stop my baby&rsquo;s crying?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors and nurses recommend trying different things to help stop your baby&rsquo;s crying (",
"      <a class=\"graphic graphic_table graphicRef69458 \" href=\"mobipreview.htm?28/63/29691\">",
"       table 2",
"      </a>",
"      ). For example, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use a bottle that keeps your baby from swallowing too much air",
"       </li>",
"       <li>",
"        Have your baby sit up during feedings",
"       </li>",
"       <li>",
"        Carry your baby more in your arms, a sling, or a front carrier",
"       </li>",
"       <li>",
"        Go for a car ride",
"       </li>",
"       <li>",
"        Give your baby a warm bath",
"       </li>",
"       <li>",
"        Put your baby in a baby swing",
"       </li>",
"       <li>",
"        Swaddle your baby (",
"        <a class=\"graphic graphic_figure graphicRef57880 \" href=\"mobipreview.htm?8/7/8309\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Put your baby near a clothes dryer or other source of background noise",
"       </li>",
"       <li>",
"        Massage your baby&rsquo;s belly",
"       </li>",
"       <li>",
"        Change your baby&rsquo;s formula or avoid eating certain foods if you breastfeed &ndash; Before trying these, be sure to talk with your doctor or nurse.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32078006\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse as soon as possible during the day or night if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Your baby is younger than 3 months old and has a fever &mdash; To see if your baby has a fever, take his or her temperature. The most accurate way to take a baby&rsquo;s temperature is to take a rectal temperature (",
"        <a class=\"graphic graphic_figure graphicRef74460 \" href=\"mobipreview.htm?6/33/6675\">",
"         figure 2",
"        </a>",
"        ). If your baby&rsquo;s rectal temperature is 100.4&deg;F (38&deg;C) or higher, then he or she has a fever.",
"       </li>",
"       <li>",
"        Your baby cries for longer than 2 hours without stopping",
"       </li>",
"       <li>",
"        You are afraid that you hurt your baby or shook your baby too hard",
"       </li>",
"       <li>",
"        Your baby refuses to eat or drink, is vomiting, or has bloody bowel movements",
"       </li>",
"       <li>",
"        Your baby is not responding to you or acting normally",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Call your doctor or nurse during regular office hours if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        You are worried about your baby&rsquo;s crying or don&rsquo;t know how to handle it",
"       </li>",
"       <li>",
"        Your baby spits up a lot after feedings, has diarrhea, or has trouble having bowel movements &mdash; These symptoms could mean that your baby is allergic to the formula or to certain foods.",
"       </li>",
"       <li>",
"        Your baby is older than 4 months and still having colic",
"       </li>",
"       <li>",
"        Your baby is not gaining weight normally",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32078013\">",
"      <span class=\"h1\">",
"       What if I need a break from my baby&rsquo;s crying?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Put your baby in a crib, bassinet, or other safe place for a few minutes while you take a break. Try to call a friend or relative for help. In the United States, there is also a parent help line (1-800-422-4453) that people can call any time.",
"     </p>",
"     <p>",
"      If you need a break, be sure to take one so that you don&rsquo;t hurt your baby. Shaking, hitting, or hurting a baby can cause serious brain problems, or even death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32078020\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/27/35250?source=see_link\">",
"       Patient information: Food allergy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/49/26386?source=see_link\">",
"       Patient information: Poor weight gain in babies and children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"       Patient information: Fever in children (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/7/1140?source=see_link\">",
"       Patient information: Colic (excessive crying) in infants (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/53/38738?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15897 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38738=[""].join("\n");
var outline_f37_53_38738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32077971\">",
"      What is colic?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32077978\">",
"      What else besides colic can make a baby cry more than usual?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32077985\">",
"      How is colic different from normal crying?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32077992\">",
"      Is there a test for colic?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32077999\">",
"      What can I do to stop my baby&rsquo;s crying?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32078006\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32078013\">",
"      What if I need a break from my baby&rsquo;s crying?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32078020\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/7/8309\">",
"      How to swaddle a baby",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/33/6675\">",
"       Measuring rectal temperature",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/0/2059\">",
"        Symptoms of increased muscle tone in babies with colic",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/63/29691\">",
"         Tips for reducing colic",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/7/1140?source=related_link\">",
"      Patient information: Colic (excessive crying) in infants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/27/35250?source=related_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/49/26386?source=related_link\">",
"      Patient information: Poor weight gain in babies and children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_53_38739="Glycerin: Patient drug information";
var content_f37_53_38739=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glycerin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/32/14852?source=see_link\">",
"     see \"Glycerin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/10/26787?source=see_link\">",
"     see \"Glycerin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet&reg; Glycerin Suppositories [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Liquid Glycerin [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Glycerin Suppositories [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Liquid Glycerin Suppositories [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Dry Mouth [OTC];",
"     </li>",
"     <li>",
"      Sani-Supp&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dry mouth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glycerin or any other part of the drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly cramps.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding from rectum or rectal pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696194",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use oral gel on the tongue and inside the mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using this drug for hard stools (constipation), drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store suppositories in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699309",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect suppositories from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699531",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store oral gel at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11960 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FE8AB3007C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38739=[""].join("\n");
var outline_f37_53_38739=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176849\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019591\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019590\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019595\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019596\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019598\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019593\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019594\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019599\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019600\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/32/14852?source=related_link\">",
"      Glycerin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/10/26787?source=related_link\">",
"      Glycerin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_53_38740="CT imaging findings";
var content_f37_53_38740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan showing typical findings of a presenting patient with malignant peritoneal mesothelioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 592px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows medial displacement of the liver and Panel C shows compression of the rectosigmoid in the pelvis. Panel B shows diffuse ascites and shortened mesentery due to malignant infiltration of tissues.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. H Richard Alexander, Jr., as published for the National Institutes of Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38740=[""].join("\n");
var outline_f37_53_38740=null;
var title_f37_53_38741="Condyloma acuminatum2";
var content_f37_53_38741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar condyloma acuminatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38741=[""].join("\n");
var outline_f37_53_38741=null;
var title_f37_53_38742="Hyponatremia in patients with heart failure";
var content_f37_53_38742=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyponatremia in patients with heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38742/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38742/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38742/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38742/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38742/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38742/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38742/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/53/38742/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia can develop in patients with severe myocardial dysfunction. Issues related to hyponatremia in heart failure will be reviewed here. An overview of the treatment of hyponatremia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like most other causes of hyponatremia, heart failure impairs the ability to excrete ingested water by increasing antidiuretic hormone levels. When cardiac output and systemic blood pressure are reduced, \"hypovolemic\" hormones, such as renin (with a subsequent increase in angiotensin II formation), antidiuretic hormone (ADH), and norepinephrine, respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although edematous patients with heart failure have increased plasma and extracellular fluid volumes, the body perceives volume depletion (reduced effective arterial blood volume) since the low cardiac output decreases the pressure perfusing the baroreceptors in the carotid sinus and the renal afferent arteriole.",
"   </p>",
"   <p>",
"    The degree of neurohumoral activation is generally related to the severity of cardiac dysfunction, as assessed by left ventricular ejection fraction or functional class [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/2\">",
"     2",
"    </a>",
"    ]. The neurohumoral changes limit both sodium and water excretion in an attempt to return perfusion pressure to normal. ADH release directly enhances water reabsorption in the collecting tubules, whereas angiotensin II and norepinephrine limit distal water delivery (and thereby water excretion) by lowering the glomerular filtration rate (due to a marked reduction in renal perfusion) and by increasing proximal sodium and water reabsorption. In addition, both the low cardiac output and high angiotensin II levels are potent stimuli to thirst, leading to enhanced water intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREDICTOR OF ADVERSE PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both antidiuretic hormone (ADH) release and the associated reduction in the serum sodium concentration",
"    <strong>",
"     parallel the severity",
"    </strong>",
"    of the heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/1\">",
"     1",
"    </a>",
"    ]. This relationship has prognostic importance since patient survival is significantly reduced (in comparison to normonatremic patients) once the serum sodium concentration falls below 137",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef55554 \" href=\"mobipreview.htm?29/6/29805\">",
"     figure 1",
"    </a>",
"    ), and even mild hyponatremia is associated with an adverse prognosis following an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A similar inverse correlation exists between patient survival and the degree of elevation in serum norepinephrine levels (",
"    <a class=\"graphic graphic_figure graphicRef62001 \" href=\"mobipreview.htm?42/52/43853\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=see_link&amp;anchor=H15#H15\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Neurohumoral activation and heart rate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients whose serum sodium levels fall below 125",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    solely as a result of heart failure usually have near end-stage disease. Patients with heart failure who have this severity of hyponatremia also frequently have hyperkalemia. Distal sodium and water delivery are so low in advanced cardiac disease that potassium excretion (primarily dependent upon distal potassium secretion) falls below the level of intake.",
"   </p>",
"   <p>",
"    In addition to its long-term prognostic value, hyponatremia is an adverse predictor of short-term outcomes in patients who are hospitalized for worsening heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. This was illustrated in a post-hoc analysis from the Outcomes of a Prospective Trial of Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     Milrinone",
"    </a>",
"    for Exacerbations of Chronic Heart Failure (OPTIME-CHF) trial of milrinone therapy in 949 such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients in the lowest quintile of serum sodium (mean 134",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [range 132 to 135",
"    <span class=\"nowrap\">",
"     meq/L])",
"    </span>",
"    had significant increases in mortality both in-hospital (5.9 versus 1.0 to 2.3 percent in the other quartiles) and at 30 days (15.9 versus 6.4 to 7.8 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyponatremic patients are also at increased risk for worsening of cardiac and renal function after the administration of a Nonsteroidal anti-inflammatory drugs (NSAID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/3\">",
"     3",
"    </a>",
"    ]. In this setting of advanced heart failure and a high level of circulating vasoconstrictors, there is increased renal secretion of vasodilator prostaglandins which act to preserve renal perfusion and to lower systemic vascular resistance. Decreasing prostaglandin synthesis with a NSAID in such a patient is likely to cause renal ischemia, a rise in the serum creatinine concentration, and a fall in cardiac output due to increased afterload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia in patients with heart failure usually develops slowly (paralleling the rate of progression of the heart disease) and produces no obvious symptoms until the serum sodium concentration falls below 120",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Such patients have severe heart disease and a poor prognosis. Similar findings have been noted in patients with cirrhosis, which is also associated with hormonal activation due to a reduction in effective arterial blood volume. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17608?source=see_link\">",
"     \"Hyponatremia in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is possible that some patients with chronic moderate hyponatremia (serum sodium 120 to 129",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    have subtle neurologic manifestations that may be improved by gradually raising the serum sodium. These include reduced scores on tests of mental, social, and physical functioning and, in elderly patients, unsteadiness and falls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=see_link&amp;anchor=H6#H6\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Subtle manifestations in mild to moderate chronic hyponatremia'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Vasopressin-receptor antagonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is",
"    <strong>",
"     no",
"    </strong>",
"    evidence that correction of hyponatremia improves the hemodynamic abnormalities associated with the severe underlying chronic heart failure or that it improves clinical outcomes. Thus, the main indications for specific therapy to correct hyponatremia are a serum sodium concentration below 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (severe hyponatremia)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of symptoms that might be due to hyponatremia. As noted above, the severity of hyponatremia parallels the severity of the heart failure, and a serum sodium concentration below 125",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    represents near end-stage disease (",
"    <a class=\"graphic graphic_figure graphicRef55554 \" href=\"mobipreview.htm?29/6/29805\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Predictor of adverse prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fluid restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restricting fluid intake is the mainstay of therapy in hyponatremic patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients with severely noncompliant hearts (ie, diastolic dysfunction), restricting water intake may have a second benefit, minimizing acute increases in intravascular volume that can promote the development of pulmonary congestion.",
"   </p>",
"   <p>",
"    Despite these potential benefits, significantly limiting water intake is often not well tolerated in heart-failure patients because the reduction in tissue perfusion that enhances antidiuretic hormone (ADH) release also stimulates thirst. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     ACE inhibitors and loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with heart failure are typically treated with angiotensin inhibition with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) and a loop diuretic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These therapies may raise the serum sodium concentration via one or more of the following mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACE inhibitors and ARBs improve cardiac function. The associated increase in cardiac output following angiotensin inhibition can diminish the release of ADH and norepinephrine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ACE inhibitors (via the local generation of prostaglandins) appear to antagonize the effect of ADH on the collecting tubules, thereby decreasing water reabsorption at this site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Loop diuretics decrease the concentration gradient in the renal medulla, thereby reducing the driving force for water reabsorption in the collecting duct.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increment in cardiac output and fall in angiotensin II levels may also reduce the sensation of thirst, thereby making the patient more comfortable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vasopressin-receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple receptors for vasopressin (ADH): the V1a, V1b, and V2 receptors. The V2 receptors primarily mediate the antidiuretic response, while V1a and V1b receptors principally mediate vasoconstriction and adrenocorticotropin release, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vasopressin-receptor antagonists produce a selective water diuresis without affecting sodium and potassium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The ensuing loss of free water will tend to correct the hyponatremia. Thirst increases significantly with these agents, which may limit the rise in serum sodium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Vasopressin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some oral formulations, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    , satavaptan, and lixivaptan, are selective for the V2 receptor, while an intravenous agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/17/18711?source=see_link\">",
"     conivaptan",
"    </a>",
"    , blocks both the V2 and V1a receptors. Only tolvaptan and conivaptan are currently available in the United States; both are approved for the treatment of hyponatremia in patients with heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with heart failure,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/17/18711?source=see_link\">",
"     conivaptan",
"    </a>",
"    produces a water diuresis, raises the serum sodium concentration, and, via blockade of the V1a receptors, diminishes afterload, possibly improving systemic hemodynamics in patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/16\">",
"     16",
"    </a>",
"    ]. It may be useful in heart-failure patients with symptomatic hyponatremia and as part of a diuretic regimen in managing hyponatremic patients with fluid overload. The safety and efficacy of conivaptan as a treatment for heart failure in patients without hyponatremia have",
"    <strong>",
"     not",
"    </strong>",
"    been established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18809?source=see_link&amp;anchor=H12#H12\">",
"     \"Possibly effective emerging therapies for heart failure\", section on 'Vasopressin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The oral selective V2 receptor antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    raises the serum sodium concentration in patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/9,17,18\">",
"     9,17,18",
"    </a>",
"    ]. The magnitude of this effect was demonstrated in two randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The EVEREST Outcome trial included over 4100 patients hospitalized for worsening heart failure who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/17\">",
"       17",
"      </a>",
"      ]. Among the approximately 330 patients with a baseline serum sodium concentration below 134",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      tolvaptan significantly increased the serum sodium within the first seven days (5.5 versus 1.9",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      with placebo). The difference tended to become smaller over time. There was",
"      <strong>",
"       no",
"      </strong>",
"      improvement in long-term outcomes in patients who received tolvaptan.",
"     </li>",
"     <li>",
"      The Study of Ascending Levels of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"       Tolvaptan",
"      </a>",
"      in Hyponatremia 1 and 2 (SALT-1 and SALT-2) trials included 138 hyponatremic patients with chronic heart failure as well as hyponatremic patients with cirrhosis and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion, who were randomly assigned to tolvaptan or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/9\">",
"       9",
"      </a>",
"      ]. Tolvaptan raised the serum sodium significantly more than placebo (approximately 7.0 versus 2.5",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      <br/>",
"      <br/>",
"      Among all patients (ie, not limited to those with heart failure) who had a serum sodium below 130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at baseline, tolvaptan was also associated with a statistically significant improvement in mental status scores. However, this difference was of uncertain clinical importance, and the duration of follow-up was only 30 days.",
"      <br/>",
"      <br/>",
"      In an open-label extension (called SALTWATER), 111 patients were treated with tolvaptan for a mean follow-up of almost two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/19\">",
"       19",
"      </a>",
"      ]. The mean serum sodium was maintained at more than 135",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      compared with 131",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at baseline. The responses were similar in heart failure and SIADH and more modest in cirrhosis. The main adverse effects were abnormally frequent urination, thirst, dry mouth, fatigue, polyuria, and polydipsia. Adverse effects that were possibly or probably related to tolvaptan led to discontinuation of therapy in six patients (5.4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major potential adverse effects associated with oral V2 receptor antagonists:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased thirst, which may limit the rise in serum sodium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overly rapid correction of the hyponatremia, which can lead to irreversible neurologic injury. In the SALT trials, 1.8 percent of patients exceeded the study goal of limiting daily correction to 12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in 24 hours (and more probably exceeded the currently recommended correction limit of 10",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38742/abstract/9\">",
"       9",
"      </a>",
"      ]. However, the true risk may be greater because most patients enrolled in these trials had serum sodium concentrations higher than 130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and were therefore protected from overcorrection by thirst. Thus, the actual risk of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      in patients with severe hyponatremia is unknown.",
"      <br/>",
"      <br/>",
"      Because of the risk of overcorrection, hospitalization is required for the initiation or reinitiation of tolvaptan therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of the treatment of hyponatremia\", section on 'Rate of correction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10074?source=see_link\">",
"       \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another limiting factor is the",
"    <strong>",
"     cost",
"    </strong>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    , which is as high as $300 per tablet in some areas.",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    and, when approved for use, other oral selective V2 receptor antagonists, may have a role in the management of hyponatremia in patients with chronic heart failure when other management options have failed to increase the serum sodium above 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ameliorate symptoms of hyponatremia. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/20/9537?source=see_link\">",
"       \"Patient information: Hyponatremia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21527696\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Like most other causes of hyponatremia, heart failure impairs the ability to excrete ingested water by increasing antidiuretic hormone (ADH) levels. In addition, neurohumoral activation in heart failure limits distal water delivery (and thereby water excretion) by lowering the glomerular filtration rate (due to a marked reduction in renal perfusion) and by increasing proximal sodium and water reabsorption. Heart failure also stimulates thirst, leading to enhanced water intake. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both ADH release and the associated reduction in the serum sodium concentration parallel the severity of the heart failure. This relationship has prognostic importance since patient survival is significantly reduced (in comparison with normonatremic patients) once the serum sodium concentration falls below 137",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef55554 \" href=\"mobipreview.htm?29/6/29805\">",
"       figure 1",
"      </a>",
"      ). Patients whose serum sodium levels fall below 125",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      solely as a result of heart failure usually have near end-stage disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Predictor of adverse prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyponatremia in patients with heart failure usually develops slowly (paralleling the rate of progression of the heart disease) and produces no obvious symptoms until the serum sodium concentration falls below 120",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Such patients have severe heart disease and a poor prognosis. It is possible that some patients with chronic moderate hyponatremia (serum sodium 120 to 129",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      have subtle neurologic manifestations that may be improved by gradually raising the serum sodium. These include reduced scores on tests of mental, social, and physical functioning and, in elderly patients, unsteadiness and falls. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is",
"      <strong>",
"       no",
"      </strong>",
"      evidence that correction of hyponatremia improves the hemodynamic abnormalities associated with the severe underlying chronic heart failure or that it improves clinical outcomes. Thus, the main indications for specific therapy to correct hyponatremia are a serum sodium concentration below 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (severe hyponatremia)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of symptoms that might be due to hyponatremia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Restricting fluid intake is the mainstay of therapy in hyponatremic patients with heart failure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Fluid restriction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiotensin inhibition with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) and a loop diuretic may raise the serum sodium concentration. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'ACE inhibitors and loop diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"       Tolvaptan",
"      </a>",
"      and, when approved for use, other oral selective V2 receptor antagonists, may have a role in the management of hyponatremia in patients with chronic heart failure when other management options have failed to increase the serum sodium above 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ameliorate symptoms of hyponatremia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Vasopressin-receptor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/1\">",
"      Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994; 128:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/2\">",
"      Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/3\">",
"      Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. N Engl J Med 1984; 310:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/4\">",
"      Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/5\">",
"      Goldberg A, Hammerman H, Petcherski S, et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med 2006; 166:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/6\">",
"      Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005; 111:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/7\">",
"      Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007; 28:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/8\">",
"      Sato N, Gheorghiade M, Kajimoto K, et al. Hyponatremia and In-Hospital Mortality in Patients Admitted for Heart Failure (from the ATTEND Registry). Am J Cardiol 2013; 111:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/9\">",
"      Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/10\">",
"      Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119:71.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/11\">",
"      Dzau VJ, Hollenberg NK. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med 1984; 100:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/12\">",
"      Riegger GA, Kochsiek K. Vasopressin, renin and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1986; 58:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/13\">",
"      Rouse D, Dalmeida W, Williamson FC, Suki WN. Captopril inhibits the hydroosmotic effect of ADH in the cortical collecting tubule. Kidney Int 1987; 32:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/14\">",
"      Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/15\">",
"      Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/16\">",
"      Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/17\">",
"      Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/18\">",
"      Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38742/abstract/19\">",
"      Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2321 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7EC3A6EE76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38742=[""].join("\n");
var outline_f37_53_38742=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21527696\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREDICTOR OF ADVERSE PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fluid restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACE inhibitors and loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vasopressin-receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21527696\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2321\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2321|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/6/29805\" title=\"figure 1\">",
"      Hyponatremia in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/52/43853\" title=\"figure 2\">",
"      Norepinephrine in HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/20/9537?source=related_link\">",
"      Patient information: Hyponatremia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_53_38743="Retinal vein occlusion: Treatment";
var content_f37_53_38743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retinal vein occlusion: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38743/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38743/contributors\">",
"     Douglas J Covert, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38743/contributors\">",
"     Dennis P Han, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38743/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38743/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38743/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38743/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/53/38743/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7612432\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal vein occlusion (RVO) is an important cause of visual loss among older adults throughout the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/1\">",
"     1",
"    </a>",
"    ]. RVO is the second most common cause of vision loss from retinal vascular disease, following diabetic retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no widely-accepted guidelines for the treatment of retinal vein occlusion (RVO). Studies of treatment options are limited by lack of randomization, small sample sizes, inappropriate controls, and insufficient follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Furthermore, studies often report findings combining both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), although these entities differ in pathophysiology and treatment response.",
"   </p>",
"   <p>",
"    Treatment modalities, including laser photocoagulation, medical therapies, isovolemic hemodilution, and surgery, will be discussed here. Epidemiology, pathophysiology, clinical manifestations, and diagnosis of RVO are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4311?source=see_link\">",
"     \"Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1816831228\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for patients with RVO is dependent on the type of retinal vein occlusion (branch RVO or central RVO) and whether or not there is concomitant macular edema or neovascularization. In the absence of either macular edema or neovascularization, there is no evidence that treatment improves outcomes, and treatment is associated with some adverse effects.",
"   </p>",
"   <p>",
"    Patients who have neovascularization should be treated at the time of diagnosis to prevent progression. Patients with CRVO and macular edema are less likely to improve spontaneously than those with BRVO and macular edema. Therefore, ophthalmologists often initiate treatment for CRVO and macular edema at the time of diagnosis, while it is reasonable to wait three months for patients with BRVO and visual impairment due to macular edema to see if vision will spontaneously improve.",
"   </p>",
"   <p>",
"    Treatment options for RVO include laser photocoagulation and medical therapy with either vascular endothelial growth factor (VEGF) inhibitors or intravitreal glucocorticoids. The choice of initial therapy is undergoing reassessment as familiarity with VEGF inhibitors is increasing and data from randomized trials are emerging. Laser photocoagulation is an established therapy for patients with BRVO and either macular edema with visual impairment or with neovascularization. Laser therapy is also usually initiated in patients with CRVO and neovascularization. Medical therapy is first-line treatment for CRVO patients with macular edema and is an alternative to laser therapy in patients with BRVO or in those who respond suboptimally to laser therapy.",
"   </p>",
"   <p>",
"    Duration of treatment for BRVO and CRVO varies based on the treatment modality and response to treatment, but can last several weeks to months. The main goals of treatment include improvement or stabilization of visual acuity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612439\">",
"    <span class=\"h1\">",
"     LASER PHOTOCOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main forms of laser photocoagulation treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macular grid, which creates small burns in a grid-like distribution over the macula and is used for macular edema in patients with BRVO",
"     </li>",
"     <li>",
"      Peripheral scatter, which involves photocoagulation of small sections within the retina and is used for neovascularization in patients with BRVO",
"     </li>",
"     <li>",
"      Panretinal, which involves photocoagulation of the entire retina and is used for neovascularization in patients with CRVO",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612446\">",
"    <span class=\"h2\">",
"     Branch RVO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual acuity in patients with BRVO and neovascularization often resolves spontaneously. For patients who have visual impairment persisting for at least three months, several randomized trials have shown efficacy of laser photocoagulation for the treatment of macular edema associated with BRVO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, one of the largest randomized trials available in patients with BRVO was the Branch Vein Occlusion Study (BVOS), which found that laser photocoagulation could improve visual acuity in patients with macular edema as well as prevent some complications associated with neovascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/6,9\">",
"     6,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6186319\">",
"    <span class=\"h3\">",
"     Macular edema with visual impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the BVOS, 139 eyes with macular edema, visual acuity &le;",
"    <span class=\"nowrap\">",
"     20/40,",
"    </span>",
"    and onset of BRVO 3 to 18 months prior to study entry were evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/6\">",
"     6",
"    </a>",
"    ]. Eligible eyes were randomly assigned to macular grid laser photocoagulation or to observation. During the three-year follow-up period, the treatment arm was more likely to gain &ge;two lines of vision at two consecutive visits compared to the observation arm (65 versus 37 percent, respectively). In addition, the treatment arm was more likely to achieve visual acuity &ge;",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    at the end of follow-up (60 versus 34 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612460\">",
"    <span class=\"h3\">",
"     Prophylaxis for neovascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In BVOS, 319 eyes with BRVO involving at least five disk diameters of retina and no neovascularization were randomly assigned to peripheral scatter photocoagulation or observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients randomly assigned to photocoagulation were less likely to develop neovascularization (12 percent) compared to the control arm (22 percent).",
"   </p>",
"   <p>",
"    However, a large prospective cohort study found an increased risk of peripheral vision loss with scatter photocoagulation compared to untreated eyes, despite modest protection from neovascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, it is our clinical practice NOT to use scatter laser photocoagulation for prevention of neovascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612467\">",
"    <span class=\"h3\">",
"     Treatment of neovascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scatter laser photocoagulation can be used for the treatment of neovascularization, regardless of when the neovascularization develops and regardless of the degree of visual acuity loss. The evidence for treatment of neovascularization in patients with BRVO is largely extrapolated from experience with neovascularization in diabetic retinopathy, in which photocoagulation leads to improved visual outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although scatter photocoagulation has not been found to improve visual acuity in patients with neovascularization from BRVO, it can reduce the rate of vitreous hemorrhage associated with neovascularization. Vitreous hemorrhage may produce visual disturbances such as severe floaters and intermittent visual obscurations that may not be reflected by visual acuity measurements alone. In BVOS, 82 eyes in patients with BRVO who developed neovascularization were randomly assigned to scatter photocoagulation versus observation. Those randomly assigned to scatter photocoagulation were less likely to develop vitreous hemorrhage compared to the observation group (29 versus 61 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4311?source=see_link&amp;anchor=H7614396#H7614396\">",
"     \"Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis\", section on 'Ocular neovascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612474\">",
"    <span class=\"h2\">",
"     Central RVO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials have found no significant effect on visual acuity of panretinal and macular grid laser photocoagulation in the treatment of CRVO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. Panretinal photocoagulation is not effective for prevention of neovascularization, but is used to treat neovascularization when it develops in patients with CRVO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/11,14\">",
"     11,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988604598\">",
"    <span class=\"h3\">",
"     Macular edema with visual impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Central Vein Occlusion Study (CVOS) of 155 eyes with CRVO-related macular edema and visual acuity &le;",
"    <span class=\"nowrap\">",
"     20/50,",
"    </span>",
"    patients were randomly assigned to macular grid photocoagulation or to observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/17\">",
"     17",
"    </a>",
"    ]. No differences in visual acuity were found at any point during three-year follow-up between those randomly assigned to laser photocoagulation versus observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988604605\">",
"    <span class=\"h3\">",
"     Prophylaxis for neovascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iris neovascularization or anterior chamber angle neovascularization are considered harbingers of neovascular glaucoma and are most likely to occur in eyes with ischemic CRVO. In CVOS, 181 eyes with ischemic CRVO were randomly assigned to prophylactic panretinal photocoagulation versus observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/11\">",
"     11",
"    </a>",
"    ]. There was no difference in visual acuity improvement between the two arms. In addition, prophylactic photocoagulation did not prevent neovascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988604613\">",
"    <span class=\"h3\">",
"     Treatment of neovascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In CVOS, eyes that developed neovascularization had a better response to subsequent panretinal photocoagulation if no prophylactic photocoagulation had been performed (56 versus 22 percent regression rate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, we do not administer prophylactic photocoagulation. We use panretinal photocoagulation in patients with CRVO only if they develop iris or angle neovascularization, regardless of when the neovascularization develops and regardless of visual acuity. We monitor patients with recent onset of ischemic CRVO at monthly intervals for at least three months after onset and periodically thereafter so that iris or angle neovascularization can be detected and treated before onset of neovascular glaucoma.",
"   </p>",
"   <p>",
"    Treatment of retinal neovascularization, a less frequent occurrence than iris or angle neovascularization in CRVO, is largely an extrapolation from experience with neovascularization in diabetic retinopathy, in which photocoagulation leads to improved visual outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612481\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although laser treatments for RVO are well-tolerated, there are rare complications (&lt;1 percent) that can lead to worsening visual acuity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinal scarring",
"     </li>",
"     <li>",
"      Choroidal neovascularization",
"     </li>",
"     <li>",
"      Subretinal fibrosis",
"     </li>",
"     <li>",
"      Visual field deterioration",
"     </li>",
"     <li>",
"      Paracentral scotomata",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complication rates depend largely on user characteristics, including clinical experience with photocoagulation, and possibly on the type of laser used. Preliminary reports suggest that subthreshold macular grid laser treatment using an infrared (810nm) diode laser may have fewer side effects than conventional threshold treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of permanent paracentral scotoma may occur, justifying withholding laser treatment for a period of three months in many cases to allow the possibility of spontaneous improvement of visual acuity. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612488\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several medical treatments for retinal vein occlusion (RVO) have been evaluated in observational studies and some randomized trials. These treatments include vascular endothelial growth factor (VEGF) inhibitors, intravitreal glucocorticoids, and",
"    <span class=\"nowrap\">",
"     antithrombotic/thrombolytic",
"    </span>",
"    therapy. In all studies involving pharmacologic agents, the length of follow-up has been limited, such that the long-term value of therapy remains unclear. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43582010\">",
"    <span class=\"h2\">",
"     Vascular endothelial growth factor inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;VEGF is a potent mitogen and vascular permeability factor that plays a pivotal role in neovascularization. Anti-VEGF molecules limit the destructive effects of choroidal neovascular membranes in patients with exudative age-related macular degeneration. In RVO, they have been hypothesized to limit macular edema and improve vision by decreasing vascular permeability. Four anti-VEGF intravitreal agents available for clinical use are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/54/42851?source=see_link\">",
"     pegaptanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    . Only ranibizumab and aflibercept are approved for the indication of RVO by the US Food and Drug Administration, the latter only for central RVO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43582066\">",
"    <span class=\"h3\">",
"     Branch RVO",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the six-month BRAVO trial in which 397 patients with macular edema from BRVO were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    (0.3 or 0.5 mg intraocularly) or sham, more patients receiving low- and high-dose ranibizumab had improvements in visual acuity of at least 15 letters (55 and 61 versus 29 percent) and achieved visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better (68 and 65 versus 42 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/18\">",
"     18",
"    </a>",
"    ]. A 12-month update of the BRAVO trial has confirmed longer-term benefits, as more patients receiving low- and high-dose ranibizumab had improvements in visual acuity of at least 15 letters compared to sham (56 and 60 versus 44 percent, respectively) and achieved visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better (68 and 66 versus 57 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the improvement in visual acuity observed in the BRAVO trial, intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    is considered a reasonable alternative to grid laser photocoagulation in patients with BRVO and macular edema, particularly in whom retinal hemorrhage precludes laser treatment or in those who have not responded to laser treatment. Ranibizumab&rsquo;s advantage over laser treatment is that, because it is not associated with the risk of permanent paracentral scotoma induced by laser therapy, it could be given at the onset of significant visual loss at a time during which laser therapy is usually withheld. However, the long-term superiority of VEGF inhibitors over laser therapy as primary treatment has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43582073\">",
"    <span class=\"h3\">",
"     Central RVO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observational studies and randomized trials have found",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    to be efficacious and well-tolerated for the treatment of macular edema due to CRVO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/20\">",
"     20",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    In the six-month CRUISE trial in which 392 patients with macular edema from CRVO were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    intraocular injections (0.3 or 0.5 mg) or sham injections, more patients receiving ranibizumab had greater improvements in visual acuity of at least 15 letters (46 and 48 percent versus 17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/21\">",
"     21",
"    </a>",
"    ]. Ranibizumab-treated eyes were also more likely to achieve visual acuity of &ge;",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    (44 and 47 percent versus 21 percent). Patients would receive intraocular ranibizumab injections as often as monthly if they met prespecified criteria (best-corrected visual acuity",
"    <span class=\"nowrap\">",
"     &le;20/40",
"    </span>",
"    or mean central subfield thickness &gt;250 &micro;m on optical coherence tomography). An update to the CRUISE trial has extended and confirmed the results through month 12, as more patients receiving ranibizumab had greater improvements in visual acuity of at least 15 letters (47 and 51 percent versus 33 percent, for each ranibizumab arm versus sham) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, at month 12, ranibizumab-treated eyes were also more likely to achieve",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better visual acuity (43 and 43 percent versus 35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/22\">",
"     22",
"    </a>",
"    ]. As ranibizumab is well-tolerated and consistently leads to significantly improved visual acuity, we suggest intraocular ranibizumab (0.3 mg) as first-line treatment for patients with macular edema due to CRVO. Ranibizumab is usually administered monthly, as needed for several months.",
"   </p>",
"   <p>",
"    A phase two randomized controlled trial reported some success in using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/54/42851?source=see_link\">",
"     pegaptanib",
"    </a>",
"    in patients with macular edema due to CRVO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/23\">",
"     23",
"    </a>",
"    ]. There was no difference in the proportion of patients who had an improvement of 15 letters of visual acuity between the treatment arms and the control arm at 30-week follow-up. In a secondary endpoint analysis, treated patients were less likely to lose 15 letters of visual acuity. This study was limited in its follow-up and sample size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612495\">",
"    <span class=\"h2\">",
"     Intravitreal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravitreal glucocorticoids are administered as injections or as a slow-release implant. Given significant side effects, glucocorticoid injections are considered a second-line drug treatment for RVO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43581479\">",
"    <span class=\"h3\">",
"     Injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some randomized trials and cohort studies have found that intravitreal glucocorticoid injections improve visual acuity in patients with BRVO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] and in CRVO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Use of intravitreal glucocorticoid injections is limited by adverse effects, including increased intraocular pressure, cataract formation, and ocular complications related to the procedure such as endophthalmitis, hemorrhage, and retinal detachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients require periodic monitoring for elevation of intraocular pressure and if necessary, treatment of glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612502\">",
"    <span class=\"h4\">",
"     Branch RVO",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) trial for BRVO, intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    in doses of 1 or 4 mg were compared to macular grid laser photocoagulation in 411 patients with visual acuity loss from BRVO-related macular edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/25\">",
"     25",
"    </a>",
"    ]. In this randomized trial, there was no difference in visual acuity between the treatment arms. Increasing intraocular pressure and cataract formation were more common in the triamcinolone arms, particularly the 4 mg treatment group. Given these complications, other therapies such as macular grid laser photocoagulation or intravitreal anti-VEGF agents are preferred options for patients with persistent vision loss secondary to BRVO-related macular edema. (See",
"    <a class=\"local\" href=\"#H7612439\">",
"     'Laser photocoagulation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H43582010\">",
"     'Vascular endothelial growth factor inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612509\">",
"    <span class=\"h4\">",
"     Central RVO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of intravitreal glucocorticoids is emerging in the treatment of macular edema and visual acuity loss associated with CRVO. A systematic review including four prospective observational studies found inadequate evidence to support the use of intravitreal glucocorticoids for treatment of macular edema secondary to CRVO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequently published multicenter randomized trial (SCORE) found that intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    was effective in limiting visual acuity loss from macular edema secondary to CRVO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/27\">",
"     27",
"    </a>",
"    ]. This trial compared intravitreal triamcinolone (1 mg or 4 mg) with observation. Patients randomly assigned to triamcinolone had improved visual acuity after 12 months. The 4 mg triamcinolone group had higher rates of intraocular pressure elevation and cataract compared to 1 mg and control groups. After initial injection of triamcinolone, patients were re-treated as needed at four month intervals. This trial suggests that patients with visual acuity loss from macular edema secondary to perfused CRVO may benefit from treatment with 1 mg of preservative-free triamcinolone at baseline and at four month intervals as needed for one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43581510\">",
"    <span class=\"h3\">",
"     Implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two six-month randomized trials in which 1267 patients with macular edema from either BRVO or CRVO were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    intravitreal implant (a 0.35 mg or 0.7 mg) versus sham, patients receiving treatment were more likely to have improvement of at least 15 letters compared to sham over a 60 to 90 day observation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/29\">",
"     29",
"    </a>",
"    ]. At the end of six-month follow-up, improvement of visual acuity persisted for both treatment groups, compared to the control group. A single treatment was administered, and a low rate of adverse effects was observed. An intravitreal glucocorticoid implant may provide a more convenient dosing regimen and possibly a safer alternative to more frequent injections of other agents. A dexamethasone implant (0.7 mg) is approved by the FDA for use in treating CRVO and BRVO. The long-term impact of intravitreal glucocorticoid implants are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612523\">",
"    <span class=\"h2\">",
"     Antithrombotic and thrombolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis is one of the main pathogenic causes of RVO. Antithrombotic and thrombolytic medications, therefore, have been studied for the treatment of both BRVO and CRVO. These medications include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , streptokinase, and recombinant tissue plasminogen activator. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4311?source=see_link&amp;anchor=H7614363#H7614363\">",
"     \"Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review including four small randomized trials in BRVO and five small randomized trials in CRVO found limited evidence of effectiveness and precluded any strong recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/30\">",
"     30",
"    </a>",
"    ]. There was some evidence that antithrombotic therapy, and low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) in particular, may be beneficial for the affected eye. However, the studies were small (&lt;100 patients per study) and most studies evaluated combination therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    used another anti-platelet agent as the control rather than placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612537\">",
"    <span class=\"h1\">",
"     ISOVOLEMIC HEMODILUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isovolemic hemodilution is a procedure that reduces vascular occlusion and improves blood flow by decreasing blood viscosity and red cell aggregation.",
"   </p>",
"   <p>",
"    In a six-week trial in which patients with symptomatic macular BRVO were randomly assigned to outpatient isovolemic hemodilution with venesection (removal of blood) and intravenous Hespan (a plasma expander) versus control, visual acuity in the hemodilution group was higher than in the control group at one year (average",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     20/80,",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/31\">",
"     31",
"    </a>",
"    ]. All patients received photocoagulation treatment. Larger randomized trials are needed prior to clinical use of hemodilution in patients with BRVO.",
"   </p>",
"   <p>",
"    It remains unclear whether isovolemic hemodilution is effective in treating patients with CRVO. Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], randomized trials have found some benefit in preserving visual acuity in patients with CRVO. However, one trial suggested worsening of visual acuity compared to the control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/35\">",
"     35",
"    </a>",
"    ]. A systematic review found the data to be conflicting with several limitations, including small sample sizes and combination with other interventions preventing direct comparisons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isovolemic hemodilution is generally well-tolerated but can be associated with adverse effects such as lethargy, exertional dyspnea, and syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612544\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence to support specific surgical options for the treatment of RVO.",
"   </p>",
"   <p>",
"    Surgery for branch RVO is largely restricted to vitrectomy (surgical removal of the vitreous humor) with or without an arteriovenous sheathotomy, in which the overlying retinal artery is separated from the vein to improve blood flow. In a randomized trial comparing intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    versus",
"    <span class=\"nowrap\">",
"     vitrectomy/arteriovenous",
"    </span>",
"    sheathotomy in 40 eyes with BRVO-related macular edema, no differences were found in visual acuity or foveal thickness at three and six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/36\">",
"     36",
"    </a>",
"    ]. Definitive conclusions cannot be drawn from this study due to the short follow-up period and small sample size.",
"   </p>",
"   <p>",
"    Studies evaluating surgical options in central RVO are limited to small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38743/abstract/37\">",
"     37",
"    </a>",
"    ]. These surgical options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitrectomy",
"     </li>",
"     <li>",
"      Radial optic neurotomy",
"     </li>",
"     <li>",
"      Chorioretinal venous anastomosis to bypass the site of obstruction of venous outflow",
"     </li>",
"     <li>",
"      Direct injection of thrombolytic medication into the retinal vein via retinal vein cannulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do not consider surgical intervention for primary therapy of BRVO or CRVO given the associated risks of surgery and the lack of controlled trials showing benefit. We consider vitrectomy to be indications for complications of BRVO or CRVO such as persistent vitreous hemorrhage or traction retinal detachment from severe neovascularization despite laser photocoagulation and medical therapy. (See",
"    <a class=\"local\" href=\"#H7612439\">",
"     'Laser photocoagulation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7612488\">",
"     'Medical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7612551\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) patients without macular edema or neovascularization, we suggest observation rather than initiation of treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients with BRVO and macular edema who present with visual acuity of",
"      <span class=\"nowrap\">",
"       &gt;20/40,",
"      </span>",
"      we recommend observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1816831228\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with BRVO and macular edema who present with visual acuity &le;",
"      <span class=\"nowrap\">",
"       20/40,",
"      </span>",
"      we suggest either intravitreal anti-VEGF agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      ), the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      0.7 mg implant, or, if duration of symptoms is at least three months, macular grid laser photocoagulation treatment rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Ranibizumab, dexamethasone 0.7 mg implant, and laser photocoagulation have documented efficacy versus observation but have not been compared directly in clinical trials. (See",
"      <a class=\"local\" href=\"#H6186319\">",
"       'Macular edema with visual impairment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with neovascularization from BRVO, we suggest peripheral scatter photocoagulation rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients with neovascularization from CRVO, we suggest panretinal photocoagulation rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7612439\">",
"       'Laser photocoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with CRVO and macular edema, we suggest intravitreal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H43582073\">",
"       'Central RVO'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravitreal glucocorticoids are another treatment option that has at least short-term benefit in patients with RVO. However, given adverse effects such as cataract formation and intraocular pressure elevation with intravitreal glucocorticoids, the use of anti-VEGF agents is first line treatment. However, we suggest intravitreal glucocorticoids as viable options in patients with the following conditions: those who do not respond to intravitreal anti-VEGF agents, pseudophakic patients who are at low risk of glaucomatous visual field loss or who have functioning glaucoma filtering blebs or glaucoma implants (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These patients require periodic monitoring for elevation of intraocular pressure and treatment for glaucoma if needed. (See",
"      <a class=\"local\" href=\"#H7612495\">",
"       'Intravitreal glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/1\">",
"      Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/2\">",
"      Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006; 124:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/3\">",
"      McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/4\">",
"      Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/5\">",
"      Branch vein occlusion study. Invest Ophthalmol Vis Sci 1979; 18:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/6\">",
"      Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/7\">",
"      Parodi MB, DI Stefano G, Ravalico G. Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion. Retina 2008; 28:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/8\">",
"      Parodi MB, Spasse S, Iacono P, et al. Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser. Ophthalmology 2006; 113:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/9\">",
"      Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol 1986; 104:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/10\">",
"      Hayreh SS, Rubenstein L, Podhajsky P. Argon laser scatter photocoagulation in treatment of branch retinal vein occlusion. A prospective clinical trial. Ophthalmologica 1993; 206:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/11\">",
"      A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995; 102:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/12\">",
"      Parodi MB, Friberg TR, Pedio M, et al. Panretinal photocoagulation and photodynamic therapy for anterior segment neovascularization secondary to ischemic central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2007; 38:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/13\">",
"      May DR, Klein ML, Peyman GA. A prospective study of xenon arc photocoagulation for central retinal vein occlusion. Br J Ophthalmol 1976; 60:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/14\">",
"      May DR, Klein ML, Peyman GA, Raichand M. Xenon arc panretinal photocoagulation for central retinal vein occlusion: a randomised prospective study. Br J Ophthalmol 1979; 63:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/15\">",
"      Laatikainen L, Kohner EM, Khoury D, Blach RK. Panretinal photocoagulation in central retinal vein occlusion: A randomised controlled clinical study. Br J Ophthalmol 1977; 61:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/16\">",
"      Antcliff RJ, Mayer EJ, Williamson TH, Shilling JS. Early chorioretinal anastomosis in non-ischaemic CRVO: a randomised trial. Br J Ophthalmol 2005; 89:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/17\">",
"      Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/18\">",
"      Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/19\">",
"      Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/20\">",
"      Braithwaite T, Nanji AA, Greenberg PB. Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2010; :CD007325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/21\">",
"      Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/22\">",
"      Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/23\">",
"      Wroblewski JJ, Wells JA 3rd, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009; 127:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/24\">",
"      Prasad AG, Schadlu R, Apte RS. Intravitreal pharmacotherapy: applications in retinal disease. Compr Ophthalmol Update 2007; 8:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/25\">",
"      Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/26\">",
"      Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2009; :CD007324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/27\">",
"      Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/28\">",
"      Han DP, Heuer DK. Intravitreal corticosteroid therapy: putting the problem of glaucoma in perspective. Arch Ophthalmol 2012; 130:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/29\">",
"      Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/30\">",
"      Squizzato A, Manfredi E, Bozzato S, et al. Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost 2010; 103:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/31\">",
"      Chen HC, Wiek J, Gupta A, et al. Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 1998; 82:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/32\">",
"      Hansen LL, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 1989; 73:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/33\">",
"      Wolf S, Arend O, Bertram B, et al. Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study. Graefes Arch Clin Exp Ophthalmol 1994; 232:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/34\">",
"      Hansen LL, Danisevskis P, Arntz HR, et al. A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation. Br J Ophthalmol 1985; 69:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/35\">",
"      Luckie AP, Wroblewski JJ, Hamilton P, et al. A randomised prospective study of outpatient haemodilution for central retinal vein obstruction. Aust N Z J Ophthalmol 1996; 24:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/36\">",
"      Chung EJ, Lee H, Koh HJ. Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008; 246:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38743/abstract/37\">",
"      Berker N, Batman C. Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 2008; 86:245.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15263 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38743=[""].join("\n");
var outline_f37_53_38743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7612551\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7612432\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1816831228\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7612439\">",
"      LASER PHOTOCOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7612446\">",
"      Branch RVO",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6186319\">",
"      - Macular edema with visual impairment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7612460\">",
"      - Prophylaxis for neovascularization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7612467\">",
"      - Treatment of neovascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7612474\">",
"      Central RVO",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1988604598\">",
"      - Macular edema with visual impairment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1988604605\">",
"      - Prophylaxis for neovascularization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1988604613\">",
"      - Treatment of neovascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7612481\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7612488\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43582010\">",
"      Vascular endothelial growth factor inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43582066\">",
"      - Branch RVO",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43582073\">",
"      - Central RVO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7612495\">",
"      Intravitreal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43581479\">",
"      - Injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7612502\">",
"      Branch RVO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7612509\">",
"      Central RVO",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43581510\">",
"      - Implant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7612523\">",
"      Antithrombotic and thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7612537\">",
"      ISOVOLEMIC HEMODILUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7612544\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7612551\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4311?source=related_link\">",
"      Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_53_38744="Evaluation of the endometrium for malignant or premalignant disease";
var content_f37_53_38744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the endometrium for malignant or premalignant disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38744/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38744/contributors\">",
"     Sarah Feldman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38744/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38744/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38744/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38744/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/53/38744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the endometrium is the key component in the diagnostic evaluation of women suspected of endometrial cancer or a premalignant endometrial lesion. An endometrial sampling procedure is the gold standard for diagnostic evaluation of women with abnormal uterine bleeding in whom endometrial hyperplasia or carcinoma is a possibility (",
"    <a class=\"graphic graphic_table graphicRef58600 \" href=\"mobipreview.htm?18/38/19052\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/131?source=see_link\">",
"     \"Endometrial sampling procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INVASIVE METHODS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endometrial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of equipment and techniques for office-based endometrial biopsy has generally replaced the need for diagnostic dilation and curettage (D&amp;C) performed in the operating room [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/1\">",
"     1",
"    </a>",
"    ]. Advantages of office biopsy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimal to no cervical dilation is required.",
"     </li>",
"     <li>",
"      Local or no anesthesia is generally required.",
"     </li>",
"     <li>",
"      Performing the procedure in an office setting is less expensive than a procedure in the operating room.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is an excellent correlation between the histopathology of endometrial specimens taken by biopsy instruments in the office and D&amp;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, since less than 50 percent of the endometrium is sampled, malignancy can be missed (",
"    <a class=\"graphic graphic_table graphicRef69145 \" href=\"mobipreview.htm?8/37/8795\">",
"     table 2",
"    </a>",
"    ). Despite some limitations, numerous studies have shown that the endometrium is adequately sampled with biopsy techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 39 studies involving 7914 women compared the results of endometrial sampling with histopathology at D&amp;C, hysteroscopy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hysterectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/5\">",
"       5",
"      </a>",
"      ]. The significant findings from this analysis were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Pipelle device was more sensitive for the detection of endometrial cancer and atypical hyperplasia than all other sampling devices.",
"     </li>",
"     <li>",
"      The sensitivity for the diagnosis of endometrial cancer (by Pipelle) in postmenopausal women was 99.6 percent and in premenopausal women was 91 percent. The sensitivity for the diagnosis of atypical endometrial hyperplasia was 81 percent.",
"     </li>",
"     <li>",
"      The specificity for all endometrial biopsy devices for the diagnosis of endometrial carcinoma was 98 to 100 percent.",
"     </li>",
"     <li>",
"      Fewer than 5 percent of patients had an insufficient or no sample.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another meta-analysis assessed the accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/6\">",
"       6",
"      </a>",
"      ]. The posttest probability of endometrial cancer after a positive test was 82 percent (95% CI, 60 to 93 percent), and after a negative test it was 0.9 percent (95% CI, 0.4 to 2.4 percent). In this analysis, 15 percent (138 of 945) of specimens were inadequate (no sample or insufficient tissue for assessment) and one case of cancer was subsequently found among these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All sampling devices perform better when pathology is global rather than focal; this has been demonstrated repeatedly in multiple studies. As an example, the importance of the volume of disease was illustrated in a study of 65 patients with known cancer who underwent Pipelle biopsy prior to hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/7\">",
"     7",
"    </a>",
"    ]. Endometrial sampling was most reliable when at least one-half of the endometrium was affected by disease. Five patients had tumors present only in an endometrial polyp.",
"   </p>",
"   <p>",
"    For this reason, additional endometrial assessment should be performed if abnormal uterine bleeding persists after a \"benign\" endometrial biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/8\">",
"     8",
"    </a>",
"    ]. Benign endometrial histology includes atrophy (absence of a hormonal effect), proliferative endometrium (estrogen effect), secretory endometrium (progestin effect), disordered or dyssynchronous endometrium (implies irregular shedding of the endometrium secondary to unopposed estrogen), and endometritis. Further endometrial assessment should also be considered when the endometrial biopsy is nondiagnostic, but a high suspicion of cancer remains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/9\">",
"     9",
"    </a>",
"    ]. Nondiagnostic biopsies may be associated with polyps, fibroids, endometrial cancer or other lesions occupying an area of the uterus that was not sampled. Additional endometrial assessment may include a combination of repeat endometrial biopsy or D&amp;C hysteroscopy combined with transvaginal ultrasonography (TVUS) with or without sonohysterography.",
"   </p>",
"   <p>",
"    If endometrial biopsy does not yield sufficient tissue for pathological diagnosis, then the clinical setting should dictate further management. We suggest TVUS if the woman is postmenopausal and the bleeding has not been persistent; a thin endometrial stripe in this setting is most consistent with atrophy and does not require further invasive studies. A thick endometrial stripe, persistent bleeding, or bleeding in women who are in the menopausal transition or are postmenopausal should be followed by additional endometrial sampling, such as hysteroscopy with curettage.",
"   </p>",
"   <p>",
"    The diagnosis of early grade endometrial cancer by pathologic evaluation is sometimes controversial, as the distinction between high grade precancers and cancer may be unclear, and different examiners may have different opinions regarding the diagnosis. If there is a management decision that may be affected by this distinction, additional slide review or additional markers may be requested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dilation and curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, endometrial biopsy in the office has generally replaced diagnostic D&amp;C, but there is still a role for this procedure for some women. Indications for diagnostic D&amp;C include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35480?source=see_link\">",
"     \"Dilation and curettage\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a patient is not able to tolerate an office endometrial biopsy (eg, due to pain or anxiety)",
"     </li>",
"     <li>",
"      After a nondiagnostic office biopsy in women who are at high risk of endometrial carcinoma",
"     </li>",
"     <li>",
"      After benign histology on office biopsy in women who have persistent abnormal uterine bleeding",
"     </li>",
"     <li>",
"      When there is insufficient tissue for analysis on office biopsy",
"     </li>",
"     <li>",
"      When cervical stenosis prevents the completion of an office biopsy",
"     </li>",
"     <li>",
"      When a concomitant operative procedure, such as laparoscopy, is deemed necessary",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hysteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopy provides direct visualization of the endometrial cavity, thereby allowing targeted biopsy or excision of lesions identified during the procedure. However, hysteroscopy requires more skill and is more costly and invasive than most other modalities of endometrial assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have one of the indications above and who proceed to diagnostic D&amp;C should also be consented for diagnostic hysteroscopy at the same time. Multiple studies have shown that hysteroscopy can aid in the detection of focal lesions of the endometrial lining which may be missed by D&amp;C alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, in one large study of 1286 women, endometrial cancer was missed in 10 women (34.5 percent) using hysteroscopy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/12\">",
"     12",
"    </a>",
"    ]. Therefore, for women at risk for endometrial cancer, we advise performing",
"    <strong>",
"     BOTH",
"    </strong>",
"    procedures (visualization and biopsy). This is consistent with guidelines from the Society of Gynecologic Oncologists that advises that when hysteroscopy is used, biopsy should be performed of any discrete lesions as well as of the random background endometrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/13\">",
"     13",
"    </a>",
"    ]. Small polyps can usually be removed at the same time.",
"   </p>",
"   <p>",
"    The decision as to whether to perform a diagnostic hysteroscopy in the operating room or in the office depends upon provider preference and equipment, the indications for the procedure, and patient",
"    <span class=\"nowrap\">",
"     comfort/preference.",
"    </span>",
"    The option of",
"    <span class=\"nowrap\">",
"     operative/therapeutic",
"    </span>",
"    hysteroscopy should also be discussed with the patient. Because therapeutic hysteroscopy involves greater risk than diagnostic hysteroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/14\">",
"     14",
"    </a>",
"    ], its use should be reserved for women at low risk of endometrial cancer, and in whom the value of hysteroscopic resection of a lesion is clear (ie, heavy bleeding in a premenopausal woman who desires to maintain her fertility).",
"   </p>",
"   <p>",
"    Patients in whom a diagnosis of cancer is possible should have a diagnostic procedure followed by definitive treatment.",
"   </p>",
"   <p>",
"    In women at risk for cancer, the risk of possible cancer dissemination due to intraperitoneal spillage of the endometrial cells is discussed below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Risk of tumor dissemination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NONINVASIVE METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discussion below applies to use of noninvasive imaging techniques to evaluate the endometrium in women with AUB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transvaginal ultrasound",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the endometrial thickness using transvaginal ultrasound (TVUS) is a noninvasive method to evaluate women with postmenopausal bleeding for endometrial hyperplasia or cancer when the endometrium is homogeneous. Any focal endometrial lesion requires a biopsy.",
"   </p>",
"   <p>",
"    Sonographic measurement of endometrial thickness is performed by scanning the uterus in a sagittal view. The result reported is the double layer endometrial thickness measured in an anteroposterior dimension from one basalis layer to the other, excluding any fluid within the cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3255536\">",
"    <span class=\"h4\">",
"     Women with postmenopausal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with postmenopausal bleeding, an endometrial thickness of less than or equal to 4 or 5 mm is associated with a low risk of endometrial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Cancer becomes increasingly more frequent relative to benign disease as the endometrial thickness approaches 20 mm, which was the mean endometrial thickness in 759 women with endometrial cancer in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists (ACOG) and the Society of Radiologists in Ultrasound (SRU) advise that either TVUS (with an endometrial thickness of &le;4 mm [ACOG] or &le;5 mm [SRU]) or endometrial sampling are effective as a first diagnostic step in women with postmenopausal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In addition, ACOG advises that TVUS is useful as a second line test when endometrial sampling yielded insufficient tissue. In such cases, they advised that if the endometrial thickness is &le;4 mm, then malignancy is rare. In addition, ultrasound may identify a structural lesion (eg, polyp).",
"   </p>",
"   <p>",
"    These recommendations are supported by a meta-analysis of 35 prospective studies that included data from almost 6000 women with postmenopausal bleeding. The sensitivity and specificity of TVUS for detection of endometrial cancer at a 4 mm thickness threshold were 96 and 53 percent and at a 5 mm threshold were 96 and 61 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/19\">",
"     19",
"    </a>",
"    ]. Maximizing the sensitivity is the most important goal in using TVUS to evaluate postmenopausal bleeding, since the priority is to detect all cancers. A low specificity is less concerning, since positive results are followed with endometrial sampling prior to definitive treatment. The authors of this analysis calculated that the probability of endometrial cancer (based upon the average risk associated with postmenopausal bleeding) was 1 percent following a normal (&lt;5 mm endometrial thickness) TVUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, subsequent meta-analyses have reached different conclusions. The best designed meta-analysis used individual patient data from 13 studies, including almost 3000 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/20\">",
"     20",
"    </a>",
"    ]. This study reported that the sensitivity of TVUS for detection of endometrial cancer for 4 mm and 5 mm were 95 and 90 percent, respectively; at 3 mm, the sensitivity was 98 percent. A limitation of this analysis was that many studies were excluded because individual patient data were not available.",
"   </p>",
"   <p>",
"    Another meta-analysis consisted of 57 studies with 9031 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/21\">",
"     21",
"    </a>",
"    ]. The four highest quality studies used the &le;5 mm cut-off level. Using the pooled estimates from these four studies only, a positive test result raised the probability of carcinoma from 14 to 31 percent, while a negative test reduced it to 2.5 percent. The authors concluded that a negative result (&le;5 mm) usually excluded endometrial neoplasia, but ultrasound measurement of endometrial thickness alone could not be used to reliably exclude cancer.",
"   </p>",
"   <p>",
"    A meta-analysis of nine studies (3483 women without endometrial cancer and 380 with the disease) found that the detection rate for endometrial cancer varied according to the parameters used for the test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/22\">",
"     22",
"    </a>",
"    ]. The detection rate was 63 percent (95% CI 58-69) when considering an endometrial thickness that resulted in a false positive rate of only 10 percent; however, the detection rate increased to 96 percent (95% CI 94-98) if a false positive rate of 50 percent was considered acceptable. The authors concluded that even with a lower threshold for calling results suspicious, 4 percent of endometrial cancers would be missed; thus, further invasive diagnostic testing was indicated in all symptomatic women with a \"thin\" endometrial thickness. They also noted that median endometrial thickness varied among centers such that 5 mm may not be a universally reliable threshold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3255342\">",
"    <span class=\"h4\">",
"     Asymptomatic women with endometrial thickening or fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thickened endometrium or fluid within the endometrial cavity can be an incidental finding on an ultrasound examination performed for an indication other than evaluation of the endometrium. Further evaluation of the endometrium in these women is sometimes indicated. Most cases of endometrial cancer present with abnormal uterine bleeding, but no bleeding is present in approximately 5 to 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that endometrial thickness is less predictive of endometrial neoplasia in asymptomatic women (those without postmenopausal uterine bleeding, not even red, pink, or brown spotting or staining). This was illustrated in a meta-analysis of 32 studies including 11,000 asymptomatic postmenopausal women who were not using hormone therapy; the mean endometrial thickness was 2.9 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/24\">",
"     24",
"    </a>",
"    ]. An endometrial thickness of &ge;5 mm had a sensitivity of 83 percent and a specificity of 72 percent for detecting endometrial carcinoma, which are lower than in symptomatic women. There were few data for an endometrial thickness higher than 5 mm.",
"   </p>",
"   <p>",
"    A well-designed decision analysis calculated that postmenopausal women without uterine bleeding who had an endometrial thickness &gt;11 mm had an endometrial cancer risk of 6.7 percent, which is similar to that in postmenopausal women with bleeding and endometrial thickness &gt;5 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/23\">",
"     23",
"    </a>",
"    ]. Based on this analysis, we suggest sampling the endometrium of postmenopausal women without uterine bleeding who have an endometrial thickness &gt;11 mm.",
"    <br/>",
"    <br/>",
"    We also sample postmenopausal women without uterine bleeding with lesser degrees of endometrial thickening if endometrial fluid is visualized on ultrasound. In most of these women, endometrial fluid is related to cervical stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Observational studies have consistently found that asymptomatic postmenopausal women with endometrial fluid and an endometrial thickness less than 3 mm do not have endometrial cancer or hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/25,27-30\">",
"     25,27-30",
"    </a>",
"    ]. However, there is an increased risk of endometrial cancer in women with endometrial fluid and endometrial thickening &gt;3 mm; therefore, we biopsy these women.",
"    <br/>",
"    <br/>",
"    Pelvic pain, a common reason for pelvic imaging, is not an indication for endometrial sampling in the absence of abnormal uterine bleeding or suspicious sonographic findings.",
"   </p>",
"   <p>",
"    A detailed discussion of choosing a clinical approach to postmenopausal bleeding can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to postmenopausal women, the utility of TVUS for excluding endometrial abnormalities in premenopausal women has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In one study of 200 premenopausal women with AUB, 16 of 80 women (20 percent) with an endometrial stripe &lt;5 mm were subsequently found to have an endometrial polyp or submucosal leiomyoma as the source of their bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In premenopausal women, TVUS should be performed on day 4, 5, or 6 of the bleeding cycle, when the endometrium is expected to be its thinnest (in reproductive age women normal endometrial thickness in the proliferative phase is 4 to 8 mm and in the secretory phase 8 to 14 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/9\">",
"     9",
"    </a>",
"    ]) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51541 \" href=\"mobipreview.htm?2/48/2816\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/33\">",
"     33",
"    </a>",
"    ]. There is no standard threshold for abnormal endometrial thickness in premenopausal women. Further evaluation should be based on the clinical situation, including persistent abnormal bleeding not responsive to medical management or suspicion of a structural abnormality, such as a polyp, which might require removal.",
"   </p>",
"   <p>",
"    In asymptomatic premenopausal women, endometrial thickness alone is not an indication for biopsy. Endometrial evaluation should be based on a combination of factors (",
"    <a class=\"graphic graphic_table graphicRef58600 \" href=\"mobipreview.htm?18/38/19052\">",
"     table 1",
"    </a>",
"    ), including cervical cytology results showing glandular abnormalities or endometrial cells, a chronic history of estrogen excess or anovulation (polycystic ovary syndrome), as well as endometrial thickness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Women on HT",
"    </span>",
"    &nbsp;&mdash;&nbsp;TVUS does",
"    <strong>",
"     NOT",
"    </strong>",
"    appear to be a useful screening tool for excluding endometrial",
"    <span class=\"nowrap\">",
"     hyperplasia/cancer",
"    </span>",
"    in women on estrogen therapy (ET) that is unopposed or given with cyclic (rather than continuous) progesterone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Thickness thresholds are not well established for such women; as a result, endometrial sampling is still the gold standard to exclude endometrial hyperplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carcinoma.",
"   </p>",
"   <p>",
"    For women on HT therapy, TVUS should be obtained only for standard clinical indications, such as to assess adnexal pathology, or if abnormal bleeding occurs and an endometrial biopsy cannot be easily obtained. In the case of abnormal bleeding in women on cyclic progesterone, it is best to obtain the TVUS early in cycle, when the endometrium is expected to be at its thinnest. Persistent bleeding",
"    <strong>",
"     always",
"    </strong>",
"    requires endometrial biopsy regardless of ultrasound findings. We tell patients that bleeding is common when ET is initiated and should decrease over time. If it does not, and if it becomes heavier, or bleeding occurs after a long period of no bleeding, then a biopsy is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Women on tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , both for treatment and prevention of breast cancer, are known to have thickened endometrial stripes. The appearance can be cystic on TVUS due to reactivation of foci of adenomyosis. There is no clear cut-off for normal versus pathological endometrial thickness in these patients. In general, we do not feel there is a role for baseline endometrial assessment, but women should have an endometrial biopsy if any abnormal bleeding occurs, as tamoxifen confers a slight increase in endometrial cancer risk (roughly",
"    <span class=\"nowrap\">",
"     1/1000).",
"    </span>",
"    Since tamoxifen is associated with formation of endometrial polyps, sonohysterography can be helpful in these women to identify those with focal disease that would be better triaged to hysteroscopy rather than blind biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Saline infusion sonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saline infusion sonography (also called sonohysterography) is an imaging technique in which sterile saline is instilled into the endometrial cavity and TVUS is performed. This procedure allows for careful architectural evaluation of the uterine cavity to detect small lesions (eg, polyps or small submucous fibroids) which may be missed on TVUS or by blind endometrial sampling. In one study, as an example, the sensitivity and specificity of saline infusion sonography for detection of polyps were significantly higher than for TVUS alone (93 and 94 for SIS versus 75 and 76 percent for TVUS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40823?source=see_link\">",
"     \"Saline infusion sonohysterography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The disadvantage of saline infusion sonography is that no tissue is obtained for histological diagnosis and it can be uncomfortable. The lack of histologic material for diagnosis was addressed in another study that performed both endometrial biopsy and saline infusion sonography in 113 women age 25 to 69 years with persistent AUB who subsequently underwent",
"    <span class=\"nowrap\">",
"     hysteroscopy/curettage",
"    </span>",
"    or hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/37\">",
"     37",
"    </a>",
"    ]. The sensitivity, specificity, positive and negative predictive values of",
"    <span class=\"nowrap\">",
"     biopsy/saline",
"    </span>",
"    infusion sonography were 97, 70, 82, and 94 percent, respectively. False positive results were due to intrauterine debris, blood clot, thickened endometrial folds, and misidentified endometrial fragments. The combined technique of blind biopsy and saline infusion sonography permitted diagnosis of the cause of abnormal uterine bleeding in most women, without the need for more invasive procedures such as hysteroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/38\">",
"     38",
"    </a>",
"    ]. A subsequent meta-analysis came to this same conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/39\">",
"     39",
"    </a>",
"    ]. The combined technique is most useful in women with a symmetrically thickened endometrium. If saline infusion sonography shows a focal lesion, hysteroscopy should be considered.",
"   </p>",
"   <p>",
"    In randomized trials, outpatient hysteroscopy was associated with more pain than saline infusion sonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with hysteroscopy, dissemination of cancer is a theoretical concern. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Risk of tumor dissemination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In summary, because of the lack of a definitive diagnosis, the potential discomfort of the procedure, and the cost, we feel saline infusion should not be used for primary evaluation of abnormal bleeding, but only in cases in which a diagnosis is unclear after biopsy, and for whom there is a relative contraindication to proceeding to",
"    <span class=\"nowrap\">",
"     D&amp;C/hysteroscopy.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RISK OF TUMOR DISSEMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One concern with hysteroscopy and saline infusion sonography is that fluid flushed from the endometrial cavity through the fallopian tubes can contain endometrial cells, some of which remain viable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/43-55\">",
"     43-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40823?source=see_link\">",
"     \"Saline infusion sonohysterography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of tumor cells in peritoneal washings changes the stage of a woman with endometrial cancer to at least stage IIIA (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"mobipreview.htm?42/33/43549\">",
"     table 3",
"    </a>",
"    ). However, a meta-analysis of observational studies reported no significant difference in the frequency of positive peritoneal cytology in women with endometrial carcinoma who had or had not undergone diagnostic hysteroscopy (OR 1.64, 95%CI 1.0-28) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of iatrogenic upstaging is not known, as transport of these cells does not necessarily result in implantation and persistence. In the few studies that have reported long-term follow-up, there was no detriment to survival associated with pre-staging hysterosalpingography (with confirmed intraperitoneal spill) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/56\">",
"     56",
"    </a>",
"    ] or hysteroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/57\">",
"     57",
"    </a>",
"    ]. Further study is needed to clarify the clinical impact of tumor cell dissemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/55/19314?source=see_link\">",
"       \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/18/22820?source=see_link\">",
"       \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometrial biopsy is our preferred initial test for women with abnormal uterine bleeding due to its high sensitivity, low complication rate, and low cost. Endometrial biopsy is a more cost-effective initial approach than ultrasound when the prevalence of endometrial carcinoma is at least 15 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TVUS is an acceptable alternative initial test in postmenopausal women who cannot tolerate office biopsy, or in women who need concurrent evaluation of the adnexae. A summary of the literature suggests that using an endometrial cutoff of &lt;4 mm would yield a false negative rate for endometrial cancer of 0.25 to 0.5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/59\">",
"       59",
"      </a>",
"      ], which compares favorably with the false negative rate reported for endometrial biopsy.",
"     </li>",
"     <li>",
"      Endometrial biopsy is required for histological diagnosis if the endometrium is not adequately visualized, the stripe is &ge;4 mm (focal or global), and in women with persistent bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/16,59,60\">",
"       16,59,60",
"      </a>",
"      ]. Blind biopsy is most accurate in women with a globally thickened endometrium; visually directed sampling (ie, hysteroscopy) is preferable for women with focal abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Evaluation of persistent bleeding",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent abnormal bleeding in peri- or post-menopausal women is worrisome even with a benign or negative initial evaluation. Two studies have followed patients with a negative initial biopsy, and found up to 20 percent of the patients were eventually diagnosed with either complex atypical hyperplasia or cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Persistent bleeding is worrisome even when the endometrial thickness is &lt;4 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/16,63,64\">",
"       16,63,64",
"      </a>",
"      ], particularly if there are other risk factors for endometrial cancer (",
"      <a class=\"graphic graphic_table graphicRef58600 \" href=\"mobipreview.htm?18/38/19052\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62089 \" href=\"mobipreview.htm?38/30/39403\">",
"       table 4",
"      </a>",
"      ). Endometrial cancer can still occur in this setting since serous carcinoma of the endometrium may arise from atrophic endometrium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38744/abstract/65\">",
"       65",
"      </a>",
"      ]. Therefore, further diagnostic evaluation is indicated. Depending upon the prior evaluation, a combination of repeat endometrial biopsy or D&amp;C hysteroscopy combined with transvaginal sonohysterography or ultrasonography should be pursued.",
"     </li>",
"     <li>",
"      Evaluation for a nonendometrial source of bleeding, such as cervical, fallopian tube or ovarian cancer, should also be pursued.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/1\">",
"      Grimes DA. Diagnostic dilation and curettage: a reappraisal. Am J Obstet Gynecol 1982; 142:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/2\">",
"      Lipscomb GH, Lopatine SM, Stovall TG, Ling FW. A randomized comparison of the Pipelle, Accurette, and Explora endometrial sampling devices. Am J Obstet Gynecol 1994; 170:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/3\">",
"      Silver MM, Miles P, Rosa C. Comparison of Novak and Pipelle endometrial biopsy instruments. Obstet Gynecol 1991; 78:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/4\">",
"      Stovall TG, Solomon SK, Ling FW. Endometrial sampling prior to hysterectomy. Obstet Gynecol 1989; 73:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/5\">",
"      Dijkhuizen FP, Mol BW, Br&ouml;lmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/6\">",
"      Clark TJ, Mann CH, Shah N, et al. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG 2002; 109:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/7\">",
"      Guido RS, Kanbour-Shakir A, Rulin MC, Christopherson WA. Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer. J Reprod Med 1995; 40:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/8\">",
"      Clark TJ, Mann CH, Shah N, et al. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Acta Obstet Gynecol Scand 2001; 80:784.",
"     </a>",
"    </li>",
"    <li>",
"     APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/10\">",
"      Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand 2001; 80:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/11\">",
"      Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. Am J Obstet Gynecol 1988; 158:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/12\">",
"      Deckardt R, Lueken RP, Gallinat A, et al. Comparison of transvaginal ultrasound, hysteroscopy, and dilatation and curettage in the diagnosis of abnormal vaginal bleeding and intrauterine pathology in perimenopausal and postmenopausal women. J Am Assoc Gynecol Laparosc 2002; 9:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/13\">",
"      Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. Obstet Gynecol 2012; 120:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/14\">",
"      Jansen FW, Vredevoogd CB, van Ulzen K, et al. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 2000; 96:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/15\">",
"      Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990; 163:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/16\">",
"      Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study. Am J Obstet Gynecol 1995; 172:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/17\">",
"      The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. ACOG Committee Opinion No. 440. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009; 114:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/18\">",
"      Goldstein RB, Bree RL, Benson CB, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. J Ultrasound Med 2001; 20:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/19\">",
"      Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998; 280:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/20\">",
"      Timmermans A, Opmeer BC, Khan KS, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010; 116:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/21\">",
"      Gupta JK, Chien PF, Voit D, et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002; 81:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/22\">",
"      Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol 2002; 99:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/23\">",
"      Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004; 24:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/24\">",
"      Breijer MC, Peeters JA, Opmeer BC, et al. Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2012; 40:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/25\">",
"      Debby A, Malinger G, Glezerman M, Golan A. Intra-uterine fluid collection in postmenopuasal women with cervical stenosis. Maturitas 2006; 55:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/26\">",
"      Goldstein SR. Postmenopausal endometrial fluid collections revisited: look at the doughnut rather than the hole. Obstet Gynecol 1994; 83:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/27\">",
"      Schmidt T, Nawroth F, Breidenbach M, et al. Differential indication for histological evaluation of endometrial fluid in postmenopause. Maturitas 2005; 50:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/28\">",
"      Vuento MH, Pirhonen JP, M&auml;kinen JI, et al. Endometrial fluid accumulation in asymptomatic postmenopausal women. Ultrasound Obstet Gynecol 1996; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/29\">",
"      Pardo J, Kaplan B, Nitke S, et al. Postmenopausal intrauterine fluid collection: correlation between ultrasound and hysteroscopy. Ultrasound Obstet Gynecol 1994; 4:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/30\">",
"      Zalel Y, Tepper R, Cohen I, et al. Clinical significance of endometrial fluid collections in asymptomatic postmenopausal women. J Ultrasound Med 1996; 15:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/31\">",
"      Dijkhuizen FP, Br&ouml;lmann HA, Potters AE, et al. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol 1996; 87:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/32\">",
"      Breitkopf DM, Frederickson RA, Snyder RR. Detection of benign endometrial masses by endometrial stripe measurement in premenopausal women. Obstet Gynecol 2004; 104:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/33\">",
"      Goldstein SR, Zeltser I, Horan CK, et al. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 1997; 177:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/34\">",
"      Holbert TR. Transvaginal ultrasonographic measurement of endometrial thickness in postmenopausal women receiving estrogen replacement therapy. Am J Obstet Gynecol 1997; 176:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/35\">",
"      Meuwissen JH, Oddens BJ, Klinkhamer PJ. Endometrial thickness assessed by transvaginal ultrasound insufficiently predicts occurrence of hyperplasia during unopposed oestrogen use. Maturitas 1996; 24:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/36\">",
"      Kamel HS, Darwish AM, Mohamed SA. Comparison of transvaginal ultrasonography and vaginal sonohysterography in the detection of endometrial polyps. Acta Obstet Gynecol Scand 2000; 79:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/37\">",
"      Mihm LM, Quick VA, Brumfield JA, et al. The accuracy of endometrial biopsy and saline sonohysterography in the determination of the cause of abnormal uterine bleeding. Am J Obstet Gynecol 2002; 186:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/38\">",
"      Krampl E, Bourne T, Hurlen-Solbakken H, Istre O. Transvaginal ultrasonography sonohysterography and operative hysteroscopy for the evaluation of abnormal uterine bleeding. Acta Obstet Gynecol Scand 2001; 80:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/39\">",
"      de Kroon CD, de Bock GH, Dieben SW, Jansen FW. Saline contrast hysterosonography in abnormal uterine bleeding: a systematic review and meta-analysis. BJOG 2003; 110:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/40\">",
"      van Dongen H, de Kroon CD, van den Tillaart SA, et al. A randomised comparison of vaginoscopic office hysteroscopy and saline infusion sonography: a patient compliance study. BJOG 2008; 115:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/41\">",
"      Rogerson L, Bates J, Weston M, Duffy S. A comparison of outpatient hysteroscopy with saline infusion hysterosonography. BJOG 2002; 109:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/42\">",
"      Brown SE, Coddington CC, Schnorr J, et al. Evaluation of outpatient hysteroscopy, saline infusion hysterosonography, and hysterosalpingography in infertile women: a prospective, randomized study. Fertil Steril 2000; 74:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/43\">",
"      Alc&aacute;zar JL, Errasti T, Zornoza A. Saline infusion sonohysterography in endometrial cancer: assessment of malignant cells dissemination risk. Acta Obstet Gynecol Scand 2000; 79:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/44\">",
"      Dessole S, Rubattu G, Farina M, et al. Risks and usefulness of sonohysterography in patients with endometrial carcinoma. Am J Obstet Gynecol 2006; 194:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/45\">",
"      Berry E, Lindheim SR, Connor JP, et al. Sonohysterography and endometrial cancer: incidence and functional viability of disseminated malignant cells. Am J Obstet Gynecol 2008; 199:240.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/46\">",
"      Obermair A, Geramou M, Gucer F, et al. Does hysteroscopy facilitate tumor cell dissemination? Incidence of peritoneal cytology from patients with early stage endometrial carcinoma following dilatation and curettage (D &amp; C) versus hysteroscopy and D &amp; C. Cancer 2000; 88:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/47\">",
"      Egarter C, Krestan C, Kurz C. Abdominal dissemination of malignant cells with hysteroscopy. Gynecol Oncol 1996; 63:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/48\">",
"      Sagawa T, Yamada H, Sakuragi N, Fujimoto S. A comparison between the preoperative and operative findings of peritoneal cytology in patients with endometrial cancer. Asia Oceania J Obstet Gynaecol 1994; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/49\">",
"      Bradley WH, Boente MP, Brooker D, et al. Hysteroscopy and cytology in endometrial cancer. Obstet Gynecol 2004; 104:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/50\">",
"      Kuzel D, T&oacute;th D, Kobilkov&aacute; J, Dohnalov&aacute; A. Peritoneal washing cytology on fluid hysteroscopy and after curettage in women with endometrial carcinoma. Acta Cytol 2001; 45:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/51\">",
"      Lo KW, Cheung TH, Yim SF, Chung TK. Hysteroscopic dissemination of endometrial carcinoma using carbon dioxide and normal saline: a retrospective study. Gynecol Oncol 2002; 84:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/52\">",
"      Gu M, Shi W, Huang J, et al. Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma. Cancer 2000; 90:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/53\">",
"      Arikan G, Reich O, Weiss U, et al. Are endometrial carcinoma cells disseminated at hysteroscopy functionally viable? Gynecol Oncol 2001; 83:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/54\">",
"      Takac I. Saline infusion sonohysterography and the risk of malignant extrauterine spread in endometrial cancer. Ultrasound Med Biol 2008; 34:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/55\">",
"      Yazbeck C, Dhainaut C, Batallan A, et al. [Diagnostic hysteroscopy and risk of peritoneal dissemination of tumor cells]. Gynecol Obstet Fertil 2005; 33:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/56\">",
"      Devore GR, Schwartz PE, Morris JM. Hysterography: a 5-year follow-up in patients with endometrial carcinoma. Obstet Gynecol 1982; 60:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/57\">",
"      Ben-Arie A, Tamir S, Dubnik S, et al. Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer? Int J Gynecol Cancer 2008; 18:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/58\">",
"      Dijkhuizen FP, Mol BW, Br&ouml;lmann HA, Heintz AP. Cost-effectiveness of the use of transvaginal sonography in the evaluation of postmenopausal bleeding. Maturitas 2003; 45:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/59\">",
"      Gull B, Carlsson S, Karlsson B, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol 2000; 182:509.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Gynecologic ultrasonography. ACOG Technical Bulletin 215, American College of Obstetricians and Gynecologists, Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/61\">",
"      Twu NF, Chen SS. Five-year follow-up of patients with recurrent postmenopausal bleeding. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/62\">",
"      Feldman S, Shapter A, Welch WR, Berkowitz RS. Two-year follow-up of 263 patients with post/perimenopausal vaginal bleeding and negative initial biopsy. Gynecol Oncol 1994; 55:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/63\">",
"      Goldchmit R, Katz Z, Blickstein I, et al. The accuracy of endometrial Pipelle sampling with and without sonographic measurement of endometrial thickness. Obstet Gynecol 1993; 82:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/64\">",
"      Van den Bosch T, Vandendael A, Van Schoubroeck D, et al. Combining vaginal ultrasonography and office endometrial sampling in the diagnosis of endometrial disease in postmenopausal women. Obstet Gynecol 1995; 85:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38744/abstract/65\">",
"      Wang J, Wieslander C, Hansen G, et al. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol 2006; 101:120.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3232 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38744=[""].join("\n");
var outline_f37_53_38744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INVASIVE METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endometrial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dilation and curettage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NONINVASIVE METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transvaginal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3255536\">",
"      Women with postmenopausal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3255342\">",
"      Asymptomatic women with endometrial thickening or fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Women on HT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Women on tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Saline infusion sonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RISK OF TUMOR DISSEMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Evaluation of persistent bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3232\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3232|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/48/2816\" title=\"diagnostic image 1\">",
"      Endometrial stripe normal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3232|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/38/19052\" title=\"table 1\">",
"      Indications endometrial evaluat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/37/8795\" title=\"table 2\">",
"      False neg endometrial sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/33/43549\" title=\"table 3\">",
"      Staging uterine carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/30/39403\" title=\"table 4\">",
"      Risk factors endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35480?source=related_link\">",
"      Dilation and curettage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/131?source=related_link\">",
"      Endometrial sampling procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/18/22820?source=related_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/55/19314?source=related_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40823?source=related_link\">",
"      Saline infusion sonohysterography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_53_38745="Use of psychotropic medications in breastfeeding women";
var content_f37_53_38745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of psychotropic medications in breastfeeding women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38745/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38745/contributors\">",
"     Shari I Lusskin, MD, FAPA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38745/contributors\">",
"     Shaila Misri, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38745/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38745/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38745/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38745/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/53/38745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All psychotropic medications are transferred to breast milk in varying amounts, and thus are passed on to the nursing infant. The use of pharmacotherapy in postpartum lactating women must balance the risk of possible harmful drug effects on the infant against the risk of",
"    <span class=\"nowrap\">",
"     maternal/child",
"    </span>",
"    sequelae of untreated maternal psychiatric illness. Potential risks to the baby from exposure to medications through breast milk include drug toxicity and undetermined long-term effects on neurobehavioral development. Whether cumulative effects occur if the mother also took psychotropic medications during pregnancy is an additional concern. In theory, discarding breast milk obtained at the time of peak drug concentration could allow the mother to reduce the infant's exposure to her medication; however, it is usually impractical to do this [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) committee on drugs provides information on several hundred commonly prescribed medications, as well as other agents, that may pass into breast milk. They are classified into several categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cytotoxic drugs",
"     </li>",
"     <li>",
"      Drugs of abuse with adverse effects",
"     </li>",
"     <li>",
"      Radioactive compounds",
"     </li>",
"     <li>",
"      Drugs whose effects are unknown, but \"may be of concern\"",
"     </li>",
"     <li>",
"      Drugs which should be used \"with caution\"",
"     </li>",
"     <li>",
"      Drugs which are generally \"compatible with breastfeeding\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This information is often cited in drug databases (including the drug information database in UpToDate). However, there are no randomized trials in this area. Most recommendations about the relative safety of breastfeeding on medications are based on case reports and laboratory studies. Nevertheless, the data presented below shows that the exposure of most infants to antidepressants and antipsychotics via human milk is generally low and clinically insignificant, with some exceptions. Since human milk is clinically very important to the normal newborn infant, withdrawing infants from their mothers' breasts would preclude these infants from receiving the proven benefits of mother's milk. Therefore, the benefits of breastfeeding generally outweigh the relatively small risk of the psychotropic medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breastfeeding, however, should not be done at the expense of the mother's mental health. If a mother chooses to breastfeed, it is also important to minimize sleep deprivation (for example, have a family member bottle-feed the baby at night) in order to attenuate the risk of relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors should be considered when selecting an antidepressant medication in the postpartum period:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The woman's prior response to antidepressants",
"     </li>",
"     <li>",
"      Anticipated efficacy and response of the individual",
"     </li>",
"     <li>",
"      Side effect profile in each individual woman",
"     </li>",
"     <li>",
"      Concurrent medications and risk of interactions",
"     </li>",
"     <li>",
"      Potential adverse effects for the mother and her nursing infant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maternal, fetal, and neonatal systems of drug absorption, distribution, metabolism, and elimination constantly change throughout pregnancy and the postpartum period. Some of these variations require an increased or decreased dose of a specific medication. Therefore, the effectiveness of a particular medication should be monitored throughout the postpartum period to achieve the lowest possible dose that provides adequate control of depression. Pharmacodynamic issues and physiology are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20666?source=see_link\">",
"     \"Postpartum blues and depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selective serotonin reuptake inhibitors (SSRIs) are effective drugs for treatment of postpartum depression and are also used for postpartum obsessive-compulsive disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42582?source=see_link\">",
"     \"Obsessive-compulsive disorder in pregnant and postpartum women\"",
"    </a>",
"    .) The literature on use of these drugs in lactating women has expanded rapidly and includes publications of individual case reports, small case series, and pharmacokinetic investigations. This growing database is reassuring because it contains only a few reports of adverse effects in infants exposed to SSRIs via breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The long-term developmental effects of SSRI exposure through breast milk have only been minimally studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/7\">",
"     7",
"    </a>",
"    ]. As more data become available, women will be able to make a more informed choice about whether to breastfeed (or not) while taking SSRIs.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics Committee on Drugs considers the SSRIs drugs in which effects are unknown, but may be \"of concern\" in breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Fluoxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    is the SSRI most frequently studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/3,8-14\">",
"     3,8-14",
"    </a>",
"    ]. In 2004, the Center for the Evaluation of Risks to Human Reproduction (CERHR) Expert Panel reviewed data on fluoxetine in pregnancy and lactation and concluded that better designed and larger studies were needed before a definitive conclusion could be reached [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/15\">",
"     15",
"    </a>",
"    ]. Norfluoxetine, the active metabolite of fluoxetine, has a very long half-life that may predispose to accumulation in the serum of the infant. Nevertheless, fluoxetine remains one of the best studied drugs in pregnancy and lactation.",
"   </p>",
"   <p>",
"    The range of findings is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No adverse events were noted in 180 of 190 infants whose mothers took",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      during lactation; complications in the other 10 infants were minor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study comparing 11 infants exposed to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      during lactation with a matched control group reported normal weight gain and neurologic development in fluoxetine-exposed infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case report described adverse effects such as colic, fussiness, crying, seizure activity, and reduced weight gain in a three week old baby exposed to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/d)",
"      </span>",
"      during lactation; blood levels were unusually high. These adverse effects resolved when the baby was switched to formula [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective cohort study noted reduced weight gain in infants breastfed by mothers who were taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , although the weights reported were not statistically lower than the national mean [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study, of 78 mother-infant pairs, 29 of whom were on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , found that infant weight gain at six months was, on average, no different from the national average [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/19\">",
"       19",
"      </a>",
"      ]. There was a correlation between the presence of extended maternal depression (&gt;two months) and lower weight gain; however, weight gain did not correlate with the degree of medication exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Sertraline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     Sertraline",
"    </a>",
"    and its weak metabolite desmethylsertraline have been detected in breast milk, but with low or undetectable serum levels in over 70 infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/1,16,20-24\">",
"     1,16,20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study that examined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    exposure in 19 breastfeeding mother-infant pairs found that platelet serotonin uptake in these infants was unaltered, despite low levels of sertraline and its metabolite in their sera (platelet activity is used as an assay of central serotonergic activity, but is not necessarily related to adverse effects) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/25\">",
"     25",
"    </a>",
"    ]. A study of 15 mother-infant pairs that examined the pharmacokinetics of sertraline excretion in breast milk found peak levels at nine hours after the dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/1\">",
"     1",
"    </a>",
"    ]. In theory, discarding the milk at that time would reduce infant exposure. In practice, however, this may be difficult to do, and infant serum levels have been consistently low or undetectable as noted above.",
"   </p>",
"   <p>",
"    For these reasons,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    may be preferable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    in lactating women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/26\">",
"     26",
"    </a>",
"    ]. However, these data do",
"    <strong>",
"     not",
"    </strong>",
"    indicate that a woman who has given birth while taking fluoxetine and has responded well to the drug should be switched to sertraline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Paroxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     Paroxetine",
"    </a>",
"    is excreted into breast milk; there is no active metabolite. Only low or undetectable serum levels have been reported in infants and no adverse effects have been reported in more than 70 mother-infant pairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/24,27-30\">",
"     24,27-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fluvoxamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten case studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    exposure through breast milk found low levels in the breast milk, with no adverse effects in the infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/24,31-36\">",
"     24,31-36",
"    </a>",
"    ]. Very low serum levels were noted in the few infants tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Citalopram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case studies examining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    exposure through breastfeeding have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/4,37-40\">",
"     4,37-40",
"    </a>",
"    ]. One study reported uneasy sleep in the infant, which was correlated to a high serum concentration of citalopram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/4\">",
"     4",
"    </a>",
"    ]. These symptoms were short-lasting and disappeared after a dose decrease. In a series of nine mother-infant pairs followed prospectively, the concentration of citalopram and its metabolites in breast milk were two- to three-fold higher than maternal plasma concentrations, but infant concentrations were very low or undetectable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/39\">",
"     39",
"    </a>",
"    ]. Neurodevelopmental outcomes were normal at one year of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Escitalopram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a single case report of necrotizing enterocolitis in a term infant exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    in utero and in breast milk has been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/41\">",
"     41",
"    </a>",
"    ]. The infant had transient tachypnea after birth and was placed on mechanical ventilation for five hours and then weaned; there were no risk factors for development of necrotizing enterocolitis. The infant was discharged on postnatal day three, but presented with necrotizing enterocolitis on postnatal day five. Symptoms resolved after two weeks of medical management.",
"   </p>",
"   <p>",
"    As the safety data on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    is considered to be applicable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    , this case report adds to the body of knowledge on SSRIs, but should not be held as a reason to switch a patient from escitalopram to another SSRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serotonin reuptake inhibitor/antagonist",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Trazodone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast",
"    <span class=\"nowrap\">",
"     milk/maternal",
"    </span>",
"    plasma concentration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    was studied in six lactating women following administration of a single dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/42\">",
"     42",
"    </a>",
"    ]. Transfer into breast milk was low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serotonin-norepinephrine reuptake inhibitor",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Venlafaxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    is a serotonin-norepinephrine reuptake inhibitor (SNRI) and is related to the SSRI class of antidepressants and the tricyclic antidepressants. Several case reports have been published regarding venlafaxine levels in breastfeeding infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Variable, but generally low, levels of venlafaxine and its active metabolite, O-desmethyl venlafaxine were found in infant serum. There were no reports of adverse events in the infants. This drug has not been rated by the AAP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Duloxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a case report of an infant exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    for 32 days through breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/47\">",
"     47",
"    </a>",
"    ], and a second case report of an infant exposed for 18 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/48\">",
"     48",
"    </a>",
"    ], no signs of toxicity were observed.",
"   </p>",
"   <p>",
"    In one pharmacokinetic study, presumed steady state",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    levels were measured in the breast milk and maternal serum of six lactating women who discontinued breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/49\">",
"     49",
"    </a>",
"    ]. Infant exposure was calculated to be 7",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (range 4 to 15",
"    <span class=\"nowrap\">",
"     mcg/day),",
"    </span>",
"    which is less than 10 percent of the maternal dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dopamine-reuptake inhibitor",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bupropion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report of two women who took",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    before pregnancy and again upon recurrence of depression after delivery (at 15 and 29 weeks postpartum, respectively) noted the infants' serum showed no quantifiable levels of bupropion or its metabolite and no adverse events occurred in the infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/50\">",
"     50",
"    </a>",
"    ]. Another study of four mother-infant pairs estimated that each infant received 5.7 percent of the weight-adjusted maternal dose, indicative of minimal infant exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/51\">",
"     51",
"    </a>",
"    ]. The American Academy of Pediatrics Committee on Drugs rates this drug as effects unknown, but may be \"of concern\" in breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tricyclic antidepressants (TCAs) are useful in the treatment of postpartum depression when the SSRIs have failed, or when the woman has shown a previous good response to these medications. All TCAs are excreted into human breast milk in low concentrations, and a wide range of infant serum levels have been reported. However, no adverse effects have been documented for exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/33,52-62\">",
"     33,52-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The active metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    has a long half-life (37 hours) and can be hazardous due to high accumulations in nursing infants. Doxepin exposure has been associated with sedation and respiratory depression in one infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/63\">",
"     63",
"    </a>",
"    ], but another case study did not report any adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics Committee on Drugs rates all of these drugs as effects are unknown but may be \"of concern\" in breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Alpha 2 antagonist",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Mirtazapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no information in breastfeeding women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     BENZODIAZEPINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are used to treat anxiety and insomnia. They are also used to treat postpartum panic attacks, and as adjunctive treatment for postpartum depression and postpartum psychosis. We suggest low doses of medications that have no active metabolites, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/4,62\">",
"     4,62",
"    </a>",
"    ]. However, the long half-life of clonazepam may predispose to accumulation in the infant. When benzodiazepines are used as part of a multidrug regimen, it is often possible to taper benzodiazepines once the primary drug produces a therapeutic effect. For patients who are highly anxious and not responding to benzodiazepines, the diagnosis should be reevaluated and the medication regimen adjusted accordingly.",
"   </p>",
"   <p>",
"    Benzodiazepines should be used cautiously during lactation; the main concern is withdrawal in infants. Although sedation in infants (and mothers) is another potential problem, the risk appears to be low. In a prospective study of 124 mothers who used benzodiazepines (primarily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ) while breastfeeding, central nervous system depression (defined as sleepiness, poor latching, limpness, or lack of response to stimuli) occurred in 2 (1.6 percent) of the infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/65\">",
"     65",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics Committee on Drugs classifies benzodiazepines as drugs whose effects are unknown, but may be \"of concern\" in breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MEDICATIONS FOR BIPOLAR DISORDER AND PSYCHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiating treatment with an antipsychotic or mood-stabilizing medication is critical for reducing the severity and frequency of hallucinations and delusions, both of which are usually present in an acute psychotic episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/62/29670?source=see_link\">",
"     \"Treatment of postpartum psychosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17014?source=see_link\">",
"     \"Postpartum psychosis: Epidemiology, clinical manifestations, and assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear consensus on use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    in breastfeeding women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], although the American Academy of Pediatrics Committee on Drugs has classified lithium as \"incompatible\" with breastfeeding, due to documented accumulations in both maternal breast milk and infant serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    concentrations in breast milk range from 24 to 72 percent of the maternal serum concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/69-75\">",
"     69-75",
"    </a>",
"    ]. Adverse effects have been reported in 2 of 10 cases of lithium exposure during breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/69-74\">",
"     69-74",
"    </a>",
"    ]. The adverse effects noted in these infants included cyanosis, hypotonia, heart murmur, T-wave changes, lethargy, hypothermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/71\">",
"     71",
"    </a>",
"    ], and unspecified signs of lithium toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, maternal, infant, and breast milk levels were compared in 10 mother-infant pairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/75\">",
"     75",
"    </a>",
"    ]. Breast milk levels were approximately one-half of maternal levels, and infant levels were approximately one-half of breast milk levels, and one-fourth of maternal levels; the authors suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    transfer follows a \"rule of halves.\" Although all 10 infants had normal BUN, creatinine, and TSH levels at birth, during the course of breastfeeding, two developed an elevated BUN, one an elevated creatinine, and one an elevated TSH (which normalized after breastfeeding was stopped). Neurodevelopment was reportedly within normal limits, although formal testing was not done. The study group consisted of women who were very high-functioning, clinically stable, and very closely monitored. This limits the generalizability of the findings. The authors recommend careful patient selection and coordination of care with the pediatrician.",
"   </p>",
"   <p>",
"    The neonate may be more vulnerable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    accumulation because the kidney is relatively immature, and because infants easily become dehydrated.",
"   </p>",
"   <p>",
"    We do not recommend that women taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    breastfeed. If women choose to breastfeed on lithium, lithium concentrations should be closely monitored, both in the mother and the baby. Blood collection systems should not contain lithium-heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics Committee on Drugs considers both valproic acid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    \"compatible\" with breastfeeding, due to consistent reports of low-to-unquantifiable concentrations of these medications in breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/66,68,77\">",
"     66,68,77",
"    </a>",
"    ]. These medications may offer an alternative to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    for women with bipolar disorder who wish to breastfeed, as long as proper precautions are followed to prevent unintended pregnancy during lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Valproic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the American Academy of Pediatrics Committee on Drugs considers valproic acid \"compatible\" with breastfeeding. Only one published report has documented adverse effects in an infant exposed to valproic acid through breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/78\">",
"     78",
"    </a>",
"    ]. A three-month old infant developed thrombocytopenia and anemia while the mother was being treated with sodium valproate monotherapy. The authors conducted an extensive investigation as to other possible causes, but none were discovered. The abnormalities resolved 12 to 35 days after breastfeeding was discontinued.",
"   </p>",
"   <p>",
"    Nevertheless, in light of emerging concerns regarding neurodevelopmental toxicity resulting from in-utero exposure to valproic acid, we are concerned about possible neurodevelopmental effects resulting from exposure through breast milk, even though the degree would be much less than in-utero. This information should be part of the informed consent decision.",
"   </p>",
"   <p>",
"    If a nursing mother is taking valproic acid, we monitor maternal and infant serum drug levels and liver function tests (liver transaminases, gammaglutamyl peptidase) every two to four weeks, or more frequently as indicated by the clinical situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Carbamazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the American Academy of Pediatrics Committee on Drugs considers",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    \"compatible\" with breastfeeding. The use of carbamazepine during breastfeeding has been associated with infant hepatic toxicity in two case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. However, the infants in both cases were exposed to carbamazepine during both pregnancy and through breast milk, therefore it is unclear as to whether the adverse effects were the result of in-utero or breast milk exposure.",
"   </p>",
"   <p>",
"    Although this medication appears to be safe for use in breastfeeding mothers, infants should be monitored for possible hepatic complications. Maternal and infant serum drug levels and liver function tests (liver transaminases, gammaglutamyl peptidase) should be monitored every two to four weeks, or more frequently as indicated by the clinical situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Lamotrigine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics Committee on Drugs considers the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    \"of concern\" in breastfeeding. Several reports of lamotrigine use in breastfeeding women found that this medication is excreted in considerable quantities (60 percent) into human breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/81-85\">",
"     81-85",
"    </a>",
"    ]. Infant serum levels were approximately one-third of maternal levels. None of the infants in these case reports displayed adverse effects. However, there is some potential for concern with the use of lamotrigine, as this medication has been linked to severe life-threatening rashes in children who are treated directly with the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/86\">",
"     86",
"    </a>",
"    ], therefore infants exposed to this medication should be observed closely for side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    levels in three mother-infant pairs have been studied during pregnancy and postpartum. Infant levels were 10 to 20 percent of maternal levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/87\">",
"     87",
"    </a>",
"    ]. No adverse effects were observed in the infants. The American Academy of Pediatrics Committee on Drugs has not rated this drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Conventional (typical) antipsychotic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infant exposure to the typical antipsychotics",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/2/19495?source=see_link\">",
"     trifluoperazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    , chlorprothixene, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    through breast milk have been documented in one prospective controlled trial, as well as several case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/57,88-96\">",
"     57,88-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     Chlorpromazine",
"    </a>",
"    exposure was associated with drowsiness and lethargy in one breastfeeding infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/90\">",
"     90",
"    </a>",
"    ]. An important prospective controlled trial of typical antipsychotic medications described three infants who were exposed to a combination of chlorpromazine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    through breast milk, and who exhibited developmental delays at 12 to 18 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/88\">",
"     88",
"    </a>",
"    ]. However, only one of these three infants had detectable serum concentrations of the medications and the delays may have been related to other factors.",
"   </p>",
"   <p>",
"    It is also important to note that the typical antipsychotic medications, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    , have very long half-lives. Long-term maternal use of these medications during breastfeeding could lead to increased accumulations in the infant's sera; therefore the infant should be monitored closely for sedation or other adverse effects. The American Academy of Pediatrics Committee on Drugs has rated chlorpromazine as effects are unknown, but may be \"of concern\" and has not rated fluphenazine.",
"   </p>",
"   <p>",
"    A review summarizing available data on antipsychotics in pregnancy and lactation found fewer than 35 case reports on the use of typical antipsychotics in lactating women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/97\">",
"     97",
"    </a>",
"    ]. Long-term neurobehavioral effects on infants have not been documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Novel (atypical) antipsychotic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the use of the atypical antipsychotic medications during breastfeeding are limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      &mdash; One report on clozapine described a high accumulation in the breast milk of one woman; however, no details were given on the infant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/98\">",
"       98",
"      </a>",
"      ]. Therefore, use of clozapine should be limited until further information is available. The American Academy of Pediatrics Committee on Drugs rates this drug as effects unknown but may be \"of concern\".",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      &mdash; The American Academy of Pediatrics Committee on Drugs has not rated olanzapine. Information on olanzapine exposure comes from the manufacturer's safety database [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/99\">",
"       99",
"      </a>",
"      ] and a small case series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/96\">",
"       96",
"      </a>",
"      ]. Of the three infants in the database exposed to olanzapine, one infant displayed cardiomegaly, jaundice, and sedation. However, this infant was exposed to the medication both in-utero and during breastfeeding, thus the effects could not be attributed directly to exposure through breast milk. In the first case series, five mother-infant pairs were studied; all of the babies appeared to tolerate exposure to olanzapine without side-effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/96\">",
"       96",
"      </a>",
"      ]. A serum level was measured in only one infant and found to be undetectable.",
"      <br/>",
"      <br/>",
"      The second study evaluated maternal plasma levels, breast milk levels, and infant serum levels of olanzapine in seven mother-infant pairs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/100\">",
"       100",
"      </a>",
"      ]. The median milk-to-plasma ratio for olanzapine was 0.38, and the median dose ingested through breast milk was 1.02 percent of the maternal dose. Serum levels were undetectable in the six infants tested (limits of detection 1",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      to 5",
"      <span class=\"nowrap\">",
"       mcg/L).",
"      </span>",
"      No side effects were observed in all seven full-term, healthy infants whose average age was 2.4 months (range 0.1 to 4.3). The average maternal dose was 7.5 mg per day (range 5 to 20 mg per day). Breast milk levels were highest five hours after the mother took her dose. These data suggest that olanzapine may be relatively safe in breastfeeding women, but larger and longer term studies are clearly needed.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      &mdash; The American Academy of Pediatrics Committee on Drugs has not rated risperidone. There are two cases reported of infant exposure to risperidone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/101\">",
"       101",
"      </a>",
"      ]. At maternal doses of 1.5 to 4",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      neither the drug nor its metabolite were detectable in infant serum. Based upon breast milk levels, the calculated infant dose was 2.8 to 4.7 percent of the maternal dose. Both babies were healthy. Breast milk levels were also measured in one study, but the infant was bottle fed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/102\">",
"       102",
"      </a>",
"      ]. Given these limited data, if a mother chooses to breastfeed while taking risperidone, the infant should be monitored closely.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      &mdash; The American Academy of Pediatrics Committee on Drugs has not rated quetiapine. There is one case report of exposure to quetiapine during pregnancy and subsequently during lactation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/103\">",
"       103",
"      </a>",
"      ]. Estimated infant exposure was 0.43 percent of the maternal weight adjusted dose. The baby, who did not start breastfeeding until 8 weeks of age and was not exclusively breastfed, was doing well at the follow-up evaluation at 4.5 months. Infant exposure was also estimated in six breastfed infants whose mothers were taking quetiapine (25 mg to 400",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in addition to an SSRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38745/abstract/104\">",
"       104",
"      </a>",
"      ]. Breast milk levels correlated with maternal dose and ranged from undetectable (dose of 25 to 75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      to 264",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (dose 400",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      Infant exposure was estimated to range from less than 0.01",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      to 0.1",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"      Neurodevelopment was within normal limits between 9 and 18 months in four infants. One infant had mild motor and mental delays and one had mild mental delays, but the authors noted that these results could not be correlated with drug exposure.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       Ziprasidone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      &mdash; The American Academy of Pediatrics Committee on Drugs has not rated either medication. There are no published data on ziprasidone or aripiprazole use during breastfeeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=see_link\">",
"       \"Patient information: Health and nutrition for women who breastfeed (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/9/41105?source=see_link\">",
"       \"Patient information: Postpartum depression (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=see_link\">",
"       \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the woman is psychotic, she should not breastfeed, and should not be left alone with the baby. In general, we suggest that women who take antipsychotics not breastfeed due to lack of safety information. However, some women may still choose to breastfeed on these medications. In this situation, it is best to avoid polypharmacy, use the lowest effective dose (as always), and monitor the infant closely with standardized developmental screening tools, if available. Close coordination of care with the pediatrician is essential. The mother will also require close supervision, as her parenting skills may be compromised by her psychiatric disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All psychotropic medications are transferred into breast milk, and thus are passed on to the nursing infant. Exposure of most infants to antidepressants via human milk is clinically insignificant, with some exceptions. The benefits of breastfeeding generally outweigh the relatively small risk of the psychotropic medication. Rather than creating a situation in which the mother stops medication in order to breastfeed (and relapses), she should be offered the choice to breastfeed on medications when possible. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We recommend that the patient be advised of the American Academy of Pediatrics position on each medication, and also be apprised of the data that may further qualify that position.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Bipolar disorder/psychosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      and valproic acid are the only drugs for treatment of bipolar disorder and psychosis rated \"compatible\" with breastfeeding by the American Academy of Pediatrics Committee on Drugs. However, in the absence of long-term neurodevelopmental data, we do not suggest that women breastfeed on these medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H21\">",
"       'Medications for bipolar disorder and psychosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest women on antidepressants breastfeed because the benefits of breastfeeding generally outweigh the relatively small risk of the psychotropic medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In women who choose to breastfeed while using antidepressants, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      in women whose psychiatric disorder is effectively managed by these medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, if the woman was taking a different SSRI successfully during pregnancy, we do not suggest switching SSRIs during lactation (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/1\">",
"      Stowe ZN, Hostetter AL, Owens MJ, et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 2003; 64:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/2\">",
"      Hale, TW. Pharmacology Review: Drug Therapy and Breastfeeding: Antidepressants, Antipsychotics, Antimanics, and Sedatives. NeoReviews 2004; 5:e451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/3\">",
"      Lester BM, Cucca J, Andreozzi L, et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993; 32:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/4\">",
"      Schmidt K, Olesen OV, Jensen PN. Citalopram and breast-feeding: serum concentration and side effects in the infant. Biol Psychiatry 2000; 47:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/5\">",
"      Hallberg P, Sj&ouml;blom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005; 25:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/6\">",
"      Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005; 28:137.",
"     </a>",
"    </li>",
"    <li>",
"     Misri, S, et al. Am J Psychiatry (in press).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/8\">",
"      Isenberg KE. Excretion of fluoxetine in human breast milk. J Clin Psychiatry 1990; 51:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/9\">",
"      Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1992; 89:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/10\">",
"      Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 1996; 36:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/11\">",
"      Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology 1996; 53:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/12\">",
"      Yoshida K, Smith B, Craggs M, Kumar RC. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry 1998; 172:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/13\">",
"      Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr (Phila) 1998; 37:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/14\">",
"      Kristensen JH, Ilett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999; 48:521.",
"     </a>",
"    </li>",
"    <li>",
"     National Toxicology Program and Center for the Evaluation of Risks to Human Reproduction (CERHR). Expert panel report on the reproductive and developmental toxicity of fluoxetine. NTP-CERHR-Fluoxetine-04, April 2004 p. 144. Available at: file://cerhr.niehs.nih.gov/news/fluoxetine/fluoxetine_final.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/16\">",
"      Burt VK, Suri R, Altshuler L, et al. The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001; 158:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/17\">",
"      Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/18\">",
"      Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999; 104:e61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/19\">",
"      Hendrick V, Smith LM, Hwang S, et al. Weight gain in breastfed infants of mothers taking antidepressant medications. J Clin Psychiatry 2003; 64:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/20\">",
"      Epperson CN, Anderson GM, McDougle CJ. Sertraline and breast-feeding. N Engl J Med 1997; 336:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/21\">",
"      Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry 1997; 154:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/22\">",
"      Mammen OK, Perel JM, Rudolph G, et al. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997; 58:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/23\">",
"      Wisner KL, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry 1998; 155:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/24\">",
"      Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001; 179:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/25\">",
"      Epperson N, Czarkowski KA, Ward-O'Brien D, et al. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psychiatry 2001; 158:1631.",
"     </a>",
"    </li>",
"    <li>",
"     Hale, T. Medications and Mother's Milk. 9th edition. Pharmasoft Publishing, Amarillo TX, 2000. pp 597.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/27\">",
"      Ohman R, H&auml;gg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999; 60:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/28\">",
"      Begg EJ, Duffull SB, Saunders DA, et al. Paroxetine in human milk. Br J Clin Pharmacol 1999; 48:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/29\">",
"      Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry 2000; 61:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/30\">",
"      Stowe ZN, Cohen LS, Hostetter A, et al. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000; 157:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/31\">",
"      Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk. Br J Clin Pharmacol 1991; 31:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/32\">",
"      Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry 2001; 62:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/33\">",
"      Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997; 43:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/34\">",
"      H&auml;gg S, Granberg K, Carleborg L. Excretion of fluvoxamine into breast milk. Br J Clin Pharmacol 2000; 49:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/35\">",
"      Arnold LM, Suckow RF, Lichtenstein PK. Fluvoxamine concentrations in breast milk and in maternal and infant sera. J Clin Psychopharmacol 2000; 20:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/36\">",
"      Kristensen JH, Hackett LP, Kohan R, et al. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact 2002; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/37\">",
"      Spigset O, Carieborg L, Ohman R, Norstr&ouml;m A. Excretion of citalopram in breast milk. Br J Clin Pharmacol 1997; 44:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/38\">",
"      Jenson, PN, Olesen, OV, Bertelsen, A, Linnet, K. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monitor 1997; 19: 236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/39\">",
"      Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/40\">",
"      Rampono J, Kristensen JH, Hackett LP, et al. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol 2000; 50:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/41\">",
"      Potts AL, Young KL, Carter BS, Shenai JP. Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram. J Perinatol 2007; 27:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/42\">",
"      Verbeeck RK, Ross SG, McKenna EA. Excretion of trazodone in breast milk. Br J Clin Pharmacol 1986; 22:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/43\">",
"      Ilett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998; 45:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/44\">",
"      Hendrick V, Altshuler L, Wertheimer A, Dunn WA. Venlafaxine and breast-feeding. Am J Psychiatry 2001; 158:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/45\">",
"      Ilett KF, Kristensen JH, Hackett LP, et al. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol 2002; 53:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/46\">",
"      Berle J&Oslash;, Steen VM, Aamo TO, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004; 65:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/47\">",
"      Briggs GG, Ambrose PJ, Ilett KF, et al. Use of duloxetine in pregnancy and lactation. Ann Pharmacother 2009; 43:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/48\">",
"      Boyce PM, Hackett LP, Ilett KF. Duloxetine transfer across the placenta during pregnancy and into milk during lactation. Arch Womens Ment Health 2011; 14:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/49\">",
"      Lobo ED, Loghin C, Knadler MP, et al. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin Pharmacokinet 2008; 47:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/50\">",
"      Baab SW, Peindl KS, Piontek CM, Wisner KL. Serum bupropion levels in 2 breastfeeding mother-infant pairs. J Clin Psychiatry 2002; 63:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/51\">",
"      Davis MF, Miller HS, Nolan PE Jr. Bupropion levels in breast milk for 4 mother-infant pairs: more answers to lingering questions. J Clin Psychiatry 2009; 70:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/52\">",
"      Breyer-Pfaff U, Nill K, Entenmann KN, Gaertner HJ. Secretion of amitriptyline and metabolites into breast milk. Am J Psychiatry 1995; 152:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/53\">",
"      Pittard WB 3rd, O'Neal W Jr. Amitriptyline excretion in human milk. J Clin Psychopharmacol 1986; 6:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/54\">",
"      Bader TF, Newman K. Amitriptyline in human breast milk and the nursing infant's serum. Am J Psychiatry 1980; 137:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/55\">",
"      Wisner KL, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 1991; 148:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/56\">",
"      Wisner KL, Perel JM. Nortriptyline treatment of breast-feeding women. Am J Psychiatry 1996; 153:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/57\">",
"      Matheson I, Skjaeraasen J. Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between-breast differences in two patients. Eur J Clin Pharmacol 1988; 35:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/58\">",
"      Sovner R, Orsulak PJ. Excretion of imipramine and desipramine in human breast milk. Am J Psychiatry 1979; 136:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/59\">",
"      Stancer HC, Reed KL. Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant's serum. Am J Psychiatry 1986; 143:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/60\">",
"      Schimmell MS, Katz EZ, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991; 29:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/61\">",
"      Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry 1995; 56:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/62\">",
"      Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series. Pediatrics 1999; 104:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/63\">",
"      Matheson I, Pande H, Alertsen AR. Respiratory depression caused by N-desmethyldoxepin in breast milk. Lancet 1985; 2:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/64\">",
"      Kemp J, Ilett KF, Booth J, Hackett LP. Excretion of doxepin and N-desmethyldoxepin in human milk. Br J Clin Pharmacol 1985; 20:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/65\">",
"      Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. J Pediatr 2012; 161:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/66\">",
"      Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/67\">",
"      Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998; 59 Suppl 6:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/68\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/69\">",
"      Weinstein MR, Goldfield M. Lithium carbonate treatment during pregnancy; report of a case. Dis Nerv Syst 1969; 30:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/70\">",
"      Fries H. Lithium in pregnancy. Lancet 1970; 1:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/71\">",
"      Tunnessen WW Jr, Hertz CG. Toxic effects of lithium in newborn infants: a commentary. J Pediatr 1972; 81:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/72\">",
"      Schou M, Amdisen A. Lithium and pregnancy. 3. Lithium ingestion by children breast-fed by women on lithium treatment. Br Med J 1973; 2:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/73\">",
"      Sykes PA, Quarrie J, Alexander FW. Lithium carbonate and breast-feeding. Br Med J 1976; 2:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/74\">",
"      Skausig OB, Schou M. [Breast feeding during lithium therapy]. Ugeskr Laeger 1977; 139:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/75\">",
"      Viguera AC, Newport DJ, Ritchie J, et al. Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry 2007; 164:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/76\">",
"      Tanaka T, Moretti ME, Verjee ZH, et al. A pitfall of measuring lithium levels in neonates. Ther Drug Monit 2008; 30:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/77\">",
"      Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003; 61:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/78\">",
"      Stahl MM, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. J Pediatr 1997; 130:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/79\">",
"      Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast-feeding. Eur J Pediatr 1990; 150:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/80\">",
"      Merlob P, Mor N, Litwin A. Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. Ann Pharmacother 1992; 26:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/81\">",
"      Rambeck B, Kurlemann G, Stodieck SR, et al. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol 1997; 51:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/82\">",
"      Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997; 38:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/83\">",
"      Oana Y. Epileptic seizures and pseudoseizures from the viewpoint of the hierarchy of consciousness. Epilepsia 1998; 39 Suppl 5:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/84\">",
"      Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/85\">",
"      Newport DJ, Pennell PB, Calamaras MR, et al. Lamotrigine in breast milk and nursing infants: determination of exposure. Pediatrics 2008; 122:e223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/86\">",
"      Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/87\">",
"      Ohman I, Vitols S, Luef G, et al. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002; 43:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/88\">",
"      Yoshida K, Smith B, Craggs M, Kumar R. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychol Med 1998; 28:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/89\">",
"      Blacker, KH, Weinstein, BJ, Ellman, GL. Mother's milk and Chlorpromazine. Am J Psychiatry 1962; 119:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/90\">",
"      Wiles DH, Orr MW, Kolakowska T. Chlorpromazine levels in plasma and milk of nursing mothers. Br J Clin Pharmacol 1978; 5:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/91\">",
"      KRIS EB, CARMICHAEL DM. Chlorpromazine maintenance therapy during pregnancy and confinement. Psychiatr Q 1957; 31:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/92\">",
"      Olesen OV, Bartels U, Poulsen JH. Perphenazine in breast milk and serum. Am J Psychiatry 1990; 147:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/93\">",
"      Matheson I, Evang A, Over&oslash; KF, Syversen G. Presence of chlorprothixene and its metabolites in breast milk. Eur J Clin Pharmacol 1984; 27:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/94\">",
"      Whalley LJ, Blain PG, Prime JK. Haloperidol secreted in breast milk. Br Med J (Clin Res Ed) 1981; 282:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/95\">",
"      Stewart RB, Karas B, Springer PK. Haloperidol excretion in human milk. Am J Psychiatry 1980; 137:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/96\">",
"      Croke S, Buist A, Hackett LP, et al. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol 2002; 5:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/97\">",
"      Patton SW, Misri S, Corral MR, et al. Antipsychotic medication during pregnancy and lactation in women with schizophrenia: evaluating the risk. Can J Psychiatry 2002; 47:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/98\">",
"      Barnas C, Bergant A, Hummer M, et al. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994; 151:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/99\">",
"      Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000; 20:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/100\">",
"      Gardiner SJ, Kristensen JH, Begg EJ, et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am J Psychiatry 2003; 160:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/101\">",
"      Ilett KF, Hackett LP, Kristensen JH, et al. Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann Pharmacother 2004; 38:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/102\">",
"      Hill RC, McIvor RJ, Wojnar-Horton RE, et al. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. J Clin Psychopharmacol 2000; 20:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/103\">",
"      Lee A, Giesbrecht E, Dunn E, Ito S. Excretion of quetiapine in breast milk. Am J Psychiatry 2004; 161:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38745/abstract/104\">",
"      Misri S, Corral M, Wardrop AA, Kendrick K. Quetiapine augmentation in lactation: a series of case reports. J Clin Psychopharmacol 2006; 26:508.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1720 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38745=[""].join("\n");
var outline_f37_53_38745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Fluoxetine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Sertraline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Paroxetine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fluvoxamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Citalopram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Escitalopram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serotonin reuptake inhibitor/antagonist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Trazodone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serotonin-norepinephrine reuptake inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Venlafaxine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Duloxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dopamine-reuptake inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bupropion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Alpha 2 antagonist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Mirtazapine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      BENZODIAZEPINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MEDICATIONS FOR BIPOLAR DISORDER AND PSYCHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Lithium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Valproic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Carbamazepine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Lamotrigine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Topiramate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Conventional (typical) antipsychotic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Novel (atypical) antipsychotic medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Bipolar disorder/psychosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42582?source=related_link\">",
"      Obsessive-compulsive disorder in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=related_link\">",
"      Patient information: Health and nutrition for women who breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=related_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/9/41105?source=related_link\">",
"      Patient information: Postpartum depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20666?source=related_link\">",
"      Postpartum blues and depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17014?source=related_link\">",
"      Postpartum psychosis: Epidemiology, clinical manifestations, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/62/29670?source=related_link\">",
"      Treatment of postpartum psychosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_53_38746="Management of asymptomatic abdominal aortic aneurysm";
var content_f37_53_38746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of asymptomatic abdominal aortic aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     Ronald L Dalman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     Matthew Mell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     Denis L Clement, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/53/38746/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/53/38746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H611107773\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal aortic aneurysm (AAA) is a common and potentially life-threatening condition. Approximately 15,000 deaths per year are attributed to ruptured AAA in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/1\">",
"     1",
"    </a>",
"    ]. Without repair, ruptured AAA is nearly uniformly fatal. Of the 50 percent of patients with ruptured AAA who reach the hospital for treatment, between 30 and 50 percent will die in the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For asymptomatic patients, elective repair of the aneurysm is the most effective management to prevent rupture. However, elective aortic surgery is also associated with risks, and thus, elective AAA repair is not recommended until the risk of rupture exceeds the risks associated with repair. For asymptomatic patients, the risk of AAA rupture generally exceeds the risk associated with elective AAA repair when aneurysm diameter exceeds 5.5 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Other factors such as the patient&rsquo;s age, rate of aneurysm expansion, and the presence of coexistent peripheral artery disease or peripheral aneurysm are also important to consider when determining when to proceed with elective AAA repair.",
"   </p>",
"   <p>",
"    For patients with asymptomatic AAA who do not have indications for elective repair, medical treatment is aimed at reducing cardiovascular risk in the event that AAA repair is needed, and limiting the rate of aortic expansion. When elective AAA repair is indicated, the choice between open and endovascular AAA repair remains controversial. Although elective endovascular AAA repair is associated with lower rates of perioperative (30-day) morbidity and mortality compared with elective open repair (&lt;2 versus about 5 percent), long-term outcomes are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of the patient with asymptomatic AAA will be reviewed here. The clinical features and issues related to diagnosis and screening, management of symptomatic (nonruptured) and ruptured AAA, and details of surgical and endovascular repair are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24488?source=see_link\">",
"     \"Screening for abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11450?source=see_link\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=see_link\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link\">",
"     \"Endovascular repair of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30904?source=see_link\">",
"     \"Surgical and endovascular repair of ruptured abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611107780\">",
"    <span class=\"h1\">",
"     ANEURYSM TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal aorta with a maximal diameter &gt;3.0 cm is considered aneurysmal in most adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ]. Abdominal aortic aneurysm (AAA) most often affects the segment of aorta between the renal and inferior mesenteric arteries (infrarenal) (",
"    <a class=\"graphic graphic_figure graphicRef60682 \" href=\"mobipreview.htm?9/29/9683\">",
"     figure 1",
"    </a>",
"    ); approximately 5 percent involve the renal (pararenal) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87567 \" href=\"mobipreview.htm?36/57/37782\">",
"     image 1",
"    </a>",
"    ) or visceral arteries (suprarenal) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=see_link&amp;anchor=H22314302#H22314302\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Aneurysm definition and anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the purposes of this discussion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small aneurysms have a diameter &lt;4.0 cm",
"     </li>",
"     <li>",
"      Medium aneurysms have a diameter between 4.0 and 5.5 cm",
"     </li>",
"     <li>",
"      Large aneurysms have a diameter &ge;5.5 cm",
"     </li>",
"     <li>",
"      Very large aneurysms have a diameter &ge;6.0 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rapid expansion, which is thought to increase the risk for rupture, is defined as an increase in maximal aortic diameter &ge;5 mm over a six-month period of time or &gt;10 mm over a year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11450?source=see_link&amp;anchor=H91206665#H91206665\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\", section on 'Aortic expansion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933032628\">",
"    <span class=\"h2\">",
"     Clinical presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most AAAs do not produce any symptoms. An occult AAA may be discovered as a result of screening, on routine physical examination, or on imaging studies obtained to evaluate an unrelated condition. Symptomatic AAA refers to any of a number of symptoms (eg, abdominal pain, limb ischemia) that can be attributed to the aneurysm. Symptoms associated with AAA may or may not be due to AAA rupture. The clinical features and diagnosis of AAA, and the management of symptomatic (nonruptured) and ruptured AAA are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=see_link&amp;anchor=H933041496#H933041496\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191820574\">",
"    <span class=\"h1\">",
"     ANEURYSM REPAIR VERSUS CONSERVATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective AAA repair is the most effective management to prevent rupture. However, elective aortic surgery is associated with risks, and thus, elective AAA repair is not recommended until the risk of rupture exceeds the risks associated with repair (anesthetic risk, technique-related risks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/6\">",
"     6",
"    </a>",
"    ]. For asymptomatic patients, randomized trials comparing observation for medium-sized (4.0 to 5.5 cm AAA) with open or endovascular AAA repair have found that the risk of AAA rupture generally does not exceed the risk associated with elective AAA repair until aneurysm diameter exceeds 5.5 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. We agree with 2009 guidelines from the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery and recommend observation for asymptomatic AAA &lt;5.5 cm in diameter based upon these trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H431203144\">",
"     'Aneurysm diameter and rupture risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The timing of AAA repair may be affected by other factors such as the presence of coexistent peripheral artery disease or peripheral aneurysm (eg, iliac aneurysm, femoral aneurysm) and other factors that increase the risk of rupture, including advanced age and rapid aneurysm expansion. (See",
"    <a class=\"local\" href=\"#H3585400\">",
"     'Other considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although repair may not be warranted in patients with AAA diameter &lt;5.5 cm, these patients remain at risk for aneurysm expansion. As such, management consists of ongoing clinical evaluation and AAA surveillance, and risk modification. (See",
"    <a class=\"local\" href=\"#H3592986\">",
"     'Conservative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H431203144\">",
"    <span class=\"h2\">",
"     Aneurysm diameter and rupture risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysm diameter is one of the strongest predictors of aneurysm rupture, with risk increasing markedly at aneurysm diameters greater than 5.5 cm (",
"    <a class=\"graphic graphic_figure graphicRef57275 \" href=\"mobipreview.htm?43/25/44445\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9,14-21\">",
"     9,14-21",
"    </a>",
"    ]. Since it is uncommon for AAAs smaller than 5 cm to rupture, many vascular surgeons adopted this measurement as an indication for elective repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Larger aneurysm diameter and faster rate of aneurysm expansion correlate to an increased likelihood of symptoms and complications. Rupture is the most feared complication, and is associated with high morbidity and mortality. Other rare complications of AAA include aneurysm thrombosis and thromboembolism, which can lead to acute limb ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=see_link\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=see_link&amp;anchor=H1382371318#H1382371318\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Risk factors'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3586739\">",
"    <span class=\"h3\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon observational studies of the natural history of AAA showing that it was uncommon for asymptomatic AAA smaller than 5 cm to rupture, this was the traditional threshold above which open aneurysm repair was performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Whether this represented optimal management was addressed in randomized trials comparing aneurysm repair with nonoperative management plus surveillance imaging for medium-sized aneurysms (4.0 to 5.5 cm), with two trials using open AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], and three later trials using endovascular aneurysm repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/11-13,25,26\">",
"     11-13,25,26",
"    </a>",
"    ]. A metaanalysis of these trials found no advantage to early repair (open or endovascular) for AAA measuring 4.0 to 5.5 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3586232\">",
"    <span class=\"h4\">",
"     Observation versus open repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United Kingdom (UK) Small Aneurysm and Aneurysm Detection and Management (ADAM) trials, which were predominantly composed of men, the risk of death due to rupture during the period of surveillance of medium-sized (4.0 to 4.4 cm) AAA was lower than the risk of death from open AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A subsequent metaanalysis in 2007 of these trials found no significant differences in all-cause mortality between the groups at five to eight years follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The important points of these trials are summarized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      UK Small Aneurysm trial &ndash; The UK Small Aneurysm trial randomly assigned 1090 patients (83 percent men) with asymptomatic AAA with a diameter of 4.0 to 5.5 cm to elective surgery or observation with ultrasound surveillance every six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9,29\">",
"       9,29",
"      </a>",
"      ]. Open surgical repair was performed if the aneurysm diameter exceeded 5.5 cm, expanded more than 10 mm in a year, or became tender or symptomatic. The two groups had similar cardiovascular risk factors at baseline. After a mean follow-up of eight years, the following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An initial survival advantage was apparent for patients in the observation group because of a 30-day operative mortality of 5.4 percent. However, at eight years follow-up, mortality was significantly lower for patients who underwent elective surgery (43 versus 48 percent). Equipoise between the therapies was achieved at approximately five years (",
"      <a class=\"graphic graphic_figure graphicRef76015 \" href=\"mobipreview.htm?0/45/734\">",
"       figure 3",
"      </a>",
"      ) (the point at which the area under the survival curve is equal).",
"     </li>",
"     <li>",
"      The mean duration of survival was the same in the two groups (6.7 versus 6.5 years) since early mortality was offset by improved late survival in the group that underwent surgery. The authors ascribe the improved late survival in the surgery group to beneficial changes in lifestyle, particularly smoking cessation, which was more frequent in this group.",
"     </li>",
"     <li>",
"      During follow-up of the surveillance group, the median aneurysm growth rate was 3.3 mm per year and the mean risk of aneurysm rupture was 1.6 percent per year during the initial follow-up period, but increased to 3.2 percent per year during the last three years of follow-up, as expected, since the aneurysms under surveillance were larger during this later time period.",
"     </li>",
"     <li>",
"      The risk of AAA rupture was four times higher in women compared with men (hazard ratio [HR] 4.0, 95% CI 2.0-7.9). The incidence of fatal rupture was also significantly greater for women compared with men (19 versus 14 percent). (See",
"      <a class=\"local\" href=\"#H3585407\">",
"       'Female gender'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ADAM trial &ndash; The ADAM trial randomly assigned 1136 patients (over 99 percent male), aged 50 to 79 years with AAA diameter between 4.0 to 5.4 cm to open aneurysm repair or surveillance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/10\">",
"       10",
"      </a>",
"      ]. Elective surgery was performed when the aneurysm expanded to &gt;5.5 cm or became symptomatic. Operative mortality in this trial was 2.7 percent. After 4.9 years of follow-up, there were no differences in mortality (25 versus 21.5 percent) or aneurysm-related death (3 versus 2.6 percent) between the surgery and surveillance groups. In the surveillance arm, 62 percent of the patients eventually required surgery. AAA rupture occurred in 1.9 percent (0.6 percent per year).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3586239\">",
"    <span class=\"h4\">",
"     Observation versus endovascular repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UK Small Aneurysm Trial and the ADAM trial were performed prior to the widespread use of endovascular aneurysm repair (EVAR). Two trials comparing EVAR to observation for AAA &lt;5.5 cm similarly found no significant long-term differences between AAA repair and nonoperative management, and these studies lend further support to the 5.5 cm threshold established from earlier randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/11,12,25,26\">",
"     11,12,25,26",
"    </a>",
"    ]. In spite of the lower perioperative mortality rate associated with EVAR, there appears to be no advantage to elective EVAR repair for small and medium-sized aneurysms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3585400\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decision for elective repair of asymptomatic AAA relies primarily on determining rupture risk based upon aneurysm diameter &gt;5.5 cm. However, the diameter threshold for repair is not absolute. Deciding when to perform elective AAA repair should also take into account the natural history of AAA and factors that increase the risk for aneurysm expansion or rupture such as advanced age, female gender, and ongoing smoking, as well as expansion rates. Timing of AAA repair may also be affected by coexistent vascular disease or other peripheral artery aneurysms. The risk factors associated with AAA expansion and rupture are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11450?source=see_link&amp;anchor=H1428712#H1428712\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3585407\">",
"    <span class=\"h3\">",
"     Female gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The randomized trials discussed above were comprised predominately of men. For women, a lower threshold of 5 cm may be justified for elective repair of asymptomatic AAA due to the higher rate of rupture in women compared with men for AAA of the same diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9\">",
"     9",
"    </a>",
"    ]. However, because the risk of death from elective repair is also increased in women, it can be argued that the threshold for repair for women should be the same as for men, at 5.5 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Women at high risk for mortality with AAA repair are more likely to die from early intervention than from rupture. Conversely, women at low risk for mortality with repair appear to have a lower overall risk of AAA-related death following repair when the aneurysm reaches or exceeds 5 cm. A reasonable compromise may be to offer AAA repair to women who are at low operative risk at the lower threshold of 5.0 cm, while using the typical threshold for women who have a higher operative risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3585414\">",
"    <span class=\"h3\">",
"     Patient age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Younger patients with AAA with a long life expectancy will likely require repair at some point in their lives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9\">",
"     9",
"    </a>",
"    ]. The likelihood of needing surgery at some point in the future for medium-sized aneurysms (4.0 to 5.5 cm), is 50 percent at three years, 60 to 65 percent at five years, and 70 to 75 percent at eight years (",
"    <a class=\"graphic graphic_figure graphicRef77529 \" href=\"mobipreview.htm?2/6/2158\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9,10,28,29,32\">",
"     9,10,28,29,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, older patients and those with medical comorbidities often die from associated illnesses prior to expansion of the aneurysm to a size that would indicate a need for repair. Continued observation in older patients may be warranted for AAA that exceeds 5.5 cm. (See",
"    <a class=\"local\" href=\"#H3586992\">",
"     'Counseling the high-risk patient'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3585421\">",
"    <span class=\"h3\">",
"     Rapid expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earlier repair may benefit patients with well-documented rapid aneurysm expansion (&gt;5 mm in six months or 10 mm per year) on serial imaging studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9\">",
"     9",
"    </a>",
"    ]. Some data suggest that rapidly expanding AAAs are more likely to have symptoms and have a higher risk of rupture. Rapid expansion may represent instability of the aortic wall and may be a sign of impending aortic rupture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=see_link&amp;anchor=H1382371318#H1382371318\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3585428\">",
"    <span class=\"h3\">",
"     Coexistent aneurysm or PAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of AAA with a diameter that has not exceeded the threshold of 5.5 cm may be reasonable in patients with other associated arterial diseases such as aneurysmal disease of the iliac, femoral, or popliteal arteries, or symptomatic coexistent peripheral artery disease. It is important to note that aneurysm expansion tends to be less rapid in patients with peripheral artery disease or diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/10,33\">",
"     10,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link\">",
"     \"Popliteal artery aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29304?source=see_link\">",
"     \"Iliac artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repair of suprarenal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thoracoabdominal aneurysms involves more extensive surgery and greater operative risk. For this reason, and considering that the normal diameter of the proximal aorta is larger, repair of such aneurysms is typically not undertaken until the aortic diameter has exceeded 5.5 to 6.0 cm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3592638\">",
"    <span class=\"h3\">",
"     Very large aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with asymptomatic AAA can be managed on an outpatient basis. However, on occasion, a patient will present clinically with a very large (&ge;6.0 cm in diameter), asymptomatic AAA that may warrant admission and inpatient evaluation.",
"   </p>",
"   <p>",
"    Although there are no data to assist with clinical management of very large, asymptomatic AAA or any uniformly accepted standards of care, we suggest immediate referral to a vascular surgeon because of the high risk for rupture. We suggest earlier rather than later aneurysm repair once appropriate preoperative studies, medical risk assessment, and assessment of aortoiliac anatomy are completed. There is no advantage to an excessive delay. For patients found to have a very large, asymptomatic AAA in a practice setting that does not have vascular expertise, we suggest referral to a vascular center in a timely manner.",
"   </p>",
"   <p>",
"    Very large, asymptomatic AAA has an estimated rupture risk over a 12 month period of 10 to 20 percent for those between 6 and 7 cm, 20 to 40 percent for those 7 to 8 cm and 30 to 50 percent for those larger than 8 cm. The rupture risk over a period of weeks or months during the intervening period from the time of initial diagnosis and definitive treatment is not known. Rupture can occur during this interval. Because of the potential for rupture, some vascular surgeons routinely admit patients with very large, asymptomatic AAA for preoperative evaluation, but the validity of this practice has not been substantiated.",
"   </p>",
"   <p>",
"    The patient and his or her family should understand the risk of rupture prior to definitive repair and should be counseled regarding potential symptoms that can be associated with AAA and encouraged to communicate the development of symptoms to the surgeon and primary care physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3585830\">",
"    <span class=\"h1\">",
"     MEDICAL RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of elective AAA repair is to prevent rupture and minimize aneurysm-related morbidity and mortality. The assessment of risk for elective aneurysm repair versus the risks of observation should include the patient&rsquo;s expected survival from other medical conditions. Repair may not be warranted if the expected mortality rate from another condition is higher than the expected aneurysm-related mortality.",
"   </p>",
"   <p>",
"    Patients with coexistent coronary artery disease and cigarette smokers with significant chronic obstructive pulmonary disease are more likely to experience serious perioperative complications (eg, coronary ischemia, arrhythmias, pneumonia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/34\">",
"     34",
"    </a>",
"    ]. The risk for perioperative morbidity and mortality related to elective AAA repair is also increased in older patients, female patients, and those with renal dysfunction.",
"   </p>",
"   <p>",
"    Patients diagnosed with AAA have an increased risk for cardiovascular disease, and candidates for AAA repair should undergo cardiovascular risk assessment. This increase in risk was illustrated in a prospective study that identified AAA in 8.8 percent of patients screened; AAA was &lt;3.5 cm in diameter in 88 percent of the patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/35\">",
"     35",
"    </a>",
"    ]. During a 4.5 year follow-up period, patients with AAA had a higher overall mortality than those without AAA (adjusted risk [RR] 1.3, 95% CI 1.04-1.67) and an increased risk of incidental cardiovascular disease (adjusted risk 1.57, 95% CI 1.18-2.07). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of smoking in randomized trials among patients undergoing AAA repair is 24 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9,36-38\">",
"     9,36-38",
"    </a>",
"    ]. Current smokers and patients with a significant smoking history or pulmonary disease should be evaluated based upon standard guidelines for assessing perioperative risk. Patients with severe pulmonary disease who are not candidates for general anesthesia may be considered for endovascular aneurysm repair if there are no other contraindications for endovascular repair. Smoking cessation prior to elective surgery is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link&amp;anchor=H4#H4\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal failure is uncommon after AAA repair. One study identified six risk factors associated with renal failure (defined as a requirement of postoperative renal replacement therapy) following open AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/39\">",
"     39",
"    </a>",
"    ]. These included preoperative creatinine &gt;1.7",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    age &gt;75 years, symptomatic AAA, AAA rupture, treated hypertension, and pulmonary disease. Preoperative renal dysfunction was the strongest predictor of postoperative renal failure. In a study that evaluated data from the UK EVAR trials, there did not appear to be any significant long-term difference in renal function comparing endovascular with open AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3592986\">",
"    <span class=\"h1\">",
"     CONSERVATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small proportion of patients diagnosed with AAA meet the criteria for intervention at the time of the initial diagnosis. Based upon the result of randomized trials, patients with AAA &lt;5.5 cm in diameter should be managed conservatively. However, the natural history of AAA is one of progressive expansion necessitating periodic clinical evaluation and surveillance of aneurysm diameter to identify AAA that exceeds the threshold for repair or is rapidly expanding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical therapies for AAA focus on the management of modifiable risk factors for AAA and cardiovascular disease with the goals of reducing the need for intervention due to aneurysm expansion or rupture, reducing morbidity and mortality associated with repair, and reducing cardiovascular morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although many pharmacologic therapies aimed at limiting AAA expansion and preventing rupture have been tried, no pharmacologic therapy has been proven successful at achieving these goals, and as such, we suggest not implementing any of the pharmacologic therapies discussed below for the sole purpose of treating AAA. However, among the factors associated with AAA expansion and rupture, smoking is the most important modifiable risk factor and we recommend smoking cessation for all patients with AAA. Although reduced aneurysm expansion and rupture risk have not been clearly demonstrated among those who have stopped smoking, smoking cessation has other benefits. In addition, because AAA is regarded as a coronary risk equivalent, we agree with major society guidelines that recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (ASA) and statin therapy for patients with AAA to reduce the risk of a future cardiovascular event, unless contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Other medical conditions should be treated as appropriate (eg, hypertension).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91188805\">",
"    <span class=\"h2\">",
"     Therapies to limit aortic expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood that an aneurysm will expand or rupture is influenced by a number of factors including aneurysm diameter, rate of expansion, gender, ongoing smoking, recent surgery, and other medical factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/43\">",
"     43",
"    </a>",
"    ]. These risk factors are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H431203144\">",
"     'Aneurysm diameter and rupture risk'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11450?source=see_link&amp;anchor=H1428712#H1428712\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of drug targets that may inhibit AAA formation or progression have been identified in animal models and in vitro studies (",
"    <a class=\"graphic graphic_table graphicRef78741 \" href=\"mobipreview.htm?5/15/5373\">",
"     table 1",
"    </a>",
"    ). These studies have generated much interest for the treatment of patients with small aneurysms; however, to date, there is no proven evidence that any of these targets unequivocally prevents aortic expansion and rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91192084\">",
"    <span class=\"h3\">",
"     Potentially beneficial therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3584839\">",
"    <span class=\"h4\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is the risk factor most strongly associated with aneurysm formation, aneurysm expansion, and aneurysm rupture, and is the most important modifiable risk factor in patients with AAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/33,42,48-51\">",
"     33,42,48-51",
"    </a>",
"    ]. We agree with the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery guidelines and suggest that individuals diagnosed with AAA and those who have a family history of AAA be advised to stop smoking and offered cessation interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Smoking cessation has many other benefits. The management of smoking cessation is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18968?source=see_link\">",
"     \"Benefits and risks of smoking cessation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking cessation is presumed to provide a benefit by reducing the harmful effects of smoking in mediating connective tissue degradation, although this has not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/52\">",
"     52",
"    </a>",
"    ]. With smoking cessation, the risk of developing AAA slowly declines over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/43,49\">",
"     43,49",
"    </a>",
"    ], but the effect of smoking cessation on AAA that is already formed is unknown. There are no controlled trials of smoking cessation in patients with AAA, and it is unlikely that any such studies will ever be performed. However, former smokers undergoing AAA repair have lower rates of aneurysm-related mortality and all-cause mortality compared with current smokers, suggesting the importance of smoking cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Smoking cessation for at least two months prior to AAA repair was found in one prospective study to significantly reduce the incidence of postoperative respiratory complications (57 versus 15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3584846\">",
"    <span class=\"h4\">",
"     Exercise therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is widely accepted that higher levels of physical activity are associated with a lower risk of death and cardiovascular morbidity. We agree that patients with AAA should participate in an exercise program for secondary prevention of cardiovascular disease. Patients should be counseled that moderate physical activity",
"    <strong>",
"    </strong>",
"    does not precipitate AAA rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moderate physical therapy may also limit aneurysm expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/57\">",
"     57",
"    </a>",
"    ]. In experimental aneurysms, increased aortic blood flow appears to inhibit AAA expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/58\">",
"     58",
"    </a>",
"    ]. Magnetic resonance imaging in patients with AAA who have exercised has demonstrated increased abdominal aortic blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/59\">",
"     59",
"    </a>",
"    ], and thus, exercise may have the potential to limit AAA expansion in humans as well. Although the exact mechanisms remain to be determined, exercise reduces the levels of systemic markers of inflammation relevant to AAAs. A trial is ongoing to evaluate the effects of an exercise program on expansion rates of small AAAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/60\">",
"     60",
"    </a>",
"    ]. The preliminary results have shown that exercise decreases waist circumference, and reduces concentrations of C-reactive protein. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91192146\">",
"    <span class=\"h3\">",
"     Uncertain benefit for limiting AAA expansion",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3593747\">",
"    <span class=\"h4\">",
"     Beta blocker therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers have a role in managing patients with cardiovascular disease and patients with AAA who require surgical repair, but beta blockers have not been clearly shown to reduce aneurysm expansion rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of cardiac risk for noncardiac surgery\", section on 'Role of beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of early animal studies and retrospective reviews suggested that beta blockers may inhibit AAA expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. One study evaluated 121 patients with an infrarenal aortic aneurysm who were monitored by serial ultrasound examination; 38 of the patients were treated with a beta blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/62\">",
"     62",
"    </a>",
"    ]. The mean expansion rate was significantly lower in the patients receiving a beta blocker (0.36 versus 0.68 cm per year). However, two large trials found no significant differences in AAA expansion rates in patients receiving beta blockers compared with those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/61,65,66\">",
"     61,65,66",
"    </a>",
"    ]. The lack of benefit may have been related to poor compliance due to the side effects of beta blockade that measurably diminished quality of life. Although these studies did not show a benefit for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    in limiting AAA expansion, they do not exclude the possibility that a better-tolerated selective beta-adrenergic blocker could be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3593855\">",
"    <span class=\"h4\">",
"     ARBs and ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although animal studies have suggested the utility of angiotensin receptor blockers or angiotensin-converting enzyme (ACE) inhibitors in decreasing the rate of aneurysm expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], the clinical use of these agents in patients has not clearly demonstrated the same benefits. Infusion of angiotensin II into rodents promotes AAA formation, which is thought to be due to aortic inflammation and proteolysis and not due to the secondary increase in blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Angiotensin type 1 receptor blockade (ARB) usually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/72-77\">",
"     72-77",
"    </a>",
"    ], but not always [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/73\">",
"     73",
"    </a>",
"    ], inhibits aneurysm development in various animal models such as AAAs induced by angiotensin II, AAAs induced by chemical agents, and AAAs in mice genetically predisposed to aneurysm. Angiotensin converting enzyme (ACE) inhibitors are not as reliable for inhibiting experimental AAA development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/72,73,78\">",
"     72,73,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of clinical studies have associated reduced rates of AAA expansion or rupture with the use of ACE inhibitors and ARBs, but there have been no randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. A study of 15,326 patients who presented with AAA (intact or ruptured) evaluated the prehospital use of ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients taking ACE inhibitors were significantly less likely to present with ruptured aneurysm compared with those who were not on ACE inhibitors (odds ratio [OR] 0.82, 95% CI 0.74-0.90). In contrast, a report from the United Kingdom Small AAA study found an increased risk of AAA expansion for patients on ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/81\">",
"     81",
"    </a>",
"    ]. A randomized trial designed to compare AAA expansion rates for patients with small AAA taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    over a 24 month period is currently recruiting patients (ClinicalTrials.gov NCT01118520).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3593877\">",
"    <span class=\"h4\">",
"     Other antihypertensives agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics and calcium channel blockers have also been studied for their effects on AAA expansion. Although a trend toward lower expansion rates has been observed for calcium channel blockers, significant differences have not been seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/33\">",
"     33",
"    </a>",
"    ]. Diuretics appear to have no impact on expansion rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3593884\">",
"    <span class=\"h4\">",
"     Statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of AAA involves diminished integrity of the arterial wall driven by local inflammation, an altered balance in arterial wall repair, and degradation by enzymes such as matrix metalloproteinases (MMPs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/82\">",
"     82",
"    </a>",
"    ]. Statins reduce the expression of MMPs in a concentration-dependent manner, independent of their cholesterol-lowering effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal studies suggest that statins may limit AAA expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/85-90\">",
"     85-90",
"    </a>",
"    ]. However, the influence of statins for inhibiting atherosclerosis may be relatively greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/89\">",
"     89",
"    </a>",
"    ]. No randomized trials have specifically assessed the effect of statins on AAA expansion. A number of observational studies have examined the effect of statin therapy on the expansion of small AAAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/80,81,91-97\">",
"     80,81,91-97",
"    </a>",
"    ]. Early studies reported reduced rates of AAA expansion in patients treated with statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/91,92,94-97\">",
"     91,92,94-97",
"    </a>",
"    ]; however, larger studies did not confirm a relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/80,81,93,98,99\">",
"     80,81,93,98,99",
"    </a>",
"    ]. In the Tr&oslash;mso study, statin therapy was associated with an increased risk of developing AAA (OR 3.8, 95% CI 1.45-9.81) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/48\">",
"     48",
"    </a>",
"    ]. However, multiple metaanalyses found no evidence that statins impact AAA expansion rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. Thus, there is insufficient evidence to recommend the initiation of statin therapy solely for the treatment of AAAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3594091\">",
"    <span class=\"h4\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy has also been evaluated for its potential effect on AAA expansion. It was initially postulated that aneurysm progression may be enhanced by secondary microbial infection within the aortic wall. Serologic evidence of Chlamydia pneumoniae infection was associated with an increased rate of AAA expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/104\">",
"     104",
"    </a>",
"    ], and two small trials suggested that roxithromycin may decrease AAA expansion rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Although infection is known to potentially lead to the formation of aneurysms, clear evidence supporting a role for infection in the formation and progression of the majority of AAAs (noninfected) remains to be established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the late 1980s, it was recognized that the commonly used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    antibiotics inhibited matrix metalloproteinases (MMPs) in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/107\">",
"     107",
"    </a>",
"    ], and in aneurysm tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. MMPs are postulated to play a role in aneurysm formation. In at least 14 separate studies in animal models,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    has been found to inhibit aneurysm development and progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/45,110\">",
"     45,110",
"    </a>",
"    ]. In humans, doxycycline decreases inflammatory markers in AAA and may reduce the rate of AAA progression. Doxycycline is a potentially promising therapy to inhibit aneurysm progression, as evidenced by the studies summarized below, but further validation is needed before any recommendations can be made. Two large randomized trials are underway examining the efficacy of doxycycline in patients with small AAAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/45,111\">",
"     45,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One small trial randomly assigned 32 patients to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or placebo for three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/112\">",
"       112",
"      </a>",
"      ]. There were no significant differences in expansion rates between the doxycycline and placebo groups (1.5 versus 3.0 mm) over the 18-month follow-up period.",
"     </li>",
"     <li>",
"      Patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      while awaiting open AAA repair were found to have reduced inflammation on AAA biopsies (infiltration by neutrophils and T cells) at the time of repair compared with patients receiving placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study in patients who underwent endovascular AAA repair,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      reduced circulating concentrations of MMPs which may be a marker of aortic expansion signalling endograft failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3594098\">",
"    <span class=\"h4\">",
"     Antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet therapy may influence the formation of thrombus within AAA and reduce progression in patients with small AAA, but a definitive association between platelet inhibition and aneurysm progression has not been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/80\">",
"     80",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) is postulated to decrease thrombus formation, reduce aortic wall inflammation and stabilize the aortic wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/115\">",
"     115",
"    </a>",
"    ]. The volume of thrombus within AAAs correlates to maximum AAA diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/116\">",
"     116",
"    </a>",
"    ], and circulating concentrations of thrombin degradation products (D-dimer) are strongly associated with the presence of AAA and progression in patients with small AAAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Thrombus from human infrarenal AAAs also contains inflammatory cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. In animal models, platelet inhibition has been found to limit AAA formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. Although a number of clinical studies have been performed, antiplatelet therapy has not been evaluated in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/80,81,91-97,115\">",
"     80,81,91-97,115",
"    </a>",
"    ]. In one study, ASA was associated with decreased rates of progression of small AAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/115\">",
"     115",
"    </a>",
"    ]. However, larger studies have found no significant association between antiplatelet therapy and AAA expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/80,81,93\">",
"     80,81,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3594222\">",
"    <span class=\"h4\">",
"     Antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A characteristic histological feature of human AAA is a dense inflammatory infiltrate with a variety of cells including macrophages, neutrophils and lymphocytes typically present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/122,123\">",
"     122,123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elastases (proteases) secreted from these cells degrade the normal arterial wall architecture, and, particularly, the elastic lamellae. Aortic thrombus also contains neutrophils, and high concentrations of proinflammatory cytokines and proteolytic enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. Inhibition of these inflammatory cells suppresses the development of AAA in rodent models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/124\">",
"     124",
"    </a>",
"    ]. A number of protease inhibitors have been developed as antineoplastic agents, but most have side effects that would limit their use in patients with AAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mast cells, which contain chymase and other proinflammatory cytokines, may contribute to AAA formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/126\">",
"     126",
"    </a>",
"    ]. Mice that are deficient in this cell type are protected from experimental AAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. These findings have raised interest in the use of mast cell stabilizing agents in patients with small AAAs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3593134\">",
"    <span class=\"h2\">",
"     Cardiovascular risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Managing cardiovascular risk is important for improving overall outcomes associated with AAA repair (open surgical or endovascular repair) given that about half of patients with small AAA who are being conservatively managed will eventually undergo AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/129\">",
"     129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it does not appear that statins decrease rates of AAA expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/101\">",
"     101",
"    </a>",
"    ], most patients with AAA have other indications for statin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5\">",
"     5",
"    </a>",
"    ]. Statins are currently recommended for patients with AAA to reduce the progression of atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5\">",
"     5",
"    </a>",
"    ]. Long-term statin use is associated with decreased mortality in patients who have undergone repair of an AAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/91,130-138\">",
"     91,130-138",
"    </a>",
"    ]. A systematic review of statin use in patients with AAA found a significantly decreased risk of all-cause mortality at five years following AAA repair for those on statins compared with no statin therapy (odds ratio 0.57, 95% CI 0.42-0.79) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/101\">",
"     101",
"    </a>",
"    ]. Perioperative (30-day) mortality was not significantly different. Other studies have similarly found a benefit for statin therapy for patients with AAA. In the United Kingdom Heart Protection Study, 6748 patients with peripheral artery disease (including AAA) and 13,788 other participants were randomly assigned to receive 40 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/91\">",
"     91",
"    </a>",
"    ]. The incidence of a first major vascular event (coronary events, strokes, and revascularization) was reduced by 22 percent in those being treated. There was no apparent effect on the incidence of AAA between the groups (1.2 versus 1.1 percent).",
"   </p>",
"   <p>",
"    Current multidisciplinary guidelines regard AAA as a coronary heart disease equivalent and recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (ASA) therapy for patients with AAA to reduce cardiovascular risk, unless contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5\">",
"     5",
"    </a>",
"    ]. There is",
"    <strong>",
"     no",
"    </strong>",
"    evidence to suggest that ASA contributes in any way to initiating AAA expansion or rupture. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link&amp;anchor=H611365682#H611365682\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244545816\">",
"    <span class=\"h2\">",
"     Safety of antiplatelet therapy and AAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is currently unknown whether ASA alone has a substantial effect with respect to hemorrhage in association with AAA rupture. Theoretically, thrombus formation would be impeded; however, the retroperitoneal structures probably play a greater role in limiting the initial expansion of hematoma following AAA rupture. In general, we feel that the beneficial effects of ASA in reducing cardiovascular morbidity and mortality outweigh the theoretic risks of increased bleeding with AAA rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3586992\">",
"    <span class=\"h2\">",
"     Counseling the high-risk patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with AAA repair &gt;5.5 cm who have medical comorbidities that increase their risk for perioperative morbidity and mortality above the expected level for repair (open surgical or endovascular) may be best managed conservatively, reserving repair only if symptoms develop (including rupture). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=see_link\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expected rupture rates for untreated patients were identified in a study of 198 men with contraindications to repair or refusal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/139\">",
"     139",
"    </a>",
"    ]. The one-year incidence of rupture (and death) was 9.4 percent for AAA 5.5 to 5.9 cm in diameter, 10.2 percent for AAA 6.0 to 6.9 cm, and 37.5 percent for AAA &gt;7.0 cm.",
"   </p>",
"   <p>",
"    Long-term survival in high-risk patients may be unaffected by repair. The EVAR 2 (Endovascular repair of aortic aneurysm in patients physically ineligible for open repair) trial randomly assigned 404 patients with AAA &gt;5.5 cm and who were aged 60 years or older to endovascular aneurysm repair or no intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/13\">",
"     13",
"    </a>",
"    ]. The endovascular group had a lower risk of aneurysm-related mortality (adjusted hazard ratio 0.53, 95% CI 0.32-0.89) but there were no significant differences in all-cause mortality HR 0.99 (95% CI 0.78-1.27) at eight years follow-up.",
"   </p>",
"   <p>",
"    Decision-making in high-risk patients is difficult, but should include a candid discussion with the patient and his or her family members. This discussion should include counseling the patient to create an advanced directive detailing the patient&rsquo;s wishes in the event of rupture. Family members should be made aware of these wishes, given that the patient may not be able to report his or her wishes at the time of aneurysm rupture. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1045680\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with small and medium-sized AAA and high-risk patients who are being managed conservatively should undergo periodic clinical evaluation to evaluate for any symptoms that might be related to the aneurysm, and to monitor blood pressure and the success of risk-reduction strategies.",
"   </p>",
"   <p>",
"    For patients who elect no repair or who are not candidates for any type of repair, ongoing evaluation and surveillance is",
"    <strong>",
"     not",
"    </strong>",
"    needed. (See",
"    <a class=\"local\" href=\"#H3586992\">",
"     'Counseling the high-risk patient'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H766539\">",
"    <span class=\"h3\">",
"     Aneurysm surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with small aneurysms under observation should undergo periodic imaging to assess for aortic expansion, but the optimal surveillance schedule has not been clearly defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9,10,29,140\">",
"     9,10,29,140",
"    </a>",
"    ]. We obtain an annual ultrasound study for small aneurysms (&lt;4.5 cm) and annual or more frequent intervals (eg, every six months) for larger aneurysms depending upon the characteristics of the aneurysm (eg, expansion rate).",
"   </p>",
"   <p>",
"    In the United Kingdom small aneurysm study, a schedule for surveillance intervals was determined that minimized the likelihood of aneurysm growth to greater than 5.5 cm between screening visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/33\">",
"     33",
"    </a>",
"    ]. As might be expected, the recommended intervals for surveillance were shorter for larger aneurysms and longer for smaller aneurysms. Surveillance was every 3 months for AAA 5.0 to 5.4 cm, every 12 months for AAA 4.5 to 4.9 cm, every 24 months for AAA 4.0 to 4.4 cm and every 36 months for AAA 3.5 to 3.8 cm. In this study, less frequent surveillance was felt to be safe, and the suggested surveillance schedule resulted in a &lt;1 percent chance of an aneurysm surpassing 5.5 cm in diameter between screening visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based largely upon these results, the 2009 Society of Vascular Surgery guidelines and the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines for the diagnosis and management of peripheral artery disease recommend surveillance every 6 to 12 months using ultrasound or computed tomography (CT) for aneurysms 4.0 to 5.4 cm in diameter, but a less frequent interval (every two to three years) for aneurysms 3.0 to 4.0 cm in diameter, and every five years for aortic diameter between 2.6 to 2.9 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Recommendations for AAA surveillance schedule vary widely around the globe with several national programs advocating annual screening for AAA as small as 3.0 cm, and more frequent intervals (every three to six months) for larger aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer a more frequent interval because of the low cost of ultrasound and the reasons given below, obtaining an annual ultrasound study for small aneurysms (&lt;4.5 cm) and a more frequent interval for larger aneurysms, as needed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the aneurysm surveillance interval is extended beyond a year, the inherent inaccuracies associated with aortic measurements using ultrasound and computed tomography (CT) become more relevant. Multiple studies obtained over more frequent intervals help resolve conflicts and are more likely to capture rapid aortic expansion.",
"     </li>",
"     <li>",
"      There is a potential for patients to be lost to follow-up when extended surveillance intervals are used. If a longer interval is chosen, it is important to have a reminder system is in place.",
"     </li>",
"     <li>",
"      Significant anxiety is often associated with a diagnosis of AAA and many patients find reassurance with a fixed surveillance interval [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/142\">",
"       142",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Annual clinical examination and risk-reduction assessment can be performed concurrently [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/143,144\">",
"       143,144",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191821755\">",
"    <span class=\"h1\">",
"     AAA REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective AAA repair is the most effective management to prevent rupture. Two methods of aneurysm repair are currently available: open surgery and endovascular aneurysm repair (EVAR). The mortality of elective AAA repair is 3 to 5 percent for open AAA repair, but lower at 0.5 to 2 percent for EVAR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/145-147\">",
"     145-147",
"    </a>",
"    ]. When choosing the type of repair, it is important to take into account the patient&rsquo;s expected survival (short-term and long-term), which depends upon the patient&rsquo;s age and medical comorbidities. (See",
"    <a class=\"local\" href=\"#H3585830\">",
"     'Medical risk assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open AAA repair &ndash; Open aneurysm repair involves replacement of the diseased aortic segment with a tube or bifurcated prosthetic graft (",
"      <a class=\"graphic graphic_figure graphicRef56289 \" href=\"mobipreview.htm?32/11/32949\">",
"       figure 5",
"      </a>",
"      ) through a midline abdominal or retroperitoneal incision [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/148\">",
"       148",
"      </a>",
"      ]. With technical refinements for open AAA repair, complications such as acute renal failure, distal embolization, wound infection, colonic ischemia, false aneurysm formation, aorto-duodenal fistula, graft infection, and perioperative bleeding have become less common following routine elective surgery but remain significant issues following emergent open AAA repair.",
"     </li>",
"     <li>",
"      EVAR &ndash; Endovascular aneurysm repair (EVAR) involves the placement of modular graft components delivered via the iliac or femoral arteries to line the aorta (",
"      <a class=\"graphic graphic_figure graphicRef56289 \" href=\"mobipreview.htm?32/11/32949\">",
"       figure 5",
"      </a>",
"      ) and exclude the aneurysm sac from the circulation. EVAR requires fulfillment of specific anatomic criteria. Up to 70 percent of patients are EVAR candidates. This percentage is expected to increase with the approval of specialized endograft designs that will allow the treatment of more challenging aortic aneurysm anatomy. Although EVAR is associated with lower perioperative mortality, late AAA rupture has been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H786575\">",
"    <span class=\"h2\">",
"     Summary of indications for elective AAA repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of AAA is generally indicated under the circumstances listed below. These indications are discussed in more detail elsewhere. (See",
"    <a class=\"local\" href=\"#H1191820574\">",
"     'Aneurysm repair versus conservative management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic AAA &gt;5.5 cm",
"     </li>",
"     <li>",
"      Rapidly expanding AAA",
"     </li>",
"     <li>",
"      AAA associated with peripheral arterial aneurysm (eg, iliac, popliteal) or peripheral artery disease (eg, iliac occlusive disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783678\">",
"    <span class=\"h2\">",
"     Open versus endovascular aneurysm repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;When it has been determined that a patient should undergo AAA repair, the choice between open surgical or endovascular aneurysm repair is individualized based upon the patient&rsquo;s age, risk for perioperative morbidity and mortality, and aortoiliac anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5,56,149\">",
"     5,56,149",
"    </a>",
"    ]. Given the need for lifelong surveillance with endovascular repair, younger patients with low operative risk may benefit more from open surgical repair, whereas older patients and those with high perioperative risk may benefit more from endovascular repair, provided their aortoiliac anatomy is appropriate for repair.",
"   </p>",
"   <p>",
"    Randomized trials comparing open AAA repair with EVAR have found significantly improved short-term (30-day) morbidity and mortality for EVAR, but no significant differences in long-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/37,150-154\">",
"     37,150-154",
"    </a>",
"    ]. A pooled analysis of these trials identified a 69 percent reduction in the risk for perioperative mortality for endovascular compared with open repair (odds ratio [OR] .33, 95% CI 0.17-0.64) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/155\">",
"     155",
"    </a>",
"    ]. EVAR appears to be associated with the need for more secondary procedures, and an ongoing future risk of aortic rupture. The important points of these randomized trials are summarized below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3594568\">",
"    <span class=\"h3\">",
"     DREAM trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Dutch Randomized Endovascular Aneurysm Management (DREAM) trial randomly assigned 351 patients to open repair or EVAR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/36\">",
"     36",
"    </a>",
"    ]. All patients had AAA &gt;5 cm in maximal diameter and were suitable candidates for either technique.",
"   </p>",
"   <p>",
"    The perioperative (30-day) mortality rate was lower for EVAR compared with open AAA repair (1.2 versus 4.6 percent), though this result was not significant. At two-years post-randomization, the cumulative rates of aneurysm-related death remained less for EVAR (2.1 versus 5.7 percent) compared with open repair, a difference that was entirely due to the initial perioperative outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/150\">",
"     150",
"    </a>",
"    ]. However, there were no significant differences in overall survival (89.7 percent for EVAR and 89.6 percent for open repair). The perioperative survival advantage seen with EVAR was not sustained after the first postoperative year, due to an increase in non-aneurysm-related mortality in the EVAR group. These results were maintained at six years with survival rates for EVAR at 68.9 percent and open repair at 69.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/151\">",
"     151",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p>",
"    The rate of moderate and severe systemic complications was significantly lower for EVAR (11.7 versus 26.4 percent) compared with open repair. Rates of moderate and severe vascular or graft-related complications were significantly greater for EVAR (16.4 versus 8.6 percent) compared with open repair. The need for secondary vascular intervention was significantly higher for EVAR (29.6 versus 18.1 percent) compared with open repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3594590\">",
"    <span class=\"h3\">",
"     EVAR 1 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endovascular aneurysm repair versus open repair in patients with AAA (EVAR1) trial randomly assigned 1252 patients to AAA repair with EVAR (n = 626) or open AAA repair (n = 626) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The perioperative (30-day) mortality was significantly less for EVAR (1.8 versus 4.3 percent). No significant differences were seen in overall mortality, and graft-related complications occurred more frequently with EVAR. New complications related to EVAR continued to occur out to eight-years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reintervention rates were significantly higher for EVAR compared with open repair. A criticism of this trial was that all complications related to open repair, such as incisional hernia, were not included in the study. The short-term benefit of EVAR was lost due to late fatal aneurysm ruptures. The authors concluded that treatment by EVAR significantly reduced the operative mortality compared with open repair, but there were no long-term advantages of one type of repair for aneurysm-related or overall mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3594604\">",
"    <span class=\"h3\">",
"     OVER trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Open Versus Endovascular Repair (OVER) trial is an ongoing multicenter trial at the Veterans Affairs Medical Centers that randomly assigned 881 veterans &ge;49 with AAA &gt;5.0 cm, an associated iliac aneurysm with maximal diameter &ge;3.0 cm, or a diameter of &ge;4.5 cm with rapid enlargement (defined as 0.5 cm growth in six months or 1.0 cm in one year) to open AAA repair or EVAR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients were candidates for either type of repair.",
"   </p>",
"   <p>",
"    Overall mortality was not significantly different between the groups at two (7.0 percent EVAR, 9.8 percent open repair) or nine years follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/154\">",
"     154",
"    </a>",
"    ]. Six aneurysm ruptures were confirmed in the endovascular-repair group compared with none in the open-repair group (mean follow-up 5.2 years); however, this was not statistically significant.",
"   </p>",
"   <p>",
"    EVAR was associated with significantly shorter procedure times (2.9 versus 3.7 hours), a shorter duration of mechanical ventilation (3.6 versus 5.0 hours), shorter intensive care unit stay (1 versus 4 days), shorter length of hospital length (3 versus 7 days), and lower transfusion requirements (0 versus 1 unit).",
"   </p>",
"   <p>",
"    In this trial, incisional hernia was included as an open repair-related complication. As a result, the rates of secondary intervention were found to be similar between the groups (13.7 percent EVAR, 12.5 percent open AAA repair) with the majority of secondary procedures in the EVAR group due to endovascular revisions, and due to repair of incisional hernia in the open AAA group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3594618\">",
"    <span class=\"h3\">",
"     ACE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Aneurysme de l'aorte abdominale: Chirurgie versus Endoprothese (ACE) trial randomly assigned 316 patients with AAA &gt;5 cm to EVAR or open surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/153\">",
"     153",
"    </a>",
"    ]. As with the studies above, there were no significant differences in the cumulative survival or major adverse events rates (95.9 versus 93.2 percent at one-year follow-up, and 85.1 versus 82.4 percent, respectively, at three-years follow up). In-hospital mortality was also not significantly different (0.6 versus 1.3 percent). The need for reintervention was higher in the EVAR group (16 versus 2.4 percent), compared with open AAA repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783739\">",
"    <span class=\"h2\">",
"     Choice of AAA repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the randomized trials presented above, the main benefits of EVAR appear to be the greatest in the short-term, and thus, EVAR may be the most appropriate choice for patients with a limited life expectancy and those with a high level of perioperative risk. However, whether younger patients who are",
"    <strong>",
"     not",
"    </strong>",
"    at high risk for open surgery should undergo open surgical versus EVAR remains controversial. Surveillance of endovascular stent-grafts over an extended period of time exposes the patient to greater levels of cumulative radiation, and EVAR does not eliminate the risk of future aortic rupture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link\">",
"     \"Complications of endovascular abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with guidelines from major medical and surgical societies that emphasize an individualized approach when choosing the type of AAA repair, taking into account the patient's age, gender, risk for AAA rupture, and risk factors for perioperative morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5,56,149\">",
"     5,56,149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open surgical repair may be preferred for younger patients who have a low or average perioperative risk.",
"     </li>",
"     <li>",
"      Endovascular repair may be preferred in patients with favorable anatomy (as defined by the instructions for use [IFU] of a given device) who are at a high level of perioperative risk.",
"     </li>",
"     <li>",
"      Endovascular repair may be appropriate in patients with favorable anatomy but who do not have a high surgical risk; however, the early perioperative benefit may not be sustained in the long-term.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/39/22130?source=see_link\">",
"       \"Patient information: Abdominal aortic aneurysm (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/62/34787?source=see_link\">",
"       \"Patient information: Abdominal aortic aneurysm (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909597049\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal aortic aneurysm (AAA) is a common and potentially life-threatening condition. Approximately 15,000 deaths per year are attributed to ruptured AAA in the United States. Without repair, ruptured AAA is nearly uniformly fatal. For asymptomatic patients, elective repair of the aneurysm is the most effective management to prevent rupture. (See",
"      <a class=\"local\" href=\"#H611107773\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with asymptomatic infrarenal AAA &lt;5.5 cm, we recommend conservative management (watchful waiting) rather than elective AAA repair (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The risk of aneurysm rupture does not exceed the risk of repair until the aneurysm diameter reaches 5.5 cm. For good risk surgical candidates (open or endovascular repair) with AAA &gt;5.5 cm, we recommend elective AAA repair (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Situations for which elective repair of AAA &lt;5.5 cm may also be appropriate include (see",
"      <a class=\"local\" href=\"#H1191820574\">",
"       'Aneurysm repair versus conservative management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rapidly expanding (&gt;0.5 cm in six months or &gt;1 cm per year) infrarenal AAA in well-documented serial studies. Rapid expansion may represent instability of the aortic wall, and some studies suggest that rapidly expanding AAAs have a higher risk of rupture.",
"     </li>",
"     <li>",
"      Patients with associated arterial disease such as coexisting iliac, femoral, or popliteal artery aneurysms, or symptomatic peripheral artery disease.",
"     </li>",
"     <li>",
"      For the same diameter AAA, the risk for AAA rupture is higher for women than for men. Elective repair of asymptomatic AAA &gt;5 cm may be appropriate; however, the risk of death from elective repair is also increased in women. A lower threshold for repair is best reserved for women who have a low risk for perioperative morbidity and mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with AAA &gt;5.5 cm who have a short life-expectancy (&lt;2 years) due to advanced comorbidities, particularly cardiopulmonary disease or malignancy, we suggest no repair over endovascular aneurysm repair (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For these patients and others who elect not to undergo repair, ongoing AAA surveillance is",
"      <strong>",
"       not",
"      </strong>",
"      needed. The patient should be encouraged to create an advanced directive detailing their wishes for no repair of any kind in the event of rupture. Family members should be made aware of these wishes, given that the patient may not be able to report his or her wishes at the time of aneurysm rupture. (See",
"      <a class=\"local\" href=\"#H3586992\">",
"       'Counseling the high-risk patient'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1045680\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conservative management consists of periodic clinical evaluation and surveillance of aneurysm diameter to identify AAA that exceeds the threshold for repair or is rapidly expanding. Medical therapies for patients with AAA focus on the management of modifiable risk factors for AAA and cardiovascular disease with the goals of reducing the need for intervention due to aneurysm expansion or rupture, reducing morbidity and mortality associated with AAA repair, and reducing cardiovascular morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H3592986\">",
"       'Conservative management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with AAA who smoke, we recommend smoking cessation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Smoking is strongly associated with AAA expansion and rupture, and is the most important modifiable risk factor. Even though reduced aneurysm expansion and rupture risk have not been clearly demonstrated among those who have stopped smoking, smoking cessation has other clear benefits. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18968?source=see_link\">",
"       \"Benefits and risks of smoking cessation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with AAA are considered to have a coronary equivalent. Statins and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      are considered appropriate therapies to decrease the risk of future cardiovascular events, as discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although many pharmacologic therapies aimed at limiting AAA expansion and preventing rupture have been tried, no therapy has been proven successful at achieving these goals, and as such, we suggest not implementing any of the pharmacologic therapies discussed above for the sole purpose of treating AAA. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal surveillance schedule for patients who are not undergoing AAA repair has not been clearly defined. Based largely upon the surveillance intervals identified in the United Kingdom Small Aneurysm Trial, the 2009 Society of Vascular Surgery (SVS) guidelines for the diagnosis and management of peripheral artery disease recommend surveillance every 6 to 12 months using ultrasound or computed tomography (CT) for medium-sized aneurysms (4.0 to 5.4 cm in diameter) but less frequent intervals (every two to three years) for smaller aneurysms. We prefer to screen small aneurysms annually to minimize imaging variability and alleviate patient anxieties. Annual clinical examination and risk-reduction assessment can also be performed concurrently with AAA surveillance. (See",
"      <a class=\"local\" href=\"#H766539\">",
"       'Aneurysm surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary goals of aneurysm repair are to prevent rupture while minimizing morbidity and mortality associated with repair. Two methods of aneurysm repair are currently available: traditional open surgery and endovascular aneurysm repair (EVAR). In randomized trials, EVAR is associated with lower perioperative morbidity and mortality compared with open AAA repair, but does not completely eliminate the future risk of AAA rupture, whereas open repair is associated with higher perioperative morbidity and mortality than EVAR, but provides a more definitive repair. Perioperative mortality for elective open AAA repair is 3 to 5 percent, and for EVAR is 0.5 to 2 percent. Long-term mortality rates are not significantly different. (See",
"      <a class=\"local\" href=\"#H783678\">",
"       'Open versus endovascular aneurysm repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We agree with guidelines from major medical and surgical societies that emphasize an individualized approach when choosing the approach to AAA repair, taking into account the patient's age, aortic anatomy, life-expectancy, and risk factors for perioperative morbidity and mortality. In general (see",
"      <a class=\"local\" href=\"#H783739\">",
"       'Choice of AAA repair'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For young patients (&lt;60) who have a low or average perioperative risk and an expected lifespan &gt;10 years, we suggest open surgical repair over endovascular repair (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with favorable anatomy for endovascular repair (as defined by the instructions for use [IFU] of a given device) and a high level of perioperative risk, we recommend endovascular repair over open repair (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Creager, MA, Halperin, JL, Whittemore, AD. Aneurysmal disease of the aorta and its branches. In: Vascular Medicine, Loscalzo, J, Creager, MA, Dzau, VJ (Eds), New York 1996. p.901.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/2\">",
"      Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. Br J Surg 2002; 89:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/3\">",
"      Hoornweg LL, Storm-Versloot MN, Ubbink DT, et al. Meta analysis on mortality of ruptured abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2008; 35:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/4\">",
"      Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1991; 13:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/5\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/6\">",
"      Chaikof EL, Brewster DC, Dalman RL, et al. SVS practice guidelines for the care of patients with an abdominal aortic aneurysm: executive summary. J Vasc Surg 2009; 50:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/7\">",
"      Wanhainen A. How to define an abdominal aortic aneurysm--influence on epidemiology and clinical practice. Scand J Surg 2008; 97:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/8\">",
"      Jongkind V, Yeung KK, Akkersdijk GJ, et al. Juxtarenal aortic aneurysm repair. J Vasc Surg 2010; 52:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/9\">",
"      Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet 1998; 352:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/10\">",
"      Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/11\">",
"      Cao P, De Rango P, Verzini F, et al. Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR): results from a randomised trial. Eur J Vasc Endovasc Surg 2011; 41:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/12\">",
"      Ouriel K, Clair DG, Kent KC, et al. Endovascular repair compared with surveillance for patients with small abdominal aortic aneurysms. J Vasc Surg 2010; 51:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/13\">",
"      United Kingdom EVAR Trial Investigators, Greenhalgh RM, Brown LC, et al. Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med 2010; 362:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/14\">",
"      Szilagyi DE, Smith RF, DeRusso FJ, et al. Contribution of abdominal aortic aneurysmectomy to prolongation of life. Ann Surg 1966; 164:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/15\">",
"      Foster JH, Bolasny BL, Gobbel WG Jr, Scott HW Jr. Comparative study of elective resection and expectant treatment of abdomianl aortic aneurysm. Surg Gynecol Obstet 1969; 129:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/16\">",
"      Thompson AR, Cooper JA, Ashton HA, Hafez H. Growth rates of small abdominal aortic aneurysms correlate with clinical events. Br J Surg 2010; 97:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/17\">",
"      Szilagyi DE, Elliott JP, Smith RF. Clinical fate of the patient with asymptomatic abdominal aortic aneurysm and unfit for surgical treatment. Arch Surg 1972; 104:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/18\">",
"      Katz DA, Littenberg B, Cronenwett JL. Management of small abdominal aortic aneurysms. Early surgery vs watchful waiting. JAMA 1992; 268:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/19\">",
"      Nevitt MP, Ballard DJ, Hallett JW Jr. Prognosis of abdominal aortic aneurysms. A population-based study. N Engl J Med 1989; 321:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/20\">",
"      Powell JT, Greenhalgh RM. Clinical practice. Small abdominal aortic aneurysms. N Engl J Med 2003; 348:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/21\">",
"      Brewster DC, Cronenwett JL, Hallett JW Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg 2003; 37:1106.",
"     </a>",
"    </li>",
"    <li>",
"     Mitchell, MB, Rutherford, RB, Krupski, WC. Infrarenal aortic aneurysms. In: Vascular Surgery, Rutherford, RB (Ed), WB Saunders, Philadelphia, 1995, p. 1032.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/23\">",
"      Ernst CB. Abdominal aortic aneurysm. N Engl J Med 1993; 328:1167.",
"     </a>",
"    </li>",
"    <li>",
"     Mitchell, MB, Rutherford, RB, Krupski, WC. Infrarenal aortic aneurysms. In: Vascular Surgery, Rutherford, RB (Eds), WB Saunders, Philadelphia 1995. p.1032.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/25\">",
"      Ouriel K. The PIVOTAL study: a randomized comparison of endovascular repair versus surveillance in patients with smaller abdominal aortic aneurysms. J Vasc Surg 2009; 49:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/26\">",
"      Cao P, CAESAR Trial Collaborators. Comparison of surveillance vs Aortic Endografting for Small Aneurysm Repair (CAESAR) trial: study design and progress. Eur J Vasc Endovasc Surg 2005; 30:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/27\">",
"      Filardo G, Powell JT, Martinez MA, Ballard DJ. Surgery for small asymptomatic abdominal aortic aneurysms. Cochrane Database Syst Rev 2012; 3:CD001835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/28\">",
"      Lederle FA, Kane RL, MacDonald R, Wilt TJ. Systematic review: repair of unruptured abdominal aortic aneurysm. Ann Intern Med 2007; 146:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/29\">",
"      United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/30\">",
"      Dimick JB, Stanley JC, Axelrod DA, et al. Variation in death rate after abdominal aortic aneurysmectomy in the United States: impact of hospital volume, gender, and age. Ann Surg 2002; 235:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/31\">",
"      Lederle FA. Should abdominal aortic aneurysm be managed differently in women? Scand J Surg 2008; 97:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/32\">",
"      Powell JT, Brown LC, Forbes JF, et al. Final 12-year follow-up of surgery versus surveillance in the UK Small Aneurysm Trial. Br J Surg 2007; 94:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/33\">",
"      Brady AR, Thompson SG, Fowkes FG, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004; 110:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/34\">",
"      Dawson J, Vig S, Choke E, et al. Medical optimisation can reduce morbidity and mortality associated with elective aortic aneurysm repair. Eur J Vasc Endovasc Surg 2007; 33:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/35\">",
"      Newman AB, Arnold AM, Burke GL, et al. Cardiovascular disease and mortality in older adults with small abdominal aortic aneurysms detected by ultrasonography: the cardiovascular health study. Ann Intern Med 2001; 134:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/36\">",
"      Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med 2004; 351:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/37\">",
"      United Kingdom EVAR Trial Investigators, Greenhalgh RM, Brown LC, et al. Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med 2010; 362:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/38\">",
"      Lederle FA, Freischlag JA, Kyriakides TC, et al. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA 2009; 302:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/39\">",
"      Grant SW, Grayson AD, Grant MJ, et al. What are the risk factors for renal failure following open elective abdominal aortic aneurysm repair? Eur J Vasc Endovasc Surg 2012; 43:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/40\">",
"      Brown LC, Brown EA, Greenhalgh RM, et al. Renal function and abdominal aortic aneurysm (AAA): the impact of different management strategies on long-term renal function in the UK EndoVascular Aneurysm Repair (EVAR) Trials. Ann Surg 2010; 251:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/41\">",
"      Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005; 111:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/42\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/43\">",
"      Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 2010; 52:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/44\">",
"      Bergqvist D. Pharmacological interventions to attenuate the expansion of abdominal aortic aneurysm (AAA) - a systematic review. Eur J Vasc Endovasc Surg 2011; 41:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/45\">",
"      Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis 2011; 217:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/46\">",
"      Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database Syst Rev 2012; 9:CD009536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/47\">",
"      Assar AN. Medical treatment of small abdominal aortic aneurysm. J Cardiovasc Surg (Torino) 2012; 53:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/48\">",
"      Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Troms&oslash; Study, 1994-2001. Circulation 2009; 119:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/49\">",
"      Wilmink TB, Quick CR, Day NE. The association between cigarette smoking and abdominal aortic aneurysms. J Vasc Surg 1999; 30:1099.",
"     </a>",
"    </li>",
"    <li>",
"     Kent, KC, Zwolak, RM, Egorova, NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 2010 Jul 12 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/51\">",
"      Lederle FA, Nelson DB, Joseph AM. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg 2003; 38:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/52\">",
"      Buckley C, Wyble CW, Borhani M, et al. Accelerated enlargement of experimental abdominal aortic aneurysms in a mouse model of chronic cigarette smoke exposure. J Am Coll Surg 2004; 199:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/53\">",
"      Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Ann Surg 1999; 230:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/54\">",
"      Smoking, lung function and the prognosis of abdominal aortic aneurysm. The UK Small Aneurysm Trial Participants. Eur J Vasc Endovasc Surg 2000; 19:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/55\">",
"      Warner MA, Offord KP, Warner ME, et al. Role of preoperative cessation of smoking and other factors in postoperative pulmonary complications: a blinded prospective study of coronary artery bypass patients. Mayo Clin Proc 1989; 64:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/56\">",
"      Chaikof EL, Brewster DC, Dalman RL, et al. The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg 2009; 50:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/57\">",
"      Dalman RL, Tedesco MM, Myers J, Taylor CA. AAA disease: mechanism, stratification, and treatment. Ann N Y Acad Sci 2006; 1085:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/58\">",
"      Nakahashi TK, Hoshina K, Tsao PS, et al. Flow loading induces macrophage antioxidative gene expression in experimental aneurysms. Arterioscler Thromb Vasc Biol 2002; 22:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/59\">",
"      Tenforde AS, Cheng CP, Suh GY, et al. Quantifying in vivo hemodynamic response to exercise in patients with intermittent claudication and abdominal aortic aneurysms using cine phase-contrast MRI. J Magn Reson Imaging 2010; 31:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/60\">",
"      Myers JN, White JJ, Narasimhan B, Dalman RL. Effects of exercise training in patients with abdominal aortic aneurysm: preliminary results from a randomized trial. J Cardiopulm Rehabil Prev 2010; 30:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/61\">",
"      Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg 2002; 35:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/62\">",
"      Gadowski GR, Pilcher DB, Ricci MA. Abdominal aortic aneurysm expansion rate: effect of size and beta-adrenergic blockade. J Vasc Surg 1994; 19:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/63\">",
"      Brophy CM, Tilson JE, Tilson MD. Propranolol stimulates the crosslinking of matrix components in skin from the aneurysm-prone blotchy mouse. J Surg Res 1989; 46:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/64\">",
"      Leach SD, Toole AL, Stern H, et al. Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Arch Surg 1988; 123:606.",
"     </a>",
"    </li>",
"    <li>",
"     Lindholt, JS, Henneberg, EW, Juul, S, Fasting, H. Impaired results of a randomized double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angio 1999; 18:52.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/66\">",
"      Lindholt JS, Henneberg EW, Juul S, Fasting H. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 1999; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/67\">",
"      Yamamoto D, Takai S, Jin D, et al. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol 2007; 43:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/68\">",
"      Rizzoni D, Rodella L, Porteri E, et al. Effects of losartan and enalapril at different doses on cardiac and renal interstitial matrix in spontaneously hypertensive rats. Clin Exp Hypertens 2003; 25:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/69\">",
"      Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/70\">",
"      Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/71\">",
"      Cassis LA, Gupte M, Thayer S, et al. ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 2009; 296:H1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/72\">",
"      Inoue N, Muramatsu M, Jin D, et al. Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient mice. J Atheroscler Thromb 2009; 16:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/73\">",
"      Liao S, Miralles M, Kelley BJ, et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001; 33:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/74\">",
"      Yang HH, Kim JM, Chum E, et al. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. J Thorac Cardiovasc Surg 2010; 140:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/75\">",
"      Kaschina E, Schrader F, Sommerfeld M, et al. Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J Hypertens 2008; 26:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/76\">",
"      Fujiwara Y, Shiraya S, Miyake T, et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med 2008; 22:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/77\">",
"      Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/78\">",
"      da Cunha V, Tham DM, Martin-McNulty B, et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005; 178:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/79\">",
"      Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006; 368:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/80\">",
"      Thompson A, Cooper JA, Fabricius M, et al. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 2010; 52:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/81\">",
"      Sweeting MJ, Thompson SG, Brown LC, et al. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg 2010; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/82\">",
"      Wassef M, Baxter BT, Chisholm RL, et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg 2001; 34:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/83\">",
"      Nagashima H, Aoka Y, Sakomura Y, et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/84\">",
"      Evans J, Powell JT, Schwalbe E, et al. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg 2007; 34:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/85\">",
"      Kalyanasundaram A, Elmore JR, Manazer JR, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006; 43:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/86\">",
"      Jones A, Deb R, Torsney E, et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation 2009; 119:3125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/87\">",
"      Zhang Y, Naggar JC, Welzig CM, et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol 2009; 29:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/88\">",
"      Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005; 241:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/89\">",
"      Golledge J, Cullen B, Moran C, Rush C. Efficacy of simvastatin in reducing aortic dilatation in mouse models of abdominal aortic aneurysm. Cardiovasc Drugs Ther 2010; 24:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/90\">",
"      Shiraya S, Miyake T, Aoki M, et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2009; 202:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/91\">",
"      Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/92\">",
"      Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/93\">",
"      Ferguson CD, Clancy P, Bourke B, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J 2010; 159:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/94\">",
"      Sukhija R, Aronow WS, Sandhu R, et al. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006; 97:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/95\">",
"      Karlsson L, Bergqvist D, Lindb&auml;ck J, P&auml;rsson H. Expansion of small-diameter abdominal aortic aneurysms is not reflected by the release of inflammatory mediators IL-6, MMP-9 and CRP in plasma. Eur J Vasc Endovasc Surg 2009; 37:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/96\">",
"      Mosorin M, Niemel&auml; E, Heikkinen J, et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg 2008; 7:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/97\">",
"      Schl&ouml;sser FJ, Tangelder MJ, Verhagen HJ, et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008; 47:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/98\">",
"      Dawson JA, Choke E, Loftus IM, et al. A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2011; 41:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/99\">",
"      Rahman MN, Khan JA, Mazari FA, et al. A randomized placebo controlled trial of the effect of preoperative statin use on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and peak wall stress in patients undergoing elective open repair of abdominal aortic aneurysm. Ann Vasc Surg 2011; 25:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/100\">",
"      Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/101\">",
"      Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 2011; 98:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/102\">",
"      Takagi H, Matsui M, Umemoto T. A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J Vasc Surg 2010; 52:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/103\">",
"      Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation 2008; 117:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/104\">",
"      Lindholt JS, Ashton HA, Scott RA. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J Vasc Surg 2001; 34:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/105\">",
"      Vammen S, Lindholt JS, Ostergaard L, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001; 88:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/106\">",
"      H&oslash;gh A, Vammen S, Ostergaard L, et al. Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial. Vasc Endovascular Surg 2009; 43:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/107\">",
"      Liu J, Xiong W, Baca-Regen L, et al. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg 2003; 38:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/108\">",
"      Curci JA, Mao D, Bohner DG, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/109\">",
"      Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/110\">",
"      Petrinec D, Liao S, Holmes DR, et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996; 23:336.",
"     </a>",
"    </li>",
"    <li>",
"     Mosorin, M, Juvonen, J, Biancari, F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001: 34:606.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/112\">",
"      Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/113\">",
"      Lindeman JH, Abdul-Hussien H, van Bockel JH, et al. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009; 119:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/114\">",
"      Walsh DB. Presidential address: Time to lead! J Vasc Surg 2009; 49:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/115\">",
"      Lindholt JS, Sorensen HT, Michel JB, et al. Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovascular Surg 2008; 42:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/116\">",
"      Golledge J, Wolanski P, Parr A, Buttner P. Measurement and determinants of infrarenal aortic thrombus volume. Eur Radiol 2008; 18:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/117\">",
"      Golledge J, Muller R, Clancy P, et al. Evaluation of the diagnostic and prognostic value of plasma D-dimer for abdominal aortic aneurysm. Eur Heart J 2011; 32:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/118\">",
"      Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 2008; 118:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/119\">",
"      Houard X, Touat Z, Ollivier V, et al. Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovasc Res 2009; 82:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/120\">",
"      Touat Z, Ollivier V, Dai J, et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 2006; 168:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/121\">",
"      Dai J, Louedec L, Philippe M, et al. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model. J Vasc Surg 2009; 49:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/122\">",
"      Koch AE, Haines GK, Rizzo RJ, et al. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol 1990; 137:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/123\">",
"      Newman KM, Jean-Claude J, Li H, et al. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation 1994; 90:II224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/124\">",
"      Pagano MB, Zhou HF, Ennis TL, et al. Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm. Circulation 2009; 119:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/125\">",
"      Lindeman JH, Rabelink TJ, van Bockel JH. Immunosuppression and the abdominal aortic aneurysm: Doctor Jekyll or Mister Hyde? Circulation 2011; 124:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/126\">",
"      Sun J, Zhang J, Lindholt JS, et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 2009; 120:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/127\">",
"      Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007; 117:3359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/128\">",
"      M&auml;yr&auml;np&auml;&auml; MI, Trosien JA, Fontaine V, et al. Mast cells associate with neovessels in the media and adventitia of abdominal aortic aneurysms. J Vasc Surg 2009; 50:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/129\">",
"      Lindholt JS, S&oslash;rensen J, S&oslash;gaard R, Henneberg EW. Long-term benefit and cost-effectiveness analysis of screening for abdominal aortic aneurysms from a randomized controlled trial. Br J Surg 2010; 97:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/130\">",
"      Feeney JM, Burns K, Staff I, et al. Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm. J Am Coll Surg 2009; 209:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/131\">",
"      Le Manach Y, Ibanez Esteves C, Bertrand M, et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing vascular surgery. Anesthesiology 2011; 114:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/132\">",
"      Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/133\">",
"      McNally MM, Agle SC, Parker FM, et al. Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair. J Vasc Surg 2010; 51:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/134\">",
"      Diehm N, Becker G, Katzen B, et al. Statins are associated with decreased mortality in abdominal, but not in thoracic aortic aneurysm patients undergoing endovascular repair: propensity score-adjusted analysis. Vasa 2008; 37:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/135\">",
"      Schouten O, Lever TM, Welten GM, et al. Long-term cardiac outcome in high-risk patients undergoing elective endovascular or open infrarenal abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2008; 36:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/136\">",
"      Leurs LJ, Visser P, Laheij RJ, et al. Statin use is associated with reduced all-cause mortality after endovascular abdominal aortic aneurysm repair. Vascular 2006; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/137\">",
"      Kurzencwyg D, Filion KB, Pilote L, et al. Cardiac medical therapy among patients undergoing abdominal aortic aneurysm repair. Ann Vasc Surg 2006; 20:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/138\">",
"      Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 2004; 28:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/139\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA 2002; 287:2968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/140\">",
"      RESCAN Collaborators, Bown MJ, Sweeting MJ, et al. Surveillance intervals for small abdominal aortic aneurysms: a meta-analysis. JAMA 2013; 309:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/141\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Relationship of age, gender, race, and body size to infrarenal aortic diameter. The Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Investigators. J Vasc Surg 1997; 26:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/142\">",
"      Marteau TM. Screening for aortic aneurysm: Detection is not as harmful as it might seem. BMJ 2008; 336:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/143\">",
"      Kauffmann C, Tang A, Dugas A, et al. Clinical validation of a software for quantitative follow-up of abdominal aortic aneurysm maximal diameter and growth by CT angiography. Eur J Radiol 2011; 77:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/144\">",
"      Sarangarm D, Knepper J, Marek J, et al. Post-endovascular aneurysm repair patient outcomes and follow-up are not adversely impacted by long travel distance to tertiary vascular surgery centers. Ann Vasc Surg 2010; 24:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/145\">",
"      Brady AR, Fowkes FG, Greenhalgh RM, et al. Risk factors for postoperative death following elective surgical repair of abdominal aortic aneurysm: results from the UK Small Aneurysm Trial. On behalf of the UK Small Aneurysm Trial participants. Br J Surg 2000; 87:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/146\">",
"      Dillavou ED, Muluk SC, Makaroun MS. Improving aneurysm-related outcomes: nationwide benefits of endovascular repair. J Vasc Surg 2006; 43:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/147\">",
"      Lee WA, Carter JW, Upchurch G, et al. Perioperative outcomes after open and endovascular repair of intact abdominal aortic aneurysms in the United States during 2001. J Vasc Surg 2004; 39:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/148\">",
"      Sieunarine K, Lawrence-Brown MM, Goodman MA. Comparison of transperitoneal and retroperitoneal approaches for infrarenal aortic surgery: early and late results. Cardiovasc Surg 1997; 5:71.",
"     </a>",
"    </li>",
"    <li>",
"     file://content.onlinejacc.org/cgi/reprint/47/6/e1.pdf (Accessed on March 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/150\">",
"      Blankensteijn JD, de Jong SE, Prinssen M, et al. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med 2005; 352:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/151\">",
"      De Bruin JL, Baas AF, Buth J, et al. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med 2010; 362:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/152\">",
"      EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 2005; 365:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/153\">",
"      Becquemin JP, Pillet JC, Lescalie F, et al. A randomized controlled trial of endovascular aneurysm repair versus open surgery for abdominal aortic aneurysms in low- to moderate-risk patients. J Vasc Surg 2011; 53:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/154\">",
"      Lederle FA, Freischlag JA, Kyriakides TC, et al. Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med 2012; 367:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/53/38746/abstract/155\">",
"      Karthikesalingam A, Thompson MM. Vascular disease: Repair of infrarenal aortic aneurysm--the debate is OVER. Nat Rev Cardiol 2013; 10:122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15188 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38746=[""].join("\n");
var outline_f37_53_38746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H909597049\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H611107773\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H611107780\">",
"      ANEURYSM TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H933032628\">",
"      Clinical presentations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191820574\">",
"      ANEURYSM REPAIR VERSUS CONSERVATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H431203144\">",
"      Aneurysm diameter and rupture risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3586739\">",
"      - Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3586232\">",
"      Observation versus open repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3586239\">",
"      Observation versus endovascular repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3585400\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3585407\">",
"      - Female gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3585414\">",
"      - Patient age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3585421\">",
"      - Rapid expansion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3585428\">",
"      - Coexistent aneurysm or PAD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3592638\">",
"      - Very large aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3585830\">",
"      MEDICAL RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3592986\">",
"      CONSERVATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91188805\">",
"      Therapies to limit aortic expansion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91192084\">",
"      - Potentially beneficial therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3584839\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3584846\">",
"      Exercise therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91192146\">",
"      - Uncertain benefit for limiting AAA expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3593747\">",
"      Beta blocker therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3593855\">",
"      ARBs and ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3593877\">",
"      Other antihypertensives agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3593884\">",
"      Statin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3594091\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3594098\">",
"      Antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3594222\">",
"      Antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3593134\">",
"      Cardiovascular risk reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H244545816\">",
"      Safety of antiplatelet therapy and AAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3586992\">",
"      Counseling the high-risk patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1045680\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H766539\">",
"      - Aneurysm surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191821755\">",
"      AAA REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H786575\">",
"      Summary of indications for elective AAA repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H783678\">",
"      Open versus endovascular aneurysm repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3594568\">",
"      - DREAM trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3594590\">",
"      - EVAR 1 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3594604\">",
"      - OVER trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3594618\">",
"      - ACE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H783739\">",
"      Choice of AAA repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H909597049\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15188|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/57/37782\" title=\"diagnostic image 1\">",
"      Pararenal abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15188|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/29/9683\" title=\"figure 1\">",
"      Anatomy abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/25/44445\" title=\"figure 2\">",
"      Risk of rupture of AAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/45/734\" title=\"figure 3\">",
"      Outcome surgery vs surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/6/2158\" title=\"figure 4\">",
"      Rate of AAA repair over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/11/32949\" title=\"figure 5\">",
"      Abdominal aortic aneurysm repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15188|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/15/5373\" title=\"table 1\">",
"      Potential medical therapies for limiting progression of AAA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18968?source=related_link\">",
"      Benefits and risks of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=related_link\">",
"      Complications of endovascular abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=related_link\">",
"      Endovascular repair of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11450?source=related_link\">",
"      Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29304?source=related_link\">",
"      Iliac artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=related_link\">",
"      Management and outcome of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=related_link\">",
"      Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/62/34787?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/39/22130?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=related_link\">",
"      Popliteal artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24488?source=related_link\">",
"      Screening for abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30904?source=related_link\">",
"      Surgical and endovascular repair of ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_53_38747="CRP reactive adults";
var content_f37_53_38747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    C-reactive protein levels in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       0 to 2 mg/L (0 to 0.2 mg/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       2 to 3 mg/L (0.2 to 0.3 mg/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       3 to 10 mg/L (0.3 to 1.0 mg/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       &gt;10 mg/L (&gt;1.0 mg/dL)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       All adults",
"      </td>",
"      <td>",
"       48 percent",
"      </td>",
"      <td>",
"       14 percent",
"      </td>",
"      <td>",
"       29 percent",
"      </td>",
"      <td>",
"       10 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Men",
"      </td>",
"      <td>",
"       56 percent",
"      </td>",
"      <td>",
"       14 percent",
"      </td>",
"      <td>",
"       24 percent",
"      </td>",
"      <td>",
"       6 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Women",
"      </td>",
"      <td>",
"       40 percent",
"      </td>",
"      <td>",
"       13 percent",
"      </td>",
"      <td>",
"       33 percent",
"      </td>",
"      <td>",
"       13 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       White",
"      </td>",
"      <td>",
"       48 percent",
"      </td>",
"      <td>",
"       14 percent",
"      </td>",
"      <td>",
"       29 percent",
"      </td>",
"      <td>",
"       9 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Black",
"      </td>",
"      <td>",
"       44 percent",
"      </td>",
"      <td>",
"       12 percent",
"      </td>",
"      <td>",
"       29 percent",
"      </td>",
"      <td>",
"       15 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age 20-29",
"      </td>",
"      <td>",
"       59 percent",
"      </td>",
"      <td>",
"       12 percent",
"      </td>",
"      <td>",
"       22 percent",
"      </td>",
"      <td>",
"       7 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age &gt;70",
"      </td>",
"      <td>",
"       36 percent",
"      </td>",
"      <td>",
"       17 percent",
"      </td>",
"      <td>",
"       34 percent",
"      </td>",
"      <td>",
"       13 percent",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: National Health and Nutrition Evaluation Survey, 2005.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38747=[""].join("\n");
var outline_f37_53_38747=null;
var title_f37_53_38748="Drug therapy Parkinson disease";
var content_f37_53_38748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug treatment of Parkinson disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual starting dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual maintenance dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trihexyphenidyl",
"       </td>",
"       <td>",
"        Artane",
"       </td>",
"       <td>",
"        1 mg BID",
"       </td>",
"       <td>",
"        2 mg BID-TID",
"       </td>",
"       <td>",
"        Anticholinergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benztropine",
"       </td>",
"       <td>",
"        Cogentin",
"       </td>",
"       <td>",
"        0.5 mg BID",
"       </td>",
"       <td>",
"        1 to 2 mg BID-TID",
"       </td>",
"       <td>",
"        Anticholinergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amantadine",
"       </td>",
"       <td>",
"        Symmetrel",
"       </td>",
"       <td>",
"        100 mg BID",
"       </td>",
"       <td>",
"        100 mg BID-TID",
"       </td>",
"       <td>",
"        Anticholinergic; increases presynaptic dopamine release; NMDA antagonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selegiline",
"       </td>",
"       <td>",
"        Eldepryl",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"       <td>",
"        5 mg qam",
"       </td>",
"       <td>",
"        MAO B inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbidopa/levodopa",
"       </td>",
"       <td>",
"        Sinemet",
"       </td>",
"       <td>",
"        25/100 mg TID",
"       </td>",
"       <td>",
"        25/250 mg TID-QID",
"       </td>",
"       <td>",
"        Dopamine precursor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbidopa/levodopa",
"       </td>",
"       <td>",
"        Sinemet CR",
"       </td>",
"       <td>",
"        25/100 mg TID",
"       </td>",
"       <td>",
"        50/200 mg TID",
"       </td>",
"       <td>",
"        Dopamine precursor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apomorphine",
"       </td>",
"       <td>",
"        Apokyn",
"       </td>",
"       <td>",
"        2 mg SC test dose",
"       </td>",
"       <td>",
"        2 to 10 mg SC TID",
"       </td>",
"       <td>",
"        Dopamine agonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bromocriptine",
"       </td>",
"       <td>",
"        Parlodel",
"       </td>",
"       <td>",
"        2.5 mg daily",
"       </td>",
"       <td>",
"        5 to 10 mg QID",
"       </td>",
"       <td>",
"        Dopamine agonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pramipexole",
"       </td>",
"       <td>",
"        Mirapex",
"       </td>",
"       <td>",
"        0.125 mg TID",
"       </td>",
"       <td>",
"        1.5 mg TID",
"       </td>",
"       <td>",
"        Dopamine agonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ropinirole",
"       </td>",
"       <td>",
"        Requip",
"       </td>",
"       <td>",
"        0.25 mg TID",
"       </td>",
"       <td>",
"        1.0 mg TID",
"       </td>",
"       <td>",
"        Dopamine agonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Entacapone",
"       </td>",
"       <td>",
"        Comtan",
"       </td>",
"       <td>",
"        200 mg with L-dopa",
"       </td>",
"       <td>",
"        600 to 800 mg a day",
"       </td>",
"       <td>",
"        COMT inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tolcapone",
"       </td>",
"       <td>",
"        Tasmar",
"       </td>",
"       <td>",
"        100 mg TID",
"       </td>",
"       <td>",
"        100 to 200 mg TID",
"       </td>",
"       <td>",
"        COMT inhibitor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38748=[""].join("\n");
var outline_f37_53_38748=null;
var title_f37_53_38749="Contents: Cancer survivorship";
var content_f37_53_38749=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cancer survivorship",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cancer survivorship",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/41/16025\">",
"           Approach to the care of long-term testicular cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/12/5322\">",
"           Approach to the long-term survivor of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/34/28202\">",
"           Approach to the long-term survivor of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/54/14185\">",
"           Oral health in cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/6/32873\">",
"           Overview of cancer survivorship care for primary care and oncology providers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/5/4185\">",
"           Overview of care for adult survivors of non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/34/36394\">",
"           Overview of the approach to the adult survivor of classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/44/35530\">",
"           The approach to hematopoietic cell transplantation survivorship",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/19/43321\">",
"           The roles of diet, physical activity, and body weight in cancer survivorship",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-6EAC718A7E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_53_38749=[""].join("\n");
var outline_f37_53_38749=null;
var title_f37_53_38750="Brain cancer by race and age";
var content_f37_53_38750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    1990-94 malignant brain cancer incidence rates in the United States stratified by race and age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 320px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ries, LA, Kosary, CL, Hankey, BF (Eds). SEER Cancer Statistics Review, 1973-1995. National Cancer Institute, Bethesda, MD 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38750=[""].join("\n");
var outline_f37_53_38750=null;
var title_f37_53_38751="Classification tree Sjogren";
var content_f37_53_38751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Classification tree performance of the American-European Consensus Group classification criteria for SS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 514px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the classification tree for the classification of primary SS. Within each circle, the number of patients with primary SS (upper value) and the number of controls without SS (lower value) are reported. The boxes show the numbers of subjects who could be classified either as having SS or not having SS (No SS). The variable used in each node of the tree to discriminate between patients and controls is reported beneath the circles. Following the entire sequence allowed us to classify correctly 73/76 patients with primary SS (sensitivity 96.1 percent) and 98/104 disease controls (specificity 94.2 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sj&ouml;gren's syndrome:&nbsp;A revised version of the European criteria proposed by the American-European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554. Copyright &copy; 2002 BMJ Publishing Group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_53_38751=[""].join("\n");
var outline_f37_53_38751=null;
